<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004060.pub2" GROUP_ID="UPPERGI" ID="131102022612592681" MERGED_FROM="" MODIFIED="2013-06-11 14:29:05 +0100" MODIFIED_BY="Karin Dearness" REVIEW_NO="63" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2013-06-11 14:29:05 +0100" MODIFIED_BY="Karin Dearness">
<TITLE MODIFIED="2009-09-16 11:42:48 -0400" MODIFIED_BY="[Empty name]">Treatment for Barrett's oesophagus</TITLE>
<CONTACT MODIFIED="2013-06-11 14:29:05 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="16651" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rebecca</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Fitzgerald</LAST_NAME><POSITION>MRC Oesophageal Group Leader</POSITION><EMAIL_1>rcf@hutchison-mrc.cam.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Cancer Cell Unit</DEPARTMENT><ORGANISATION>Hutchison/MRC Research Centre</ORGANISATION><ADDRESS_1>Hills Road</ADDRESS_1><CITY>Cambridge</CITY><ZIP>CB22 2XZ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 763287</PHONE_1><PHONE_2>+44 1223 763292</PHONE_2><FAX_1>+44 1223 763241</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-06-11 14:29:05 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="DA52800282E26AA2001A7553C1D8C3C9" ROLE="AUTHOR"><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>RE</MIDDLE_INITIALS><LAST_NAME>Rees</LAST_NAME><EMAIL_1>j.r.e.rees@btinternet.com</EMAIL_1><ADDRESS><DEPARTMENT>MRC Cancer Cell Unit</DEPARTMENT><ORGANISATION>Hutchison/MRC Research Centre</ORGANISATION><ADDRESS_1>Hills Road</ADDRESS_1><CITY>Cambridge</CITY><ZIP>CB22 2XZ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 763 277</PHONE_1></ADDRESS></PERSON><PERSON ID="D21DD18D82E26AA20046B3727EFD1FFE" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pierre</FIRST_NAME><LAST_NAME>Lao-Sirieix</LAST_NAME><POSITION>Investigator Scientist</POSITION><EMAIL_1>pss29@cam.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Cancer Cell Unit</DEPARTMENT><ORGANISATION>Hutchison/MRC Research Centre</ORGANISATION><ADDRESS_1>Hills Road</ADDRESS_1><CITY>Cambridge</CITY><ZIP>CB22 2XZ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 763 277</PHONE_1><PHONE_2>+44 1223 763 241</PHONE_2></ADDRESS></PERSON><PERSON ID="16721" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Angela</FIRST_NAME><LAST_NAME>Wong</LAST_NAME><EMAIL_1>angela.Wong@whippsx.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Cancer Cell Unit</DEPARTMENT><ORGANISATION>Hutchison/MRC Research Centre</ORGANISATION><ADDRESS_1>Hills Road</ADDRESS_1><CITY>Cambridge</CITY><ZIP>CB22 2XZ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 763292</PHONE_1></ADDRESS></PERSON><PERSON ID="16651" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rebecca</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Fitzgerald</LAST_NAME><POSITION>MRC Oesophageal Group Leader</POSITION><EMAIL_1>rcf@hutchison-mrc.cam.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Cancer Cell Unit</DEPARTMENT><ORGANISATION>Hutchison/MRC Research Centre</ORGANISATION><ADDRESS_1>Hills Road</ADDRESS_1><CITY>Cambridge</CITY><ZIP>CB22 2XZ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 763287</PHONE_1><PHONE_2>+44 1223 763292</PHONE_2><FAX_1>+44 1223 763241</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-06-07 14:06:13 -0400" MODIFIED_BY="Karin Dearness">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin Dearness">
<DATE DAY="15" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Correction to the graph labels in analysis 1.2.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-05 10:14:34 -0400" MODIFIED_BY="Karin L Dearness">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-05 10:14:34 -0400" MODIFIED_BY="Karin Dearness">
<DATE DAY="7" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Correction to abstract and updating risk of bias terminology but no change to overall assessments.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-05 10:19:05 -0500" MODIFIED_BY="Karin L Dearness">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Protocol converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin Dearness">
<SUMMARY MODIFIED="2009-11-02 09:40:57 -0500" MODIFIED_BY="Karin L Dearness">
<TITLE MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">Treatment of Barrett's oesophagus</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-02 09:40:57 -0500" MODIFIED_BY="Karin L Dearness">
<P>One of the two main types of oesophageal (gullet) cancer, oesophageal adenocarcinoma, is rapidly increasing in incidence in the western world. The prognosis for patients treated for oesophageal adenocarcinoma is appalling with fewer than 15% of individuals surviving beyond five years. Barrett&#8217;s oesophagus has been identified as the pre-cancerous stage of adenocarcinoma. It is recognised that Barrett's oesophagus develops as a complication of acid and bile reflux which commonly, but not inevitably, leads to heartburn symptoms. In response to these injurious agents, the normal squamous lining of the oesophagus is replaced by a columnar lining resembling the lining of the intestine. This intestinal subtype has the highest risk of malignancy and the term Barrett's oesophagus is used only for this subtype in many areas of the world, and in most research publications. Barrett's oesophagus can gradually progress to adenocarcinoma through a series of stages called dysplasia which can be identified in biopsies examined under the microscope.</P>
<P>As outcomes after treatment of adenocarcinoma are so poor, there has been increasing interest in treatments for Barrett's oesophagus. The aim of these treatments is to eradicate the Barrett's oesophagus lining or associated dysplasia with the aim of reducing the risk of cancer developing. This systematic review has shown that acid suppression therapies (surgery or drugs) have little or no significant effect on reversing Barrett's oesophagus but anti-reflux surgery appears to reduce dysplasia and protects against the development of dysplasia. A number of endoscopic therapies have also been developed over recent years. Argon plasma coagulation, which burns away the Barrett's oesophagus segment, and photodynamic therapy, which uses light to activate an injected drug, have both been shown to be successful at eradicating Barrett&#8217;s and dysplasia. However, small areas of Barrett's oesophagus buried under the newly formed squamous oesophagus remain a concern. A relatively new technique using radiofrequency waves, called radio frequency ablation appears successful at eradicating Barrett's with fewer side effects. There are currently very few randomised controlled trials to help clinicians and patients decide on the best treatment options in the long as well as the short-term. Overall, radiofrequency ablation appears to be the most successful therapy to date for patients with early cancer or severe (high-grade) dysplasia in Barrett's oesophagus. Significantly more work is needed in this area to guide routine clinical practice for this common condition.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-06-07 13:55:09 -0400" MODIFIED_BY="Karin Dearness">
<ABS_BACKGROUND MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>Treatments for Barrett's oesophagus, the precursor lesion of adenocarcinoma, are available but whether these therapies effectively prevent the development of adenocarcinoma, and in some cases eradicate the Barrett's oesophagus segment, remains unclear.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>To summarise, quantify and compare the efficacy of pharmacological, surgical and endoscopic treatments for the eradication of dysplastic and non-dysplastic Barrett's oesophagus and prevention of these states from progression to adenocarcinoma<B>.</B>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>We searched CENTRAL (<I>The Cochrane Library</I> 2004, issue 4), MEDLINE (1966 to June 2008) and EMBASE (1980 to June 2008).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised controlled trials (RCTs) comparing medical, endoscopic or non-resectional surgical treatments for Barrett's oesophagus. The primary outcome measures were complete eradication of Barrett's and dysplasia at 12 months, and reduction in the number of patients progressing to cancer at five years or latest time point.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>Three authors independently extracted data and assessed the quality of the trials included in the analysis. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-06-07 13:55:09 -0400" MODIFIED_BY="Karin Dearness">
<P>Sixteen studies, including 1074 patients, were included. The mean number of participants in the studies was small (n = 49; range 8 to 208). Most studies did not report on the primary outcomes. Medical and surgical interventions to reduce symptoms and sequelae of gastro-oesophageal reflux disease (GORD) did not induce significant eradication of Barrett's oesophagus or dysplasia. Endoscopic therapies (photodynamic therapy (PDT with aminolevulinic acid or porfimer sodium), argon plasma coagulation (APC) and radiofrequency ablation (RFA)) all induced regression of Barrett's oesophagus and dysplasia. The data for photodynamic therapy were heterogeneous with a mean eradication rate of 51% for Barrett's oesophagus and between 56% and 100% for dysplasia, depending on the treatment regimens. The variation in photodynamic therapy eradication rates for dysplasia was dependent on the drug, source and dose of light. Radiofrequency ablation resulted in eradication rates of 77% and 86% for Barrett's oesophagus and dysplasia, while those rates were 2% and 21% in the sham treatment group respectively. Endoscopic treatments were generally well tolerated, however all were associated with some buried glands, particularly following argon plasma coagulation and photodynamic therapy, as well as photosensitivity and strictures induced by porfimer sodium based photodynamic therapy in particular.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>Despite their failure to eradicate Barrett's oesophagus, the role of medical and surgical interventions to reduce the troubling symptoms and sequelae of GORD is not questioned. Whether therapies for GORD reduce the cancer risk is not yet known. Ablative therapies have an increasing role in the management of dysplasia within Barrett's and current data would favour the use of radiofrequency ablation compared with photodynamic therapy. Radiofrequency ablation has been shown to yield significantly fewer complications than photodynamic therapy and is very efficacious at eradicating both dysplasia and Barrett's itself. However, long-term follow-up data are still needed before radiofrequency ablation can be used in routine clinical care without the need for very careful post-treatment surveillance. More clinical trial data and in particular randomised controlled trials are required to assess whether or not the cancer risk is reduced in routine clinical practice.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin Dearness">
<BACKGROUND MODIFIED="2009-11-02 10:01:29 -0500" MODIFIED_BY="Karin L Dearness">
<CONDITION MODIFIED="2009-11-02 10:01:29 -0500" MODIFIED_BY="Karin L Dearness">
<P>The incidence of oesophageal adenocarcinoma is rapidly increasing in the Western world. Its precursor lesion, Barrett's oesophagus, occurs as a consequence of chronic gastro-oesophageal reflux, with prevalence rates of 6% to 12% (<LINK REF="REF-Sarr-1985" TYPE="REFERENCE">Sarr 1985</LINK>; <LINK REF="REF-Winters-1987" TYPE="REFERENCE">Winters 1987</LINK>; <LINK REF="REF-Cameron-1990" TYPE="REFERENCE">Cameron 1990</LINK>; <LINK REF="REF-Blot-1991" TYPE="REFERENCE">Blot 1991</LINK>; <LINK REF="REF-Cameron-1992" TYPE="REFERENCE">Cameron 1992</LINK>; <LINK REF="REF-Bonelli-1993" TYPE="REFERENCE">Bonelli 1993</LINK>; <LINK REF="REF-Pera-1993" TYPE="REFERENCE">Pera 1993</LINK>; <LINK REF="REF-Robinson-1998" TYPE="REFERENCE">Robinson 1998</LINK>). Data from Sweden indicate an overall population prevalence of 1.6% (<LINK REF="REF-Ronkainen-2005" TYPE="REFERENCE">Ronkainen 2005</LINK>).</P>
<P>Barrett's oesophagus is defined as an endoscopically visible segment of columnar lined epithelium in the lower oesophagus with biopsies demonstrating (in the UK) any type of metaplasia and (in the US) intestinal metaplasia (<LINK REF="REF-BSG-2005" TYPE="REFERENCE">BSG 2005</LINK>; <LINK REF="REF-Wang-2008" TYPE="REFERENCE">Wang 2008</LINK>). Intestinal metaplasia is the most common subtype with the greatest malignant potential and for this reason many investigators restrict the definition of Barrett's to this subtype (<LINK REF="STD-Sampliner-2002" TYPE="STUDY">Sampliner 2002</LINK>). The risk of progression from Barrett's oesophagus to high-grade dysplasia and invasive adenocarcinoma is low, at approximately 0.4% and 0.77% per year respectively (<LINK REF="REF-Yousef-2008" TYPE="REFERENCE">Yousef 2008</LINK>).<BR/>
</P>
<P>The identification of a 'stepwise' progression through a metaplasia-dysplasia-adenocarcinoma sequence akin to that described in colon carcinogenesis provides the rationale for endoscopic surveillance, which aims to detect high-grade dysplasia or cancer at an early, asymptomatic and potentially curable stage. Early cancer detection is important because despite advances in multimodal treatment, the survival rates of symptomatic oesophageal cancers remain dismal. The overall survival of patients treated radically with chemotherapy and surgery is 43% at two years (<LINK REF="REF-MRC-working-party-2002" TYPE="REFERENCE">MRC working party 2002</LINK>) and 14% at five years if all patients are considered (<LINK REF="REF-Enzinger-2003" TYPE="REFERENCE">Enzinger 2003</LINK>; <LINK REF="REF-CRUK-2006" TYPE="REFERENCE">CRUK 2006</LINK>). Evidence from non-randomised retrospective studies demonstrates an improved five-year actuarial survival in patients with surveillance-detected oesophageal carcinomas of up to 80% at five years (<LINK REF="REF-Streitz-1993" TYPE="REFERENCE">Streitz 1993</LINK>; <LINK REF="REF-Bani_x002d_Hani-2000" TYPE="REFERENCE">Bani-Hani 2000</LINK>; <LINK REF="REF-Fountoulakis-2004" TYPE="REFERENCE">Fountoulakis 2004</LINK>) indicating a potential benefit for early detection, although lead time bias needs to be accounted for.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-11-02 09:47:26 -0500" MODIFIED_BY="Karin L Dearness">
<P>There has been considerable interest in treatments to reduce the risk of cancer progression through eradication of Barrett's oesophagus. Oesophagectomy is currently the only routine clinical treatment for high-grade dysplasia. However, novel research therapies may permit not to use such an invasive approach. Whether suppression of reflux, via surgical or pharmacological therapy, is sufficient to achieve this goal is uncertain. Furthermore, treatment efficacy is difficult to measure given the size of the cohort required and the duration of follow up necessary. As an alternative endpoint, investigators have measured regression or reversal of Barrett's oesophagus.</P>
<P>The primary aim of pharmacological acid-suppression and surgical anti-reflux treatments is to relieve symptoms. The medical treatments available (proton pump inhibitors and H<SUB>2</SUB> antagonists) reduce acid secretion. Anti-reflux surgery, typically a Nissen fundoplication, may be offered to carefully selected patients with proven reflux disease who are refractory to medical treatment or to those reluctant to take life-long medication. Surgery has the advantage of reducing both acid and bile reflux, which may act synergistically in the aetiopathogenesis of Barrett's oesophagus (<LINK REF="REF-Theisen-2003" TYPE="REFERENCE">Theisen 2003</LINK>; <LINK REF="REF-Jolly-2004" TYPE="REFERENCE">Jolly 2004</LINK>) and also provides both effective symptom relief and healing of oesophagitis.</P>
<P>Interest in the potential role of proton pump inhibitors in the prevention of adenocarcinoma in Barrett's oesophagus has been based on laboratory data showing that recurrent pulsatile episodes of gastro-oesophageal reflux components may have detrimental effects on the cell phenotype (reviewed in <LINK REF="REF-Fitzgerald-2005" TYPE="REFERENCE">Fitzgerald 2005</LINK>). Specifically, an <I>ex vivo</I> explant model and cell line models have demonstrated increased proliferation and proliferation-related signalling pathways (<LINK REF="REF-Fitzgerald-1996" TYPE="REFERENCE">Fitzgerald 1996</LINK>; <LINK REF="REF-Souza-2002" TYPE="REFERENCE">Souza 2002</LINK>), as well as inducing DNA double strand breaks (<LINK REF="REF-Clemons-2007" TYPE="REFERENCE">Clemons 2007</LINK>) upon exposure to pulsatile acid. Furthermore, effective acid suppression has been associated with increased cell differentiation, decreased proliferation and decreased COX-2 expression in Barrett's oesophagus metaplasia tissue biopsies (<LINK REF="REF-Ouatu_x002d_Lascar-1999" TYPE="REFERENCE">Ouatu-Lascar 1999</LINK>; <LINK REF="REF-Shirvani-2000" TYPE="REFERENCE">Shirvani 2000</LINK>; <LINK REF="REF-Adballa-2004" TYPE="REFERENCE">Adballa 2004</LINK>; <LINK REF="REF-Lao_x002d_Sirieix-2007" TYPE="REFERENCE">Lao-Sirieix 2007</LINK>). Cox-2 levels were also demonstrated to be normalized following anti-reflux surgery (<LINK REF="REF-Vallb_x00f6_hmer-2006" TYPE="REFERENCE">Vallböhmer 2006</LINK>). Outside of the laboratory in <I>in vivo </I>and <I>ex vivo</I> studies, the effect of proton pump inhibitors on Barrett's oesophagus and oesophageal adenocarcinoma is as yet unclear and animal models of reflux treated with proton pump inhibitor have not revealed a reduction in adenocarcinoma risk (<LINK REF="REF-Triadafilopoulos-2000" TYPE="REFERENCE">Triadafilopoulos 2000</LINK>; <LINK REF="REF-Moore-2001" TYPE="REFERENCE">Moore 2001</LINK>).</P>
<P>On the other hand, concerns have also arisen because of the effects of proton pump inhibitors on gastrin secretion. Most of the evidence is based on <I>in vitro</I> or <I>ex vivo</I> work and data need to be interpreted with caution. Proton pump inhibitors increase gastrin secretion and work in Barrett's oesophagus biopsies and using the Barrett's oesophagus adenocarcinoma cell line, OE33 with over expression of the CCK2 receptor, suggested that the Barrett's oesophagus epithelium is sensitive to the proliferative effects of gastrin (<LINK REF="REF-Haigh-2003" TYPE="REFERENCE">Haigh 2003</LINK>; <LINK REF="REF-Adballa-2004" TYPE="REFERENCE">Adballa 2004</LINK>). This gastrin-induced hyperproliferation <I>in vitro</I> could be inhibited by a selective COX-2 inhibitor (<LINK REF="REF-Adballa-2004" TYPE="REFERENCE">Adballa 2004</LINK>). Whether the risk of hypergastrinaemia is real or not, the benefits of proton pump inhibitors outweigh the side effects (reviewed in <LINK REF="REF-Tytgat-2001" TYPE="REFERENCE">Tytgat 2001</LINK>). Furthermore, a large general practice database study of 18,000 patients treated with omeprazole did not identify an excess mortality, secondary to omeprazole treatment, when pre-existing conditions were taken into account (<LINK REF="REF-Bateman-2003" TYPE="REFERENCE">Bateman 2003</LINK>).</P>
<P>Aside from acid suppression there has been interest in other drugs which might prevent progression to cancer (chemoprevention). The most studied are aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), which have been associated with a reduced occurrence of oesophageal cancers, including adenocarcinoma, in retrospective epidemiological studies (<LINK REF="REF-Sadeghi-2008" TYPE="REFERENCE">Sadeghi 2008</LINK>). Data from the AsPECT trial (phase III, randomised, study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia), which aims to assess the impact of high or low-dose aspirin combined with esomeprazole, are eagerly awaited (<LINK REF="REF-AspECT" TYPE="REFERENCE">AspECT</LINK>). Similarly, COX-2 inhibitors have been shown to suppress cell proliferation and induce apoptosis <I>in vitro</I> in a wide range of cell lines although the associated cardiotoxicity has limited their use in human chemoprevention strategies (reviewed in <LINK REF="REF-Thun-2002" TYPE="REFERENCE">Thun 2002</LINK>). Other potential chemopreventive agents include retinoids, however the most recent evidence in small-cell lung cancer (<LINK REF="REF-Freemantle-2006" TYPE="REFERENCE">Freemantle 2006</LINK>) and also a phase III placebo controlled trial in squamous cell carcinoma of the head and neck (<LINK REF="REF-Khuri-2006" TYPE="REFERENCE">Khuri 2006</LINK>) suggest that traditional retinoids do not confer benefit. Citral, a retinoid antagonist, has been demonstrated <I>ex vivo </I>to induce reversion of the Barrett's phenotype (<LINK REF="REF-Chang-2007" TYPE="REFERENCE">Chang 2007</LINK>).<I> </I>Whether these agents could be beneficial in preventing progression of preinvasive oesophageal disease is therefore of interest.<B> </B>
</P>
<P>The last two decades have seen the introduction of endoscopic techniques, usually in combination with acid suppression therapy or anti-reflux surgery, that remove all or part of the Barrett's epithelium. These techniques include thermal methods such as argon plasma photocoagulation (APC), multipolar electrocautery (MPEC), laser therapy, cryotherapy and radiofrequency ablation (RFA); chemical methods including photodynamic therapy (PDT); mechanical methods such as endoscopic mucosal resection (EMR) and more recently ultrasonic surgical aspiration (<LINK REF="REF-Yeh-2005" TYPE="REFERENCE">Yeh 2005</LINK>). The rationale for these is that replacement of the Barrett's epithelium with a neo-squamous epithelium removes the malignant potential. These methods must balance adequate depth of ablation and elimination of columnar mucosa with the risks of complications such as perforations and strictures. One of the concerns of ablative therapies is the presence of so-called buried Barrett's oesophagus glands, below the neosquamous epithelium, that may still harbour malignant potential.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>The goals of therapy in Barrett's oesophagus patients are wide ranging; they include relief of reflux symptoms, healing of erosive oesophagitis, prevention of inflammatory complications, ablation of the columnar-lined segment and ultimately reduction in the risk of malignant complications. The management strategies for individuals with Barrett's oesophagus and associated high-grade dysplasia include continued surveillance with an aggressive biopsy protocol, endoscopic therapies which may include endoscopic mucosal resection or an oesophagectomy for those who are deemed fit.</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-10-06 06:33:46 -0400" MODIFIED_BY="[Empty name]">
<P>A number of interventions for the treatment of Barrett's oesophagus have been investigated to date and new ones continue to emerge. It is important to assess the current state of the evidence before attempting novel therapies and before recommending these modalities in routine clinical practice.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-09-25 10:43:10 -0400" MODIFIED_BY="Karin L Dearness">
<P>To summarise, quantify and compare the efficacy of treatments to induce reversal of Barrett's oesophagus or dysplasia or to halt the progression to cancer. Three main groups of therapeutic interventions were considered.</P>
<OL>
<LI>Pharmacological treatments: H<SUB>2</SUB>-receptor antagonists, proton pump inhibitors, prokinetics and antacids, as well as chemopreventive agents such as NSAIDs, aspirin and COX-2 inhibitors.</LI>
<LI>Anti-reflux procedures. The surgical treatments have been compared with each other or with pharmacological treatment if these data are available.</LI>
<LI>Endoscopic ablative methods: thermal (argon plasma coagulation, multipolar electrocautery, laser therapy, cryotherapy and radiofrequency ablation), chemical (photodynamic therapy) and mechanical methods (endoscopic mucosal resection and ultrasonic surgical aspiration).</LI>
</OL>
<P>We reviewed these treatments either alone versus placebo or in combination versus placebo (or sham), or by direct comparison of two treatments. It was anticipated that there would be few randomised controlled trials (RCTs) such that comparison of treatments would be limited. The evidence from open non-randomised trials has necessarily formed a large part of the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-06-07 14:04:53 -0400" MODIFIED_BY="Karin Dearness">
<SELECTION_CRITERIA MODIFIED="2009-11-02 09:47:55 -0500" MODIFIED_BY="Karin L Dearness">
<CRIT_STUDIES MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised controlled trials in which one of the intervention types was compared with placebo or another intervention type. We considered studies in both abstract and peer reviewed format.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>Adults (age &gt; 18 years) of either gender in whom the diagnosis of Barrett's oesophagus has been established both endoscopically (any length of columnar appearing epithelium above the gastro-oesophageal junction) and confirmed histologically (usually intestinal metaplasia), regardless of the status of dysplasia.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-02 09:47:55 -0500" MODIFIED_BY="Karin L Dearness">
<OL>
<LI>Pharmacological therapy, either alone or in combination: any proton pump inhibitor, any H<SUB>2</SUB>RA, any prokinetic, any antacid, NSAIDs, selective or specific COX-2 inhibitor and any novel chemopreventative agents including retinoids and difluoromethylornithine (DFMO).</LI>
<LI>Anti-reflux surgery, in particular Nissen fundoplication.</LI>
<LI>Endoscopic therapies, either alone or in combination with (1) or (2):</LI>
<OL>
<LI>thermal methods: argon plasma photocoagulation, multipolar electrocautery, laser therapy, radiofrequency ablation and cryotherapy;</LI>
<LI>chemical methods: photodynamic therapy;</LI>
<LI>mechanical methods: endoscopic mucosal resection and ultrasonic surgical aspiration.</LI>
</OL>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-08-07 14:38:17 -0400" MODIFIED_BY="Karin L Dearness">
<OL>
<LI>Complete eradication of Barrett's oesophagus at 12 months.</LI>
<LI>Complete eradication of dysplasia at 12 months.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-08-27 16:07:42 -0400" MODIFIED_BY="Karin L Dearness">
<OL>
<LI>Reduction of (a) length or (b) area of Barrett's oesophagus at 12 months (where data at 12 months were not available then the nearest point in time was reported). The maximum Barrett's length was reported in most series discussing this outcome.</LI>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia.</LI>
<LI>Presence of buried sub-squamous Barrett's glands.</LI>
<LI>Adverse reactions.</LI>
<OL>
<LI>Mortality.</LI>
<LI>Serious adverse drug reaction, where serious represents a reaction requiring medical intervention.</LI>
<LI>Any complications.</LI>
</OL>
<LI>Control of acid reflux (only for acid suppression therapies and surgical anti-reflux therapies).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<ELECTRONIC_SEARCHES MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>We conducted searches to identify all published and unpublished randomised controlled trials. We included articles published in any language.</P>
<P>We identified trials by searching the following electronic databases:</P>
<UL>
<LI>the Cochrane Central register of Controlled Trials (CENTRAL) (which includes the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Trials Register) in <I>The Cochrane Library</I> (Issue 4, 2004);</LI>
<LI>MEDLINE (1966 to October 2003); and</LI>
<LI>EMBASE (1980 to October 2003).</LI>
</UL>
<P>The search was updated in October 2004, October 2005, August 2006 and June 2008.</P>
<P>The search strategy for this review was constructed by using a combination of MESH subject headings and text words relating to the use of pharmacological and endoscopic therapies and anti-reflux surgery used for the treatment of Barrett's oesophagus. To identify RCTs we combined the following search with the Cochrane highly sensitive search strategy phases, one, two and three as contained in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Details of the MEDLINE search strategy are provided in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We handsearched reference lists from trials selected by electronic searching to identify further relevant trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>We contacted members of the Cochrane UGPD Group, authors of papers and experts in the field and asked them to provide details of outstanding clinical trials and any relevant unpublished materials.</P>
<SUBSECTION>
<HEADING LEVEL="4">Abstracts</HEADING>
<P>We handsearched published abstracts from conference proceedings from the United European Gastroenterology Week (published in <I>Gut</I>), British Society of Gastroenterology Meeting (published in <I>Gut</I>) and Digestive Disease Week (published in <I>Gastroenterology</I>) for the period 1996 to 2008.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Correspondence</HEADING>
<P>We contacted the following experts in the field in relation to published and ongoing studies:</P>
<UL>
<LI>Dean Brenner, University of Michigan Medical Center, Ann Arbor, Michigan, USA;</LI>
<LI>Arlene Forastiere, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA;</LI>
<LI>Clive Kelty, Academic Surgical Oncology Unit, University of Sheffield, Sheffield, UK;</LI>
<LI>Marrku Luostarinen, Department of Surgery, Päijät-Häme Central Hospital, Lahti, Finland;</LI>
<LI>Frans Peters, University Hospital Groningen, Groningen, The Netherlands;</LI>
<LI>Stephen Sontag, VA Hines Hospital, Hines, Illinois, USA;</LI>
<LI>Stuart Jon Spechler, Division of Gastroenterology, VA Medical Centre, Dallas, TX, USA;</LI>
<LI>Nicholas Shaheen, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, NC, USA; and</LI>
<LI>Jacques Bergman, Department of Gastroenterology and Hepatology Academic Medical Centre Amsterdam, Academic Medical Center, Amsterdam.</LI>
</UL>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-06-07 14:04:53 -0400" MODIFIED_BY="Karin Dearness">
<STUDY_SELECTION MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>We reviewed titles and abstracts of studies identified through searches of electronic databases to determine whether they met the inclusion criteria. Two authors independently identified, read and reviewed titles and abstracts. We resolved uncertainties concerning the appropriateness of studies for inclusion in the review through consultation with a third author.</P>
</STUDY_SELECTION>
<QUALITY_ASSESSMENT MODIFIED="2011-06-07 14:04:53 -0400" MODIFIED_BY="Karin Dearness">
<P>The three authors independently assigned each selected study to one of four quality of randomisation categories, as guided by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The four quality of randomisation categories were:</P>
<OL>
<LI>Indicates adequate concealment of the allocation (for example, by telephone randomisation, or use of consecutively numbered, sealed, opaque envelopes);</LI>
<LI>Indicates uncertainty about whether the allocation was adequately concealed (for example, where the method of concealment is not known);</LI>
<LI>Indicates that the allocation was definitely not adequately concealed (for example, open random number lists or quasi-randomisation such as alternate days, odd/even date of birth, or hospital number).</LI>
<LI>Indicates randomisation was not used.</LI>
</OL>
<P>The authors also paid attention to the extent to which both participants and outcome assessors were blind to the allocation status of participants. This was done by rating as 'met' (low risk of bias), 'unmet' (high risk of bias), or 'unclear' (unclear risk of bias) these criteria as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Clarke-2001" TYPE="REFERENCE">Clarke 2001</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-09-25 10:53:13 -0400" MODIFIED_BY="Karin L Dearness">
<P>We entered all trials included in the systematic review into Review Manager 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). The impact of interventions for dichotomous data was expressed as odds ratios (OR) together with 95% confidence intervals (CI). For continuous data, we used the mean difference (MD), again with a 95% CI. We only attempted meta-analysis if there were sufficient trials of similar comparisons reporting the same outcomes. We assessed outcomes using a fixed-effect model, however where significant heterogeneity was detected then we also performed a random-effects assessment.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>We have reported the number of participants included in the final analysis as a proportion of all participants in each study where necessary. Reasons for missing data, if available, are provided in the narrative summary and the extent to which the results of the review could be altered by the missing data is commented upon where appropriate. For missing continuous data, a qualitative summary is provided. The standard deviations of the outcome measures are reported for each group in each trial. If these are not given, where possible the data were derived from other statistics given in the paper, for example from the CI. If this was not possible, we performed a secondary analysis if adequate data were available, with comment on the extent that the result was affected by different imputed values.</P>
</MISSING_DATA>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY_DESCRIPTION MODIFIED="2009-11-02 09:49:52 -0500" MODIFIED_BY="Karin L Dearness">
<SEARCH_RESULTS MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>We identified 2225 studies using the search strategy. We identified 157 of these as being directly relevant to the review and 20 were prospective randomised studies that had adequate randomisation and Barrett's oesophagus was defined as columnar lined oesophagus with intestinal metaplasia. Of these 20 studies, two abstracts (<LINK REF="REF-Luman-1995" TYPE="REFERENCE">Luman 1995</LINK>; <LINK REF="REF-Ortiz-1996" TYPE="REFERENCE">Ortiz 1996</LINK>) were excluded as they contained data that were also reported in more recent publications (<LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>; <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>, respectively). Two studies (<LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>; <LINK REF="REF-Overholt-2007" TYPE="REFERENCE">Overholt 2007</LINK>) were updates of previously published data (<LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK>; <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>) and therefore these were used to complement the original article since longer follow-up data were available.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-11-02 09:49:52 -0500" MODIFIED_BY="Karin L Dearness">
<SUBSECTION>
<HEADING LEVEL="4">Pharmacological therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. Anti-secretory proton pump inhibitor therapy versus H<SUB>2</SUB>RA</HEADING>
<P>
<LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK> performed a study on 106 individuals who were randomised to omeprazole 40 mg twice daily for one year followed by omeprazole 40 mg one daily for a year (n = 53) or ranitidine 150 mg for two years (n = 44) (97 completed six months and 76 the whole two-year study). pH monitoring was not performed and compliance to the drug regimen was not mentioned. The data were not published in full form and so care must be exercised when interpreting these data as no external peer review process has been undertaken.</P>
<P>The study by <LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK> also compared omeprazole 40 mg twice daily to ranitidine 150 mg twice daily. Sixty-one were randomised to omeprazole (n = 31) and ranitidine (n = 30). All patients were pH monitored and study medications were collected to assess compliance to the drug regimen. Fifty-three individuals completed the study at two years: 26/33 from the omeprazole group and 27/35 of the ranitidine group. Seven individuals withdrew from the omeprazole arm and eight from the ranitidine arm.</P>
<P>A smaller study by <LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>
<I>,</I> published in abstract form, randomised 28 individuals to omeprazole 20 mg one daily (n = 14) or Cimetidine 400 mg three times per day (n = 14). The participants were followed for two years and underwent three-monthly review. All patients were pH monitored and compliance to the drug regimen was not mentioned. Eight individuals were lost to follow up and therefore twenty completed the study; ten patients in each of the treatment arms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Selective COX-2 inhibitor versus placebo</HEADING>
<P>The study design and outcome measures were published first (<LINK REF="REF-Heath-2003" TYPE="REFERENCE">Heath 2003</LINK>) followed by the results four years later (<LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>). Barrett's oesophagus patients with either low- or high-grade dysplasia were recruited from eight clinical centres in the USA. One hundred patients were randomised to either 200 mg celecoxib (n = 49) or placebo (n = 51) twice daily for a minimum of one year and a maximum of two years. Data were recorded to assess compliance to the drug regimen. The interval between follow-up endoscopies depended on the grade of dysplasia: every three months for high-grade dysplasia and six months for low-grade dysplasia.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgical therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Nissen fundoplication combined with anti-secretory antacid therapy versus anti-secretory antacid therapy (proton pump inhibitor and H<SUB>2</SUB>RAs) alone</HEADING>
<P>The study by <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK> included individuals already described by <LINK REF="REF-Ortiz-1996" TYPE="REFERENCE">Ortiz 1996</LINK> and more patients were recruited between 1996 and 2000. One hundred and one patients were randomised to proton pump inhibitor plus H<SUB>2</SUB>RA (n = 43) and Nissen fundoplication plus proton pump inhibitor and H<SUB>2</SUB>RA<I>
<B> </B>
</I>(n = 58). All patients were pH monitored and compliance to the drug regimen was not mentioned. Patients in the proton pump inhibitor and H<SUB>2</SUB>RA<I> </I>group were initially treated with ranitidine 150 mg twice daily, which in 1992 was converted to omeprazole 20 mg twice daily. This may be a confounding factor as acid suppression is significantly more effective with omeprazole than ranitidine. Prior to 1997 only individuals with a segment more than 3 cm were included. It was unclear whether intestinal metaplasia was an inclusion criteria. After 1997, patients with Barrett's oesophagus &lt; 3 cm with intestinal metaplasia were also included, thus generating a varied patient group that may further confound the results. Fifty-six individuals in the surgical group had an open short Nissen fundoplication whilst the remaining two individuals had a Collis-Nissen procedure because they had a short oesophagus. Nine out of the 56 (16%) surgical patients with recurrent reflux as measured by pH monitoring were excluded since their surgery was unsuccessful.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Endoscopic therapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. Nd-YAG laser and omeprazole versus omeprazole</HEADING>
<P>The study by <LINK REF="REF-Luman-1995" TYPE="REFERENCE">Luman 1995</LINK> was published in abstract form and then published in full a year later (<LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>). Eight individuals with histologically proven Barrett's oesophagus containing intestinal metaplasia were recruited in a University Hospital setting in Scotland, UK. pH monitoring was not performed and compliance to the drug regimen was not mentioned. The data used were derived from the full publication. Patients were randomised to receive either omeprazole 40 mg one daily (n = 4) or omeprazole 40 mg one daily with Nd-YAG laser therapy at 25 W power in one second pulses up to a maximum dose of 1000 J for a maximum of three treatments (n = 4). Histological and endoscopic assessments were undertaken at four to six-weekly intervals for six months. No individuals were lost to follow up. This study is so small that it is difficult to interpret the findings of this work as there is a significant risk that these data are so limited that they may not adequately represent the efficacy of the intervention tested.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Argon plasma coagulation (APC) versus surveillance</HEADING>
<P>
<LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK> presents the data for the five-year follow-up data of the individuals presented in <LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK> and was therefore used for the analysis. The 40 patients who entered the study were randomised to receive either argon plasma coagulation at 60 W (n = 20) for a maximum of six sessions at four-weekly intervals or standard surveillance consisting of a repeat upper GI endoscopy at one year (n = 20). All of the study patients were asymptomatic and six had undergone pH monitoring which showed a median acid exposure of 0.4% of the 24-hour study period. One individual was lost to follow up at one year in the ablation group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. Argon plasma coagulation (APC) versus multipolar electrocoagulation (MPEC)</HEADING>
<P>
<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK> randomised 52 individuals to either argon plasma coagulation at 60 W continuous pulse using a 10F probe (n = 26) or multipolar electrocautery continuous pulse using a 10F probe and generator (n = 26). Four individuals were lost to follow up, two from each group.</P>
<P>
<LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK> randomised 35 patients according to their Barrett's oesophagus length (stratified randomisation) to receive either argon plasma coagulation (60 W, n = 19) or multipolar electrocautery (20 W, n = 16). Patients were all on rabeprazole (20 mg twice daily) for the purpose of the study and underwent 24-hour pH monitoring at least seven days after starting the course of proton pump inhibitor.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">d. Argon plasma coagulation (APC) with proton pump inhibitor (PPI) versus photodynamic therapy (PDT) with PPI</HEADING>
<P>
<LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK> randomised 40 patients with Barrett's oesophagus with intestinal metaplasia to one of three regimens:</P>
<UL>
<LI>60 mg/kg amunolevulinic acid (ALA) followed by photodynamic therapy 100 J/cm<SUP>2</SUP> with red light at four hours post 5-ALA administration (PDT100)(n = 13)</LI>
<LI>60 mg/kg ALA followed by photodynamic therapy 20 J/cm<SUP>2</SUP> and 100 J/cm<SUP>2</SUP> with red light at one and four hours post 5-ALA administration (PDT20+100)(n = 13)</LI>
</UL>
<P>The energy output for both photodynamic therapy regimes was 100 mW/cm<SUP>2</SUP>
</P>
<UL>
<LI>Argon plasma coagulation at 65 W, in two sessions ablating two-thirds of the Barrett's oesophagus at the first application and the remaining Barrett's oesophagus at the second application(n = 14).</LI>
</UL>
<P>One person died during the study from a presumed cardiac arrhythmia which was thought to be treatment-related since atrial fibrillation (AF) has been recognised as a possible complication of ALA administration (<LINK REF="REF-Overholt-1997" TYPE="REFERENCE">Overholt 1997</LINK>). Significant numbers of patients were lost to follow up as the time since treatment increased. By two years no individuals in the PDT100 group were being followed up. Only two out of 13 of the PDT20+100 group were followed up and none of the argon plasma coagulation group were followed up.</P>
<P>
<LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>
<I> </I>recruited 72 patients from a University Teaching Hospital in the United Kingdom. Sixty-eight patients with Barrett's oesophagus with intestinal metaplasia were included in the study. Individuals with low-grade dysplasia or high-grade dysplasia were excluded. Patients were randomised into two groups:</P>
<UL>
<LI>30 mg/kg ALA PDT followed by PDT 85 J/cm<SUP>2</SUP> with red light at four to six hours post ALA administration. Total energy output = 68 mW/cm<SUP>2</SUP>(n = 34).</LI>
<LI>Argon plasma coagulation at 65 W, ablating half of the Barrett's oesophagus segment at the first application and the remaining Barrett's oesophagus at subsequent treatments until complete ablation was achieved. A maximum of five treatments were undertaken(n = 34).</LI>
</UL>
<P>
<LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK> recruited 32 patients with dysplastic Barrett's oesophagus. No formal statistical comparison of the homogeneity of the two groups was shown. Individuals were randomised to receive treatment using one of the following two protocols:</P>
<UL>
<LI>Photodynamic therapy (n = 13): 2 mg/kg porfimer sodium was administered intravenously and after 48 hours photodynamic therapy was performed using 630 nm red laser light, with a power output of 840 mW delivering 200 J/cm, through an endoscopically inserted photodynamic therapy balloon at a single, one-off treatment sitting.</LI>
<LI>Argon plasma coagulation (n = 13) was undertaken at a power setting of 65 W with an argon gas flow of 1.8 l/min. Treatments were applied from the proximal gastric folds upwards with up to six treatment sessions. Follow up occurred at four and twelve months and quadrantic biopsies were taken at 1 cm intervals in the whole of the lower third of the oesophagus, including the Barrett's oesophagus segment at each follow-up time.</LI>
</UL>
<P>At 12 months four individuals had been lost from the argon plasma coagulation group, whereas no one from the photodynamic therapy group was lost to follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">e. Photodynamic therapy using 5-ALA or porfimer sodium with proton pump inhibitor (PPI) versus PPI alone</HEADING>
<P>
<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK> randomised 36 individuals with Barrett's oesophagus and low-grade dysplasia to receive either 5-ALA photodynamic therapy at 30 mg/kg using a 514 nm green laser (n = 16) or placebo (n = 16). Both groups received omeprazole. pH monitoring was not performed. Those who received photodynamic therapy were treated at a power density of 120 mW/cm<SUP>2</SUP>, for 500 seconds per 3 cm up to a maximum dosing time of 1000 seconds, i.e. treating a maximum of 6 cm at each visit.</P>
<P>
<LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK> randomised 208 patients in a 2:1 ratio to receive photodynamic therapy with porfimer sodium (2 mg/kg) and omeprazole 40 mg/day (n = 138) or omeprazole alone (40 mg /day) (n = 70). pH monitoring was not performed and compliance to the drug regimen was not mentioned. One hundred and thirty-two patients received at least one course of photodynamic therapy. Those who received photodynamic therapy were treated with 630 nm red laser light given at a 130 J/cm. Additionally, focal treatment of nodular areas was undertaken using a short (2.5 cm) bare fibre. Up to 7 cm of Barrett's oesophagus mucosa was treated at the first endoscopy. Patients underwent a further endoscopy at four to five days and any untreated Barrett's oesophagus mucosa was exposed to a further 50 J/cm using a 2.5 cm bare fibre. Photodynamic therapy was undertaken up to a maximum of three times. At two years 78/132 (59%) individuals from the photodynamic therapy group remained in the study whilst 26/69 (38%) of individuals treated with omeprazole remained in the study. <LINK REF="REF-Overholt-2007" TYPE="REFERENCE">Overholt 2007</LINK> presents the five-year follow up of these patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">f. Photodynamic therapy using 5-ALA versus porfimer sodium</HEADING>
<P>
<LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK> randomised 32 patients, stratified per length of segment, to 5-ALA (n = 16) or porfimer sodium (n = 16).The authors stated that they used the standard protocol (no more details) and 60 mg/kg 5-ALA, activated by 1178 J/cm of red laser light. Patients were then followed up with quadrantic biopsies every 2 cm at six weeks, four months and one year post-therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">g. Radiofrequency ablation (RFA) versus sham</HEADING>
<P>
<LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK> randomised 127 patients in a 2:1 to radiofrequency ablation or sham. Patients were also stratified according to their dysplasia status (low- or high-grade dysplasia) and the length of their Barrett's oesophagus segment. Patients underwent a maximum of four sessions of radiofrequency ablation using the HALO system. Patients in the ablation group were treated up to four times at baseline, two, four and nine months. Follow up biopsies were collected at six and 12 months for low-grade dysplasia and at three, six, nine and 12 months for high-grade dysplasia.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-02 09:48:38 -0500" MODIFIED_BY="Karin L Dearness">
<P>Three authors undertook an assessment of the quality of each eligible study independently and any disagreement was resolved independently by the senior author. We assessed methods of randomisation, concealment, blinding and follow up. A summary of the risk of bias is presented in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2009-08-27 09:45:38 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Twelve trials stated the method of randomisation (<LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>; <LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>; <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>; <LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>; <LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>; <LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>; <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>; <LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>; <LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK>; <LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>; <LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>; <LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK>) whilst four did not (<LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>; <LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>; <LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK>; <LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>).</P>
<P>Only <LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK> and <LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK> indicated that the treatment performed was concealed from the investigators and the patients. The other studies included in this review did not state whether any concealment was undertaken.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-08-27 09:47:00 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Ten studies did not give any indication whether blinding was used with respect to the treatments undertaken (<LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>; <LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>; <LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>; <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>; <LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>; <LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>; <LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>; <LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>; <LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK>; <LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>; <LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK>; <LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK>). Two studies were double blinded (<LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>; <LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>). <LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK> used the double dummy technique. <LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK> and <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK> blinded the interpreting pathologist to the intervention undertaken.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-11-02 09:48:38 -0500" MODIFIED_BY="Karin L Dearness">
<SUBSECTION>
<HEADING LEVEL="4">Statistical power</HEADING>
<P>Power calculations were performed for the studies undertaken by <LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>, <LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK>, <LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>, <LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>, <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>, <LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>, <LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK> and <LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow up</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Pharmacological therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Anti-secretory proton pump inhibitor therapy versus H<SUB>2</SUB>RA</HEADING>
<P>
<LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>: No information was provided as to why some individuals left the study and which statistical method was used to take this into account.</P>
<P>
<LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>: During data interpretation a per protocol analysis was undertaken in this study but it is unclear whether data were actually collected from those who left the study. In addition, the actual method used to handle the missing data within the intention-to-treat analysis is not described.</P>
<P>
<LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>: No information was provided as to why some individuals left the study and which statistical method was used to take this into account.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Selective COX-2 inhibitor versus placebo</HEADING>
<P>
<LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>: The results were presented on an intention-to-treat principle therefore all randomised patients were included in the statistical analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Surgical therapies</HEADING>
<P>Nissen fundoplication Short Collis gastroplasty combined with anti-secretory antacid therapy versus anti-secretory antacid therapy (proton pump inhibitor and H<SUB>2</SUB>RAs) alone.</P>
<P>
<LINK REF="REF-Ortiz-1996" TYPE="REFERENCE">Ortiz 1996</LINK>; <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>: The numbers of individuals leaving the study and the reasons for individuals leaving the study were not given, furthermore how the individuals leaving the study were handled statistically was not described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Endoscopic therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Nd-YAG laser and omeprazole versus omeprazole</HEADING>
<P>
<LINK REF="REF-Luman-1995" TYPE="REFERENCE">Luman 1995</LINK>; <LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>: No individuals were lost to follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Argon plasma coagulation (APC) versus surveillance</HEADING>
<P>
<LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK>: How the data from individuals lost to follow up were handled is not stated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. Argon plasma coagulation (APC) versus multipolar electrocoagulation (MPEC)</HEADING>
<P>
<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>: Individuals who were lost to follow up were handled using an intention-to-treat approach and those who left the study continued to be followed up. However the actual method used to handle the missing data within the intention-to-treat analysis is not described</P>
<P>
<LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK>: No individuals were lost to follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d. Argon plasma coagulation (APC) with proton pump inhibitor (PPI) versus photodynamic therapy (PDT) with PPI</HEADING>
<P>
<LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>: Significant numbers of patients were lost in the later period of follow up (34% and 90% lost at 18 months and 24 months respectively). No information was provided on the statistical method used to take into account individuals who dropped out of the study, nor was the reason for individuals leaving the study given.</P>
<P>
<LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>: No individuals were lost to follow up.</P>
<P>
<LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>: No information was provided on the statistical method used to take into account individuals who dropped out of the study nor was the reason for those individuals leaving the study given.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">e. Photodynamic therapy using 5-ALA or porfimer sodium with proton pump inhibitor (PPI) versus PPI alone</HEADING>
<P>
<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>: No individuals were lost to follow up.</P>
<P>
<LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>; <LINK REF="REF-Overholt-2007" TYPE="REFERENCE">Overholt 2007</LINK>: An intention-to-treat analysis was undertaken and for those patients lost to follow up survival data was censored within the Kaplan Meier analysis; however the actual method used to handle the missing data within the intention-to-treat analysis is not described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">f. Photodynamic therapy using 5-ALA versus porfimer sodium</HEADING>
<P>
<LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK>: No individuals were lost to follow up</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">g. Radiofrequency ablation (RFA) versus sham</HEADING>
<P>
<LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK>: Individuals who were lost to follow up were handled using an intention-to-treat approach and those who left the study continued to be followed up. However the actual method used to handle the missing data within the intention-to-treat analysis is not described.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin L Dearness">
<P>Sixteen RCTs were included in the review (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). The studies compared:</P>
<OL>
<LI>Pharmacological therapies</LI>
<OL>
<LI>Anti-secretory proton pump inhibitor therapy versus H<SUB>2</SUB>RA (<LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>; <LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>; <LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>)</LI>
<LI>Selective COX-2 inhibitor versus placebo (<LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>)</LI>
</OL>
<LI>Short Collis gastroplasty combined with anti-secretory antacid therapy versus anti-secretory antacid therapy (proton pump inhibitor and H<SUB>2</SUB>RAs) (<LINK REF="REF-Ortiz-1996" TYPE="REFERENCE">Ortiz 1996</LINK>; <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>)</LI>
<LI>Endoscopic therapies</LI>
<OL>
<LI>Nd-YAG laser and omeprazole versus omeprazole (<LINK REF="REF-Luman-1995" TYPE="REFERENCE">Luman 1995</LINK>; <LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>)</LI>
<LI>Argon plasma coagulation versus surveillance (<LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK>; <LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>)</LI>
<LI>Argon plasma coagulation versus multipolar electrocoagulation (MPEC) (<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>; <LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK>)</LI>
<LI>Argon plasma coagulation with proton pump inhibitor (PPI) versus photodynamic therapy (PDT) with PPI (<LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>; <LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>; <LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>)</LI>
<LI>Photodynamic therapy using 5-ALA (<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>) or porfimer sodium (<LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>; <LINK REF="REF-Overholt-2007" TYPE="REFERENCE">Overholt 2007</LINK>) with proton pump inhibitor (PPI) versus PPI alone</LI>
<LI>Photodynamic therapy using 5-ALA versus porfimer sodium (<LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK>)</LI>
<LI>Radiofrequency ablation (RFA) versus sham (<LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK>)</LI>
</OL>
</OL>
<SUBSECTION>
<HEADING LEVEL="3">1. Pharmacological therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">a. Anti-secretory proton pump inhibitor therapy versus H<SUB>2</SUB>RA</HEADING>
<P>There were three studies that compared two years treatment with proton pump inhibitor versus two years with H<SUB>2</SUB> antagonist (<LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>; <LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>; <LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>). These studies<B> </B>assessed the regression of Barrett's oesophagus (dysplasia status was not given) in terms of change in length, change in area and the development of squamous islands.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: none of the studies reported on this outcome.</LI>
<LI>Complete eradication of dysplasia at 12 months: none of the studies reported on this outcome.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point:<B> </B>none of the studies reported on this outcome.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of length of Barrett's oesophagus segment at 12 months: no overall trend was detected (mean difference (MD) (fixed-effect model) -0.42 cm; 95% CI -1.65 cm to 0.82 cm; Z = 0.31, P = 0.76). Similar results were found using the random-effects model. However, significant heterogeneity was detected (Chi² statistic = 5.35, I² statistic = 62.6%) indicating that care should be exercised when interpreting these data. If a subgroup analysis is undertaken, including the two studies that used omeprazole at a higher dose only (<LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>; <LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>) again no trend is detected (MD (fixed-effect model) -0.81; 95% CI -2.13 to 0.50; Z = 1.21, P = 0.23) and heterogeneity still persists (Chi² statistic = 2.52, P = 0.11, I² statistic = 0.604; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</LI>
<LI>Reduction of area of Barrett's oesophagus segment at 12 months: a reduction in the overall area of Barrett's oesophagus was detected with omeprazole (MD 4.06; 95% CI 0.08 to 8.04) with no heterogeneity detected between studies (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</LI>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: none of the studies reported on this outcome.</LI>
<LI>Presence of buried sub -squamous Barrett's glands: none of the studies reported on this outcome.</LI>
<LI>Adverse reactions.</LI>
<UL>
<LI>Mortality: no data available.</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: no data available.</LI>
<LI>Any complications: no data available.</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): no data available</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">b. Selective COX-2 inhibitor versus placebo</HEADING>
<P>One study compared 48 weeks of treatment with celecoxib versus 48 weeks with placebo (<LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>). This study assessed the safety and efficacy of celecoxib for regression of dysplasia in Barrett's oesophagus. The data in this publication were not presented in a format allowing easy extraction of patient numbers. The statistical results given are those reported by the authors, not using the data from the Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) unless stated otherwise.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: no data available</LI>
<LI>Complete eradication of dysplasia at 12 months: no statistical difference between the celecoxib and placebo groups.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point:<B> </B>no statistical difference (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) in the numbers of patients progressing to adenocarcinoma in the celecoxib (3/49) and placebo (3/51) groups was reported at one year. All six patients who progressed to adenocarcinoma had a baseline diagnosis of high-grade dysplasia.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: no data available;</LI>
<LI>area of Barrett's oesophagus segment at 12 months: the authors did not report any statistical difference in area between baseline and one year when comparing the two groups.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: the authors did not report any statistical difference in progression to dysplasia between baseline and one year when comparing the two groups.</LI>
<LI>Presence of buried sub-squamous Barrett's glands: no data available.</LI>
<LI>Adverse reactions.</LI>
<UL>
<LI>Mortality: two patient deaths were reported. They were not related to the trial.</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: no statistical difference in the numbers of patients presenting with trial related serious drug reactions between the two groups (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>).</LI>
<LI>Any complications: no statistical difference in the numbers of patients presenting with bleeding between the two groups (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>).</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): no data available.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Surgical therapies: Nissen Fundoplication versus PPI</HEADING>
<P>Two studies compared H&#8322; antagonist which was then converted to proton pump inhibitor versus Nissen fundoplication (<LINK REF="REF-Ortiz-1996" TYPE="REFERENCE">Ortiz 1996</LINK>; <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>). These two studies compared the results of medical treatment and anti-reflux surgery in patients with Barrett's oesophagus by clinical, endoscopic, histological and functional assessment. The report of Parilla<I> </I>et al includes all those individuals described by <LINK REF="REF-Ortiz-1996" TYPE="REFERENCE">Ortiz 1996</LINK> and includes data from an additional 42 individuals. The latest data reported by Parilla et al are therefore described.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: no data available at 12 months but no complete eradication was reported at five years for either treatment.</LI>
<LI>Complete eradication of dysplasia at 12 months: no data available at 12 months but no statistical difference was seen in the eradication of dysplasia at five years: 3/43 patients on proton pump inhibitor and 5/58 patients who underwent surgery (5/49 if only patients with successful surgery were considered).</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: there was no statistical difference in the numbers of patients progressing to cancer between the two groups: 1 in 129 patient-years of follow up for patients on proton pump inhibitor compared to 1 in 203 patient-years of follow up for patients who underwent surgery.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome</HEADING>
<UL>
<LI>Reduction of:</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: no data at 12 months. The authors did not report any statistical differences in the length of the Barrett's oesophagus segment between the two groups at five years.</LI>
<LI>area of Barrett's oesophagus segment at 12 months: no data available.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: no data at 12 months. There was a reduction in the number of patients developing <I>de novo </I>dysplasia in the surgery group compared to the proton pump inhibitor group (3/58 versus 8/43) (odds ratio (OR) 0.22; 95% CI 0.05 to 0.88; Z = 2.14, P = 0.03).</LI>
<LI>Presence of buried sub-squamous Barrett's glands: no data available.</LI>
<LI>Adverse reactions.</LI>
<UL>
<LI>Mortality: no death was reported in any group.</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: no adverse reactions to proton pump inhibitor were reported.</LI>
<LI>Any complications: one patient in the surgery group underwent splenectomy.</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): the authors did not report any statistical differences in the control of acid reflux as measured by 24-hour pH monitoring between the two groups at five years.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Endoscopic therapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">a. Nd-YAG laser and omeprazole versus omeprazole</HEADING>
<P>
<LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK> assessed whether Nd-YAG photocoagulation with proton pump inhibitor therapy was more effective than proton pump inhibitor therapy alone in the ablation of non-dysplastic Barrett's oesophagus<B>. </B>
</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: no data available.</LI>
<LI>Complete eradication of dysplasia at 12 months: no data available.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: no data available.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of:</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: this study did not identify any regression in either treatment group.</LI>
<LI>area of Barrett's oesophagus segment at 12 months: no data available.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: no data available.</LI>
<LI>Presence of buried sub-squamous Barrett's glands: buried glands were not found in any patients.</LI>
<LI>Adverse reactions.</LI>
<UL>
<LI>Mortality: No data available.</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: no data available.</LI>
<LI>Any complications: no data available.</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): no data available.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">b. Argon plasma coagulation (APC) versus surveillance</HEADING>
<P>Two prospective randomised controlled trials compared argon plasma coagulation ablation with endoscopic surveillance of patients with Barrett's oesophagus after anti-reflux surgery (<LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK>; data updated in <LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>). These studies aimed to evaluate the safety and efficacy of argon plasma coagulation ablation of Barrett's oesophagus in patients who had previously undergone surgical fundoplication.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: complete reversal of the Barrett's oesophagus segment was seen in 11/19 patients treated with argon plasma coagulation compared to 3/20 who had surveillance alone(OR 91.46; 95% CI 4.77 to 1754.50; Z = 3.00, P = 0.003). The data need to be interpreted with caution because of the wide confidence interval.</LI>
<LI>Complete eradication of dysplasia at 12 months: only two patients had dysplasia at initial endoscopy.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: none of the patients progressed to adenocarcinoma.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of:</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: the number of patients with reduction in their segment length was not reported; however the segment length was reduced from a median of 4.0 (range 3 to 8) to 0 (0 to 3) in the argon plasma coagulation group and from 4.0 (2 to 19) to 2.0 (0 to 13) in the surveillance group. The authors reported a P value of 0.0001 using a Mann-Whitney test.</LI>
<LI>area of Barrett's oesophagus segment at 12 months: no data available.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: at five years, 0/19 patients from the argon plasma coagulation group and 2/20 from the surveillance group progressed to dysplasia (not statistically significant).</LI>
<LI>Presence of buried sub-squamous Barrett's glands: at one year there was no statistically significant difference between the two groups (OR 3.51; 95% CI 0.13 to 91.87; Z = 0.75, P = 0.45).</LI>
<LI>Adverse reactions.</LI>
<UL>
<LI>Mortality: no mortality reported.</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: no data available.</LI>
<LI>Any complications: 2/19 patients in the argon plasma coagulation arm developed strictures between two and five years follow up.</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): not applicable.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">c. Argon plasma coagulation (APC) with PPI versus multipolar electrocoagulation (MPEC) with PPI</HEADING>
<P>
<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK> compared the efficacy of argon plasma coagulation and multipolar electrocautery in the ablation of Barrett's oesophagus or Barrett's oesophagus with low-grade dysplasia and assessment of whether argon plasma coagulation required fewer treatments than multipolar electrocautery. <LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK> compared argon plasma coagulation and multipolar electrocautery in reversing Barrett's oesophagus and assessed factors influencing successful ablation.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: no data available at 12 months. Dulai (<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>) reported complete eradication of Barrett's oesophagus in 88% and 81% of patients treated with argon plasma coagulation and multipolar electrocautery respectively but the length of follow up was not clearly indicated. However, Sharma et al reported lower rates of 63% and 75% for argon plasma coagulation and multipolar electrocautery respectively after two years.</LI>
<LI>Complete eradication of dysplasia at 12 months: no data available.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: no data available.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of:</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: no data available;</LI>
<LI>area of Barrett's oesophagus segment at 12 months: no data available.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: no data available.</LI>
</UL>
<UL>
<LI>Presence of buried sub-squamous Barrett's glands: only <LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK> reported on this outcome and no patients were reported to have buried glands <I>per se</I>.</LI>
<LI>Adverse reactions.</LI>
<LI>Mortality: no deaths related to the treatments were reported in these studies.</LI>
<UL>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention.</LI>
<UL>
<LI>Any complications consisting of bleeding, infection oesophageal stricture: no statistical differences between the argon plasma coagulation and multipolar electrocautery group were identified in a number of complications (pain, fever and strictures).</LI>
</UL>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): not applicable.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">d. Argon plasma coagulation (APC) with proton pump inhibitor (PPI) versus photodynamic therapy (PDT)</HEADING>
<P>Comparison of 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation (APC) with proton pump inhibitor in the treatment of Barrett's oesophagus (<LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>; <LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>).</P>
<P>Porfimer sodium photodynamic therapy versus argon plasma coagulation<B> </B>(<LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>). This study aimed to compare argon plasma coagulation and porfimer sodium photodynamic therapy in their efficacy and cost-effectiveness in ablating dysplastic Barrett's oesophagus.</P>
<P>When reviewing the results of these studies it should be noted that Hage, Kelty and Ragunath each differed markedly in their drug dosing and light delivery regimes.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: complete eradication of Barrett's oesophagus at 12 months was assessed by all three studies. There was no statistical differences in the eradication of Barrett's oesophagus between argon plasma coagulation and photodynamic therapy (OR 0.31; 95% CI 0.00 to 32.6; Z = 2.61, P = 0.62). The data however are heterogeneous (Chi² statistic = 11.75, P = 0.0006, I² statistic = 91.5%). These three studies comparing photodynamic therapy with argon plasma coagulation had different intended outcome measures. When this outcome is considered Hage showed argon plasma coagulation to be more effective for the complete ablation of Barrett's oesophagus (OR 3.00; 95% CI 0.54 to 16.64), whilst in contrast Ragunath<I> </I>was not able to demonstrate any difference between argon plasma coagulation and photodynamic therapy and furthermore no individual within Ragunath's study had complete eradication of Barrett's oesophagus. In contrast Kelty demonstrated more individuals having complete eradication of Barrett's oesophagus at 12 months after treatment with photodynamic therapy (OR 0.03; 95% CI 0.00 to 0.25). This significant heterogeneity may have arisen from the markedly different photodynamic therapy regimes employed.</LI>
<LI>Complete eradication of dysplasia at 12 months: this outcome was only reported by <LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>. There was no statistical difference in the eradication of dysplasia between argon plasma coagulation treated (6/9) and photodynamic therapy treated (10/13) patients.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: none of the trials reported data on progression to cancer at the latest time point.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of:</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: reduction in length of Barrett's oesophagus at 12 months was only reported by Ragunath and no statistically significant difference was detected between the two treatment groups (MD (fixed-effect model) -0.91 cm; 95% CI -2.10 cm to 0.28 cm; Z = 1.51, P = 0.13);</LI>
<LI>area of Barrett's oesophagus segment at 12 months: no data available.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: no data available.</LI>
<LI>Presence of buried sub-squamous Barrett's glands: reported by two studies (<LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>; <LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>) and no overall trend is detected using a fixed-effect model (Z = 0.79, P = 0.43). Similar results were identified using the random-effects model. Kelty and Hage demonstrated that buried glands occur. However, Kelty was not able demonstrate a difference in their frequency between individuals treated with photodynamic therapy versus those treated with argon plasma coagulation; whilst Hage suggested that argon plasma coagulation treatment might result in more buried glands. Overall the data are again heterogeneous and no conclusion can be reached.</LI>
<LI>Adverse reactions</LI>
<UL>
<LI>Mortality: no difference in mortality was detected between the two treatments (Z = 0.32, P = 0.75).</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: unsurprisingly only individuals receiving photodynamic therapy experienced drug reaction (OR 31.48; 95% CI 4.04 to 245.12; Z = 3.29, P = 0.0001). Disparate results were obtained for side effect symptoms.</LI>
<LI>Any complications: significant heterogeneity was demonstrated in the reporting of both "pain in general" and odynophagia perhaps due to the subjective nature of the symptoms and the lack of use of a validated tool in these studies to assess pain. Fever tended to be more frequent in individuals receiving photodynamic therapy, although the OR was 1.88 (95% CI 0.47 to 7.44) with Z = 0.90 and P = 0.37. Nausea and vomiting were much more frequently identified in individuals receiving photodynamic therapy; a previously recognised complication of the photosensitising agents(OR 19.64; 95% CI 2.51 to 153.78; Z = 2.92, P = 0.005). Finally, there was no significant difference in the frequency of strictures in the two groups nor photosensitivity although data were solely available on this final outcome from Ragunath's work which included only 13 patients in each treatment group.</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): no data available.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">e. Photodynamic therapy using 5-ALA or porfimer sodium with proton pump inhibitor (PPI) versus PPI alone</HEADING>
<P>
<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK> conducted a prospective, double blind, randomised, placebo controlled trial of photodynamic therapy for dysplastic Barrett's oesophagus and <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK> conducted an international, partially blinded, randomised phase III trial of photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's oesophagus. These studies aimed to assess the potential use of photodynamic therapy in the ablation of Barrett's oesophagus<B> </B>(<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>) and to examine the impact of porfimer sodium based photodynamic therapy for ablating high-grade dysplasia and reducing the incidence of oesophageal adenocarcinoma (<LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK> reported a statistically significant trend for a complete eradication of the Barrett's segment over the course of the study (two years) (OR 14.18; 95% CI 5.38 to 37.37; Z = 5.36, P &lt; 0.00001).</LI>
<LI>Complete eradication of dysplasia at 12 months: no data available at 12 months but both studies reported data at two years and more eradication occurred following photodynamic therapy than proton pump inhibitor (OR 9.13; 95% CI 4.42 to 18.86; Z = 5.98, P &lt; 0.0001).</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: data from <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK> suggest a statistically significant trend that photodynamic therapy reduced the likelihood of progression to cancer (OR 0.38; 95% CI 0.18 to 0.77; Z = 2.68, P = 0.007).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of length and area of Barrett's oesophagus segment at 12 months: data were available from <LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK> on reduction in length and area of Barrett's oesophagus at 12 months, which indicates a significant trend to reduction in length (cm) (MD (fixed-effect model) 1.0 cm; 95% CI 0.41 cm to 1.59 cm; Z = 3.34, P = 0.0008) and % area (MD (fixed-effect) 30.00; 95% CI 20.53 to 39.47; Z = 6.21, P = 0.00001).</LI>
</UL>
<UL>
<LI>Reduction in number of patients progressing from intestinal metaplasia to dysplasia: only <LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK> reported on the number of patients progressing from intestinal metaplasia to dysplasia and these data suggest a statistically significant trend for the reduction in progression to dysplasia after photodynamic therapy when compared to omeprazole treatment alone (OR 0.01; 95% CI 0.00 to 0.27; Z = 2.82, P = 0.005).</LI>
<LI>Presence of buried sub-squamous Barrett's glands: no data available.</LI>
<LI>Adverse reactions.</LI>
<UL>
<LI>Mortality: both studies reported data on mortality and no differences were seen between the patient groups (Z = 0.01, P = 0.99).</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: no data available.</LI>
<LI>Any complications: unsurprisingly, both studies reported on the occurrence of photosensitivity in the photodynamic therapy group (OR 372.83; 95% CI 29.17 to 4765.01; Z = 7.11, P &lt; 0.0001). Higher stricture rates (OR 77.98; 95% CI 4.73 to 1286.52; Z = 3.05, P = 0.002) and fever (OR 36.37; 95% CI 2.19 to 605.21; Z = 2.5, P = 0.01) were reported by <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK> (<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK> did not report on these outcomes).</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): data not available.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">f. Photodynamic therapy using 5-ALA versus porfimer sodium</HEADING>
<P>
<LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK> studied photodynamic therapy for high-grade dysplasia in Barrett's oesophagus where patients were stratified per length of segment prior to randomisation to 5-ALA (n = 16) or porfimer sodium (n = 16). The study aimed at assessing the safety and efficacy of 5-ALA versus porfimer sodium photodynamic therapy. All patients had a six-month follow up and half had 12-month follow up.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: data not available.</LI>
<LI>Complete eradication of dysplasia at 12 months: no data available at 12 months. The authors reported on the complete eradication of high-grade dysplasia in 14/14 patients treated with 5-ALA and 9/14 with porfimer sodium. This did not reach statistical significance.</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: data not available.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: data not available;</LI>
<LI>area of Barrett's oesophagus segment at 12 months: data not available.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: data not available.</LI>
<LI>Presence of buried sub-squamous Barrett's glands: data not available.</LI>
<LI>Adverse reactions</LI>
<UL>
<LI>Mortality: data not available.</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: none were reported.</LI>
<LI>Any complications: more strictures were seen in the porfimer sodium group (6/16) than in the 5-ALA group (1/16). This did not reach statistical significance.</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): data not available.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">g. Radiofrequency ablation versus sham</HEADING>
<P>
<LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK> compared radiofrequency ablation with sham in a randomised 2:1 controlled trial. This study aimed to compare the efficacy of radiofrequency ablation for dysplastic Barrett's oesophagus (low- or high-grade dysplasia) with a sham intervention. For all patients this was followed by an extensive surveillance protocol and high dose proton pump inhibitor. All data were presented as an intention-to-treat analysis.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<UL>
<LI>Complete eradication of Barrett's oesophagus at 12 months: radiofrequency ablation induced a reversal of Barrett's oesophagus in 74% of patients (n = 65/84) compared with 0% of patients in the sham group (0/43)(OR 143.64; 95% CI 18.53 to 1113.87; Z = 4.75, P &lt; 0.00001).</LI>
<LI>Complete eradication of dysplasia at 12 months: dysplasia was successfully eradicated in 86% of patients treated with radiofrequency ablation (72/84) and 21% of sham treated patients (9/43) (OR 22.67; 95% CI 8.72 to 58.94; Z = 6.4, P &lt; 0.00001).</LI>
<LI>Reduction in the number of patients progressing to cancer at five years or latest time point: during the year of follow up, 1/84 of the radiofrequency ablation treated patients and 4/43 of the sham treated patients progressed from high-grade dysplasia to adenocarcinoma, but this did not reach statistical significance (P = 0.06).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcome</HEADING>
<UL>
<LI>Reduction of:</LI>
<UL>
<LI>length of Barrett's oesophagus segment at 12 months: data not available;</LI>
<LI>area of Barrett's oesophagus segment at 12 months: data not available.</LI>
</UL>
<LI>Reduction in the number of patients progressing from intestinal metaplasia to dysplasia: no data available for this outcome measure but a reduction of progression to higher grades of dysplasia was reported with the radiofrequency ablation treatment (OR 0.19; 95% CI 0.05 to 0.78; Z = 2.31, P = 0.02).</LI>
<LI>Presence of buried sub-squamous Barrett's glands: data could not be extracted.</LI>
<LI>Adverse reactions</LI>
<UL>
<LI>Mortality: no deaths were reported.</LI>
<LI>Serious adverse drug reaction where serious represents a reaction requiring medical intervention: none were reported.</LI>
<LI>Any complications: there was one episode of upper gastrointestinal haemorrhage in a patient receiving anti-platelets therapy for heart disease. Two patients were admitted for overnight observation; one eight days after treatment for chest pain and one on the day of treatment for chest pain and nausea. The rate of complication did not reach statistical significance when compared to sham. A low rate of stricture rates (5/84 treated versus 0/43 sham) resolved after a mean of 2.6 dilatation sessions, chest pain and gastrointestinal bleed were reported and none were statistically higher in radiofrequency ablation compared to sham.</LI>
</UL>
<LI>Control of acid reflux (only for acid suppression therapies): data not available.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin Dearness">
<P>Despite the number of techniques available for the treatment of Barrett's oesophagus only 15 randomised controlled trials (RCTs) have been undertaken in the last 13 years. These trials compared various combinations of techniques and various doses (drugs and laser energy) of treatments and thus only limited comparisons were possible. Part of the reason for the lack of RCTs is likely to be the rapid development of new endoscopic techniques during this time, which are often costly and require specialised equipment and skills which limits their widespread availability.</P>
<SUBSECTION>
<HEADING LEVEL="2">1. Pharmacological therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">a. Proton pump inhibitors</HEADING>
<P>Three trials comparing H<SUB>2</SUB> receptor and proton pump inhibitor therapy have been undertaken (<LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>; <LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>; <LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>). When data from these studies were combined, accepting that there were missing data points, omeprazole was shown to have a significant effect to 
the overall change in length or area of Barrett's oesophagus. The number of squamous islands could not be compared as the available data were not in a format compatible with a meta-analysis. 
There was a  reduction in area of Barrett's oesophagus. 


This is contrary

to
 a number of early non-randomised studies which suggested that aggressive acid suppression did not cause clinically significant regression of Barrett's oesophagus (<LINK REF="REF-Sharma-1997" TYPE="REFERENCE">Sharma 1997</LINK>; <LINK REF="REF-Cooper-1998" TYPE="REFERENCE">Cooper 1998</LINK>). However, such data must be viewed with caution because of the subjective nature of the endoscopic assessment of these parameters. It has been demonstrated, even with the same endoscopist using a fixed landmark approach to assess the length and area of Barrett's oesophagus, that only changes in length of greater that 1.6 cm can be considered as true regression or progression (<LINK REF="REF-Dekel-2003" TYPE="REFERENCE">Dekel 2003</LINK>). However, it is possible that this variation in measurement could be avoided by using computerised analysis of digital images (<LINK REF="REF-Kim-1995" TYPE="REFERENCE">Kim 1995</LINK>).</P>
<P>Unfortunately none the RCTs included in this review, nor other RCTs of proton pump inhibitor therapy whose primary outcome was the assessment of gastro-oesophageal reflux disease (GORD), give us any information on the effect of proton pump inhibitors on the risk of developing dysplasia or adenocarcinoma. Two recent longitudinal cohort studies with larger numbers of individuals with Barrett's oesophagus (n = 236 to 350) and longer follow up (~5 years) have suggested that proton pump inhibitor therapy may be associated with a decreased risk of dysplasia within the Barrett's epithelial segment (<LINK REF="REF-El_x002d_Serag-2004" TYPE="REFERENCE">El-Serag 2004</LINK>; <LINK REF="REF-Hillman-2004" TYPE="REFERENCE">Hillman 2004</LINK>).The AspECT trial may help us understand the role of proton pump inhibitors in the prevention of adenocarcinoma in Barrett's oesophagus. The National Institute of Health and Clinical Excellence (NICE), an independent Governmental body giving recommendations on the efficacy and cost-effectiveness of treatments in the UK, recommends that patients with reflux oesophagitis or Barrett's oesophagus should receive proton pump inhibitor at a dose required to control symptoms (<LINK REF="REF-NICE-2005" TYPE="REFERENCE">NICE 2005</LINK>). Although proton pump inhibitors are usually successful in relieving patient's symptoms and preventing GORD complications, such as oesophagitis and stricture formation (<LINK REF="REF-Havelund-1988" TYPE="REFERENCE">Havelund 1988</LINK>), they are associated with hypergastrinaemia. There has been concern that hypergastrinaemia may increase the risk of Barrett's oesophagus progression or adenocarcinoma development (<LINK REF="REF-Harris-2004" TYPE="REFERENCE">Harris 2004</LINK>) and some parties have suggested that surgical anti-reflux procedures may be a better alternative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">b. NSAIDs and COX-2 inhibitors</HEADING>
<P>A meta-analysis of observational human studies demonstrated a 33% reduction in the odds ratio of developing oesophageal adenocarcinoma for patients using aspirin and/or NSAIDs (OR 0.67). There was also evidence for a dose effect with greater reduction of the odds ratio of progression with increasing doses of NSAIDs and aspirin; however the data were presented in a combined form for any squamous carcinoma and adenocarcinomas (<LINK REF="REF-Corley-2003" TYPE="REFERENCE">Corley 2003</LINK>). Data from a prospective study demonstrated a lower five-year cumulative cancer incidence of 6.6% for current NSAID users, 9.7% for previous users and 14.3% for non-users. The frequency and duration of usage did not impact on the risk of oesophageal cancer development (<LINK REF="REF-Vaughan-2005" TYPE="REFERENCE">Vaughan 2005</LINK>). Some experimental evidence also exists for the protective effect of aspirin in oesophageal adenocarcinoma (<LINK REF="REF-Sturmer-1998" TYPE="REFERENCE">Sturmer 1998</LINK>; <LINK REF="REF-Baron-2003" TYPE="REFERENCE">Baron 2003</LINK>; <LINK REF="REF-Sandler-2003" TYPE="REFERENCE">Sandler 2003</LINK>).</P>
<P>The role of COX-2 inhibitors in patients with Barrett's oesophagus is less clear. A rat model of Barrett&#8217;s using oesophago-jejunostomy demonstrated that sulindac (NSAID) and MF-tricyclic (selective COX-2 inhibitor) reduced the incidence of adenocarcinoma by 79% (P &lt; 0.008) and 55% (P &lt; 0.001) respectively when compared to control animals. The prevalence of Barrett's oesophagus was, however, not altered by treatment, suggesting a chemopreventative effect for the development of adenocarcinoma but not Barrett's oesophagus (<LINK REF="REF-Buttar-2002" TYPE="REFERENCE">Buttar 2002</LINK>). However, <LINK REF="REF-Miwa-2005" TYPE="REFERENCE">Miwa 2005</LINK>
<I> </I>reported a decrease in the incidence of Barrett's oesophagus and adenocarcinoma. A recent RCT reported in this review has failed to show any benefit of celecoxib above that of placebo for the reversal of dysplasia in the context of Barrett's oesophagus (<LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>). Caution is necessary when using COX-2 inhibitors since Rofecoxib use has been associated with a &gt; 50% increase in the risk of cardiovascular events (<LINK REF="REF-Bresalier-2005" TYPE="REFERENCE">Bresalier 2005</LINK>). There were no increased cardiovascular complications in patients in the celecoxib group compared to the placebo group (<LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007)</LINK>; this is in keeping with data from a meta-analysis which suggests the cardiovascular effects may be rofecoxib specific (<LINK REF="REF-Simon-2005" TYPE="REFERENCE">Simon 2005</LINK>). However, studies of other COX-2 inhibitors (valdecoxib) suggest that the deleterious cardiovascular effects may affect the COX-2 inhibitor drug class as a whole (<LINK REF="REF-Andersohn-2006" TYPE="REFERENCE">Andersohn 2006</LINK>). Thus increasing caution is being applied in the use of COX-2 inhibitors. Overall, aspirin may be beneficial but RCT data are required to substantiate this.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">c. Novel oral agents</HEADING>
<P>The role of the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) is not clear. In a rat model for the development of oesophageal adenocarcinoma there was a reduction in cancer risk only when DFMO was combined with a NSAID (<LINK REF="REF-Chen-2002" TYPE="REFERENCE">Chen 2002</LINK>). A pilot clinical trial showed suppression of Barrett's oesophagus tissue polyamine levels in individuals treated with DFMO, which further suggested a potential therapeutic role for the drug (<LINK REF="REF-Gerner-1994" TYPE="REFERENCE">Gerner 1994</LINK>). A clinical trial of NSAIDs combined with DFMO was recently completed at the University of Michigan Medical Centre, but has yet to report and preliminary data are not yet available from the authors (Personal Communication Dr D Brenner). <I>In vitro</I> and early <I>in vivo</I> studies of retinoids suggested that they may impair epithelial cancer formation (<LINK REF="REF-Freemantle-2003" TYPE="REFERENCE">Freemantle 2003</LINK>). Despite disappointing phase III clinical trials in small cell lung cancer and head and neck cancers (<LINK REF="REF-Freemantle-2006" TYPE="REFERENCE">Freemantle 2006</LINK>; <LINK REF="REF-Khuri-2006" TYPE="REFERENCE">Khuri 2006</LINK>), further work continues in non-small cell lung carcinoma using novel synthetic retinoids targeting the non-classical nuclear retinoid X receptor in combination with epidermal growth factor receptor inhibitors (<LINK REF="REF-Dragnev-2005" TYPE="REFERENCE">Dragnev 2005</LINK>), since a multimodality approach using retinoids in combination with other agents may be necessary to achieve clinical benefits.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">2. Surgical therapies</HEADING>
<P>A single randomised surgical trial comparing antacid therapy with an open Collis Nissen gastroplasty has been undertaken which was reported initially in 1996 (<LINK REF="REF-Ortiz-1996" TYPE="REFERENCE">Ortiz 1996</LINK>) and then in 2003 with longer-term results, including additional patients (<LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>). No benefit was shown for the histological regression of Barrett's oesophagus. Individuals who had successful surgery, as defined by normal pH studies, were statistically significantly less likely to develop <I>de novo</I> high-grade dysplasia. However, this study was performed in a single centre and treatment protocols, acid suppression methods and surgical interventions were variable for both groups in the study. The reduction in the incidence of oesophagitis and strictures suggested a benefit for surgical intervention when GORD complications are considered and these data are consistent with previous findings (<LINK REF="STD-Spechler-1992" TYPE="STUDY">Spechler 1992</LINK>; <LINK REF="STD-Spechler-2001" TYPE="STUDY">Spechler 2001</LINK>). It should also be remembered that both the medication used and the surgical approaches followed have now changed.</P>
<P>The role of surgery in the management of GORD symptoms in patients with Barrett's oesophagus was controversial. Although early surgical anti-reflux operations were associated with high morbidity and were considered to have high failure rates in patients with Barrett's oesophagus, it has now become clear that laparoscopic anti-reflux surgery (LARS) (most commonly laparoscopic Nissen fundoplication) is safe (<LINK REF="REF-Hinder-1997" TYPE="REFERENCE">Hinder 1997</LINK>; <LINK REF="REF-Viljakka-1997" TYPE="REFERENCE">Viljakka 1997</LINK>; <LINK REF="REF-Pessaux-2002" TYPE="REFERENCE">Pessaux 2002</LINK>) and has been shown to have a better symptomatic improvement compared to proton pump inhibitor (<LINK REF="REF-Mehta-2006" TYPE="REFERENCE">Mehta 2006</LINK>). Furthermore, there are data to suggest that it is more effective in GORD symptom control in the short and medium-term than proton pump inhibitor therapy (<LINK REF="STD-Spechler-1992" TYPE="STUDY">Spechler 1992</LINK>) and failure is uncommon at approximately 2.8% (<LINK REF="REF-Smith-2005" TYPE="REFERENCE">Smith 2005</LINK>). Procedural failure tends to occur early because of fundoplication wrap herniation (<LINK REF="REF-Gopal-2006" TYPE="REFERENCE">Gopal 2006</LINK>). There is however concern that individuals with Barrett's oesophagus are at a higher risk of LARS failure due to the presence of a large hiatus hernia. It is therefore recommended that these individuals should have a thorough dissection and mobilisation of the oesophagus, appropriate reduction of any hiatus hernia and reduction in the hiatal defect size by suturing the crura or the application of a crural patch. Furthermore, some groups suggest that "liberal use" of a Collis gastroplasty to lengthen the oesophagus should be employed to reduce fundoplication wrap herniation (<LINK REF="REF-Jackson-2005" TYPE="REFERENCE">Jackson 2005</LINK>). A recent non-randomised study suggests that the Collis Nissen approach may be superior to Nissen fundoplication in individuals with Barrett's oesophagus (<LINK REF="REF-Chen-2005" TYPE="REFERENCE">Chen 2005</LINK>) but this too remains controversial. Non-randomised controlled trial evidence however suggested that surgical therapy was associated with significant regression of the Barrett's segment in 14% to 35% of patients and complete regression of low-grade dysplasia in 44% to 93% of patients (<LINK REF="STD-Hofstetter-2001" TYPE="STUDY">Hofstetter 2001;</LINK> <LINK REF="STD-O_x0027_Riordan-2004" TYPE="STUDY">O'Riordan 2004</LINK>; <LINK REF="REF-Rossi-2006" TYPE="REFERENCE">Rossi 2006</LINK>). Caution must be applied when interpreting these data since diagnosis of low-grade dysplasia is notoriously difficult and even the most stringent biopsy protocol can still miss foci.</P>
<P>The long-term efficacy of surgical anti-reflux procedures must also be borne in mind. Long-term follow up of individuals treated with open Nissen fundoplication as part of a larger RCT assessing reflux therapy as an outcome (<LINK REF="STD-Spechler-2001" TYPE="STUDY">Spechler 2001</LINK>), showed that after ten years follow up without acid suppression therapy standardised treatment scores (Gastro-oesophageal Reflux Disease Activity Index (GRACI) scores) in the surgical group were significantly better than in the medically treated group (P = 0.03). However, there were no significant differences between the groups in terms of grade of oesophagitis, frequency of oesophageal stricture and subsequent anti-reflux operations. There were also similar effects of both treatments in terms of SF-36 standardised physical and mental component scale scores, and overall satisfaction with anti-reflux therapy.</P>
<P>Overall, laparoscopic anti-reflux surgery is a valuable approach for the control of reflux symptoms. However, at present no randomised trial has been published comparing the laparoscopic Nissen fundoplication, which is the currently favoured anti-reflux approach, with proton pump inhibitor therapy for the regression of Barrett's oesophagus and prevention of adenocarcinoma. Such a study would be difficult to perform because the low incidence of adenocarcinoma in individuals with Barrett's oesophagus means that a very large, probably multinational study, would be required to achieve adequate statistical power.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">3. Endoscopic therapies</HEADING>
<P>The biggest body of data exists for the endoscopic therapies, although as mentioned previously this rapidly evolving field has led to a paucity of appropriately powered RCTs.</P>
<P>In a pilot study of only eight patients, differences could be detected between Nd-YAG laser treatment and proton pump inhibitor alone in altering Barrett's oesophagus length or inducing squamous islands at six months (<LINK REF="REF-Luman-1995" TYPE="REFERENCE">Luman 1995</LINK>; <LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>). However, the pilot nature of this study limits the conclusions that can be drawn. Nd-YAG laser therapy has also been studied in non-randomised descriptive studies where complete regression rates of 40% have been reported (<LINK REF="REF-Norberto-2004" TYPE="REFERENCE">Norberto 2004</LINK>). On the basis of these studies, the true efficacy of Nd-Yag therapy in the eradication of Barrett's oesophagus is unclear.</P>
<P>Three randomised trials have compared various ablative techniques, both as the primary treatment and after anti-reflux surgery. Argon plasma coagulation was more effective than proton pump inhibitor alone in achieving ablation and maintenance of ablation of Barrett's oesophagus (<LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK>) but glands buried underneath squamous epithelium remain a concern (<LINK REF="REF-Basu-2002b" TYPE="REFERENCE">Basu 2002b</LINK>; <LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>). The eradication of Barrett's oesophagus by argon plasma coagulation is relatively stable since 40% of patients were reported to be eradicated at one and five years of follow up (<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>; <LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>). Argon plasma coagulation and multipolar electrocautery were shown to be of equal efficacy for the decrease in length and area of Barrett's oesophagus (<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>) as well as for complete eradication of Barrett's oesophagus (<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>; <LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK>). Multipolar electrocoagulation has high complete ablation rates after six treatment sessions achieving 85% macroscopic resolution and 78% histological regression of Barrett's oesophagus (<LINK REF="REF-Sampliner-2001" TYPE="REFERENCE">Sampliner 2001</LINK>).</P>
<P>Drawing conclusions on the efficacy of photodynamic therapy compared to argon plasma coagulation is difficult since the efficacy of photodynamic therapy to eradicate Barrett's oesophagus is dictated by the choice of drug and regimens of treatment used. Photodynamic therapy can be either more, less or equally effective as argon plasma coagulation depending on the study or the photodynamic therapy regimens used within a single study (<LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>; <LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>; <LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>). This is also true for the presence of buried glands after treatment. Overall argon plasma coagulation has equal and perhaps greater efficacy than photodynamic therapy depending on the dosing regimes and the dysplasia status of Barrett's oesophagus being treated; however, because of the conflicting reports of the incidence of buried glands the relative merits of argon plasma coagulation over photodynamic therapy may be blunted.</P>
<P>Two trials compared proton pump inhibitor therapy with photodynamic therapy (<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>; <LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>) and Overholt's data were updated in <LINK REF="REF-Overholt-2007" TYPE="REFERENCE">Overholt 2007</LINK>. Although these groups used different photosensitisers and different light dosing regimes, both showed that photodynamic therapy was significantly more efficacious at ablating Barrett's oesophagus when compared with proton pump inhibitor alone. It should be noted, however, that Ackroyd's study was not designed to show any change in dysplastic Barrett's oesophagus using 5-ALA. Overholt reported that photodynamic therapy with porfimer sodium, using both diffuse and focal light application to discrete lesions resulted in a statistically significant decrease in high-grade dysplasia and adenocarcinoma risk when compared with proton pump inhibitor alone (P &lt; 0.004). This is the first randomised study to demonstrate a reduction in adenocarcinoma risk in Barrett's oesophagus patients with any therapeutic intervention. The follow-up data from this trial confirm that porfimer sodium photodynamic therapy with omeprazole remains more effective than omeprazole alone in eliminating high-grade dysplasia (P &lt; 0.0001) and in preventing progression to cancer after five years (<LINK REF="REF-Overholt-2007" TYPE="REFERENCE">Overholt 2007</LINK>). However, the low conversion rate (28%) of high-grade dysplasia patients on omeprazole should also be noted. Longer-term follow up would be necessary to correctly assess the protective effect of photodynamic therapy for the development of adenocarcinoma. The RCT by <LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK> highlighted the difference in efficacy and safety between 5-ALA and porfimer sodium photodynamic therapy despite not reaching statistical significance. Overall, 5-ALA seems to be better tolerated and has fewer complications (such as strictures) than porfimer sodium and may also be more efficacious in the reversal of dysplasia (reviewed in <LINK REF="REF-Dunn-2008" TYPE="REFERENCE">Dunn 2008</LINK>).</P>
<P>The timing at which intervention should occur in patients with high-grade dysplasia, however, remains unclear. Descriptive studies of individuals offered surgical treatment for high-grade dysplasia in Barrett's oesophagus suggest that early intervention is safer (<LINK REF="REF-Romagnoli-2003" TYPE="REFERENCE">Romagnoli 2003</LINK>). This report described two groups of individuals with dysplasia in Barrett's oesophagus: individuals with high-grade dysplasia were offered oesophagectomy either soon after diagnosis or after a period of follow up (range seven to 70 months) as part of routine clinical management; no randomisation took place. This revealed a higher overall stage of invasive disease, an increased lymph node burden and poorer cancer related survival in the follow-up group when compared to the early intervention group (early intervention group survival at 168 months = 100% versus 52% survival in the follow-up group, P = 0.0094).</P>
<P>Radiofrequency ablation has first been shown in porcine and phase two clinical trials to be efficacious in treating the oesophageal mucosa without injuring the sub-mucosa (<LINK REF="REF-Ganz-2004" TYPE="REFERENCE">Ganz 2004</LINK>). Radiofrequency ablation has been demonstrated to successfully eradicate Barrett's oesophagus and dysplasia without significant side effects (<LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK>). Until this year, most publications were in abstract form or pilot studies. The two largest studies of 70 (<LINK REF="STD-Fleischer-2008" TYPE="STUDY">Fleischer 2008</LINK>) and 44 (<LINK REF="STD-Pouw-2008" TYPE="STUDY">Pouw 2008</LINK>) patients treated with radiofrequency ablation reported 98% complete eradication of intestinal metaplasia at 25 and 21 months respectively. The study by Pouw<I> </I>included only patients with high-grade dysplasia and dysplasia was cleared in 98% of patients at 21 months. These two studies had 16% to 22% minor complications (<LINK REF="STD-Fleischer-2008" TYPE="STUDY">Fleischer 2008</LINK>; <LINK REF="STD-Pouw-2008" TYPE="STUDY">Pouw 2008</LINK>); mild bleeds and nausea were the most common. There was one incidence of perforation. None of these studies reported any strictures and buried glands were only found in 0.01% of neo-squamous biopsies. Longer-term follow-up data are required to confirm the lasting efficacy of this treatment.</P>
<P>A number of other endoscopic modalities have been studied but these have not undergone RCT assessment in the context of Barrett's oesophagus treatment. These include cryotherapy which was first described in a porcine model (<LINK REF="REF-Johnston-1999" TYPE="REFERENCE">Johnston 1999</LINK>) and has been shown in a pilot prospective study (n = 11) to partially ablate Barrett's oesophagus in 100% patients and to completely ablate Barrett's oesophagus, both macroscopically and histologically, in 78% of those treated. The treatment was undertaken using a low pressure spray cryoablation technique and no complications were described. There was no recurrence of Barrett's oesophagus seen in those completely ablated at six months follow up (<LINK REF="STD-Johnston-2005" TYPE="STUDY">Johnston 2005</LINK>).</P>
<P>Endomucosal resection (EMR) of Barrett's oesophagus lesions has also been employed. It has predominantly been used in individuals with discrete visible lesions, and has been shown to produce a complete remission in 97% of individuals with smaller, lower risk lesions (&lt; 20 mm in size, high-grade dysplasia or well/moderately differentiated adenocarcinoma on histology with a polypoid or flat macroscopic morphology) and 59% in those with large higher risk lesions (&gt; 20 mm in size, poorly differentiated adenocarcinoma on histology and ulcerated macroscopically; <LINK REF="REF-Ell-2000" TYPE="REFERENCE">Ell 2000</LINK>). It has also been recognised to be a useful diagnostic adjunct as the larger and more complete nature of specimens obtained may make histological examination easier. This is particularly evident if a cut and lift rather than a suction cap approach is used, since this reduces both the cautery (<LINK REF="REF-Nijhawan-2000" TYPE="REFERENCE">Nijhawan 2000</LINK>) and crushing artefact. RCTs comparing this technique with other therapeutic interventions have not yet been undertaken in Barrett's oesophagus. Although, EMR is used increasingly in combination with endoscopic therapy aiming to ablate a larger segment (<LINK REF="STD-Pouw-2008" TYPE="STUDY">Pouw 2008</LINK>), none of the RCTs included in this review used this in conjunction with other treatment modalities.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-09-22 16:09:08 -0400" MODIFIED_BY="Karin L Dearness">
<IMPLICATIONS_PRACTICE MODIFIED="2009-09-22 16:09:08 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised controlled trial evidence shows that surgical and pharmacological anti-reflux therapies do not appear to eradicate Barrett&#8217;s and existing dysplasia; at best they induce a regression of the segment but eradication of low-grade dysplasia was apparent in prospective surgical series. Furthermore, there may be a reduction in the development of de <I>novo</I> dysplasia, although this has not been confirmed by a meta-analysis of non-randomised, surgical anti-reflux trials. Anti-reflux therapies are valuable for providing symptomatic control of gastro-oesophageal reflux disease (GORD) and prevention of inflammatory complications and may allow for a reduction of dysplasia. With regards to endoscopic therapies, a comparison of porfimer sodium photodynamic therapy compared with proton pump inhibitor therapy is the first RCT evidence to demonstrate superiority of an endoscopic intervention in reducing progression to adenocarcinoma. Both argon plasma coagulation and photodynamic therapy have similar success rates in the eradication of Barrett's oesophagus and dysplasia. The presence of buried glands following argon plasma coagulation would suggest not using argon plasma coagulation for full segment eradication. Compared with porfimer sodium, data published since the 2004 guidelines (<LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>) suggest that 5-ALA has lower side effects is effective at treating Barrett's oesophagus and dysplasia compared with porfimer sodium (as reviewed by <LINK REF="REF-Dunn-2008" TYPE="REFERENCE">Dunn 2008</LINK>). The data available so far suggest that radiofrequency ablation is promising for the treatment of Barrett's oesophagus with and without dysplasia. Provided that the NICE guidelines endorse radiofrequency ablation in Barrett's oesophagus, it would be the treatment of choice. However, until longer-term RCT data are published, radiofrequency ablation should only be used in expert centres with careful follow up.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>The only surgical study discussed here was limited by the use of different acid suppression therapies with an open Collis Nissen gastroplasty, which is now outmoded. The efficacy of surgery using LARS techniques compared to proton pump inhibitor alone in the prevention of Barrett's oesophagus, the regression of Barrett's oesophagus and the prevention of adenocarcinoma requires further study. The relative efficacy of photodynamic therapy using 5-ALA and porfimer sodium is unknown and a comparison of these photosensitising drugs would allow the identification of the most efficacious agent in this setting. Furthermore, the safety profile of photodynamic therapy types with particular reference to stricture risk and photosensitivity complications that are seen with porfimer sodium need to be taken into account. However, with the advent of radiofrequency ablation, it is likely that photodynamic therapy will become an obsolete technique. Long-term, multicentre studies on the efficacy of radiofrequency ablation to eradicate Barrett's oesophagus and dysplasia, and the incidence of strictures and buried glands, are needed before radiofrequency ablation can be used in routine clinical care without very careful surveillance post-treatment. It would also be important to assess whether or not the risk of progression to adenocarcinoma is reduced following radiofrequency ablation compared to surveillance. The results of the AspECT trial may inform debate on the utility of chemopreventive agents for Barrett's associated adenocarcinoma. Overall, the field is in dire need of long-term RCT with a primary endpoint of cancer development. However, the relatively low conversion rate of Barrett's oesophagus may lead to difficulties obtaining funding for such long-term studies. It may therefore be appropriate to use biomarkers predictive of progression as an endpoint.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>Andrej Corovic and The Cochrane Collaboration for their assistance in identifying and obtaining the relevant references.</P>
<P>Professor David Forman for his advice on the format and content of the review and the relevant statistical comparisons.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>Jonathan Rees, Pierre Lao-Sirieix and Rebecca Fitzgerald are funded by the Medical Research Council.</P>
<P>Jonathan Rees has also received research funding awards from the Royal College of Surgeons of Edinburgh and Cancer Research UK.</P>
<P>Rebecca Fitzgerald has occasionally acted as a consultant to Astra Zeneca and has research collaboration with Merck and GlaxoSmithKline.<B>
<BR/>
</B>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-08-27 16:07:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>Jonathan Rees and Pierre Lao-Sirieix contributed equally to this review.</P>
<P>Jonathan Rees and Angela Wong reviewed all manuscripts identified by the search strategy, selected those meeting the inclusion criteria, abstracted data from the included studies and entered these data into RevMan.</P>
<P>Jonathan Rees prepared the manuscript, updated the searches, identified the most recent studies included and abstracted data from these.</P>
<P>Pierre Lao-Sirieix edited the manuscript following editors' comments, updated the searches, identified the studies published since 2006 and abstracted data from these.</P>
<P>Rebecca Fitzgerald reviewed the included studies and reviewed the prepared manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-06-07 14:10:09 -0400" MODIFIED_BY="Karin Dearness">
<STUDIES MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness">
<INCLUDED_STUDIES MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY DATA_SOURCE="PUB" ID="STD-Ackroyd-2000" MODIFIED="2009-07-30 15:01:36 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ackroyd 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 15:01:36 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, et al</AU>
<TI>Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>612-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bright-2007" MODIFIED="2009-08-27 11:56:05 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Bright 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-27 11:56:05 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bright T, Watson DI, Tam W, Game PA, Astill D, Ackryod R, et al</AU>
<TI>Randomised trial of argon plasma coagulation versus endoscopic surveillance for Barrett's esophagus after antireflux surgery: late results</TI>
<SO>Annals of Surgery</SO>
<YR>2007</YR>
<VL>246</VL>
<NO>6</NO>
<PG>1016-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caldwell-1996" MODIFIED="2009-08-27 11:56:19 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Caldwell 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-08-27 11:56:19 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell MTP, Byrne PJ, Walsh TN, Hennessey TPJ</AU>
<TI>A randomized trial on the effect of acid suppression on regression of Barrett's oesophagus</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>4</NO>
<PG>A074</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dulai-2005" MODIFIED="2009-08-27 11:56:31 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Dulai 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-27 11:56:31 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dulai GS, Jensen DM, Cortina G, Fontana L, Ippoliti A</AU>
<TI>Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2005</YR>
<VL>61</VL>
<NO>2</NO>
<PG>232-40</PG>
<IDENTIFIERS MODIFIED="2009-08-27 11:56:31 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hage-2004" MODIFIED="2009-08-27 11:56:40 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Hage 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-27 11:56:40 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hage M, Siersema PD, van Dekken H, Steyerberg EW, Haringsma J, van de Vrie W, et al</AU>
<TI>5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial</TI>
<SO>Gut</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>6</NO>
<PG>785-90</PG>
<IDENTIFIERS MODIFIED="2009-08-27 11:56:40 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heath-2007" MODIFIED="2009-09-22 16:10:15 -0400" MODIFIED_BY="Karin L Dearness" NAME="Heath 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-09-22 16:10:15 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, et al</AU>
<TI>Secondary chemoprevention of Barrett's esophagus with Celecoxib: results of a randomized trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2007</YR>
<VL>99</VL>
<PG>545-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-22 16:10:06 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, et al</AU>
<TI>Chemoprevention for Barrett's esophagus trial. Design and outcome measures</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>177-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelty-2004" MODIFIED="2009-07-30 15:05:54 -0400" MODIFIED_BY="Karin L Dearness" NAME="Kelty 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-30 15:05:54 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MWR</AU>
<TI>Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>1289-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luman-1996" MODIFIED="2009-08-27 16:13:59 -0400" MODIFIED_BY="Karin L Dearness" NAME="Luman 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-08-27 16:13:59 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luman W, Lessels AM, Palmer KR</AU>
<TI>Failure of Nd-YAG photocoagulation therapy as treatment for Barrett's oesophagus - a pilot study</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>7</NO>
<PG>627-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-27 16:13:50 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luman W, Lessels AM, Palmer KR</AU>
<TI>Laser photoablation of Barrett's oesophagus - Nd-YAG is ineffective</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>A95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mackenzie-2008" MODIFIED="2009-08-27 11:58:03 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Mackenzie 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-27 11:58:03 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mackenzie GD, Dunn JM, Novelli MR, Mosse S, Thorpe SM, Bown SG, et al</AU>
<TI>Preliminary results of a randomised controlled trial into the safety and efficacy of ALA versus photofrin photodynamic therapy for high grade dysplasia in Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>2008</YR>
<VL>57</VL>
<NO>Suppl 1</NO>
<PG>A034</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overholt-2005" MODIFIED="2009-08-27 11:58:14 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Overholt 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-04 11:06:29 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, et al</AU>
<TI>Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>4</NO>
<PG>488-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-27 11:58:14 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overholt BF, Wang KK, Durdick JS, Lightdale CJ, Kimmey M, Nava HR, et al</AU>
<TI>Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>3</NO>
<PG>460-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parrilla-2003" MODIFIED="2009-08-27 11:58:24 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Parrilla 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-04 11:10:16 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J, et al</AU>
<TI>Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study</TI>
<SO>British Journal of Surgery</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>2</NO>
<PG>274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-27 11:58:24 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parrilla P, Martinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, et al</AU>
<TI>Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus</TI>
<SO>Annals of Surgery</SO>
<YR>2003</YR>
<VL>237</VL>
<NO>3</NO>
<PG>291-8</PG>
<IDENTIFIERS MODIFIED="2009-08-27 11:58:24 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1999" NAME="Peters 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al</AU>
<TI>Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>4</NO>
<PG>489-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ragunath-2005" MODIFIED="2009-08-27 16:13:39 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ragunath 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-27 16:13:39 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ragunath K, Krasner N, Haqqani M T,Phillips CJ, Cheung I</AU>
<TI>Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>750-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaheen-2008" MODIFIED="2009-08-27 11:58:54 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Shaheen 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-27 11:58:54 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaheen NJ, Sharma P, Overholt BF, Lightdale CJ, Wolfsen HC, Sampliner RE, et al</AU>
<TI>Radiofrequency ablation in Barrett's esophagus with dysplasia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<PG>2277-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-07-07 11:46:52 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2006" MODIFIED="2009-08-27 11:59:02 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Sharma 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-27 11:59:02 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Wani S, Weston AP, Bansal A, Hall M, Mathur S, et al</AU>
<TI>A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results</TI>
<SO>Gut</SO>
<YR>2006</YR>
<VL>55</VL>
<PG>1233-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinstein-1996" MODIFIED="2009-08-27 16:13:29 -0400" MODIFIED_BY="Karin L Dearness" NAME="Weinstein 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-08-27 16:13:29 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein WM, Lieberman D, Lewin DN, Weber LJ, Berger ML, Ippoliti A</AU>
<TI>Omeprazole-induced regression of Barrett's oesophagus: a 2 year randomized controlled double blind trial</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>4</NO>
<PG>A294</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-08-27 16:13:19 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY DATA_SOURCE="PUB" ID="STD-Ackroyd-1996" MODIFIED="2009-07-30 15:19:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ackroyd 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-30 15:19:33 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackroyd R, Brown Nj, Reed MWR</AU>
<TI>Photodynamic therapy (PDT) for Barrett's oesophagus: establishing optimal treatment parameters</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>5</NO>
<PG>551</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ackroyd-1996b" MODIFIED="2009-07-30 15:19:53 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ackroyd 1996b" YEAR="1996">
<REFERENCE MODIFIED="2009-07-30 15:19:53 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackroyd R, Roberts DJH, Vernon DI, Brown NJ, Reed MWR</AU>
<TI>Photodynamic therapy for Barrett's oesophagus: a dosimetric pilot study</TI>
<SO>British Journal of Surgery</SO>
<YR>1996</YR>
<VL>83</VL>
<PG>1637</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ackroyd-1999" MODIFIED="2009-08-27 16:13:19 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ackroyd 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-08-27 16:13:19 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0031-8655&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 16:13:19 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackroyd R, Brown N, Vernon D, Roberts D, Stephenson T, Marcus S, et al</AU>
<TI>5-Aminolevulinic acid photosensitization of dysplastic Barrett's esophagus: a pharmacokinetic study</TI>
<SO>Photochemistry and Photobiology</SO>
<YR>1999</YR>
<VL>70</VL>
<NO>4</NO>
<PG>656-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ackroyd-2004" MODIFIED="2009-08-27 12:00:02 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Ackroyd 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-27 12:00:02 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackroyd R, Tam W, Schoeman M, Devitt PG, Watson DI</AU>
<TI>Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS MODIFIED="2009-08-27 12:00:02 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aguirre-2003" MODIFIED="2009-08-27 13:56:57 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Aguirre 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-27 13:56:57 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aguirre TV, Sampliner RE</AU>
<TI>Comment on: Endoscopic surveillance of columnar liner oesophagus: Frequency of intestinal metaplasia detection and impact of antireflux surgery</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>4</NO>
<PG>931-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aguirre-2003b" MODIFIED="2009-07-30 15:22:16 -0400" MODIFIED_BY="Karin L Dearness" NAME="Aguirre 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:22:16 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aguirre TV, Sampliner RE</AU>
<TI>Comment on: Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>4</NO>
<PG>933-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Attwood-2003" MODIFIED="2009-07-30 15:23:56 -0400" MODIFIED_BY="Karin L Dearness" NAME="Attwood 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:23:56 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1542-3565&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:23:56 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attwood SE, Lewis CJ, Caplin S, Hemming K, Armstrong G</AU>
<TI>Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>4</NO>
<PG>258-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barham-1995" MODIFIED="2009-07-30 15:24:09 -0400" MODIFIED_BY="Karin L Dearness" NAME="Barham 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-07-30 15:24:09 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barham C, Hardwick RH, Shepherd N, Alderson D, Barr H</AU>
<TI>Regression of columnar-lined oesophagus following laser ablation and acid supression</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>Suppl 2</NO>
<PG>A4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-1996" MODIFIED="2009-07-30 15:24:50 -0400" MODIFIED_BY="Karin L Dearness" NAME="Barr 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-30 15:24:50 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N</AU>
<TI>Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with exogenously generated protoporphyrin 1X</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9027</NO>
<PG>584-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basu-2002" MODIFIED="2009-07-30 15:25:10 -0400" MODIFIED_BY="Karin L Dearness" NAME="Basu 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:25:10 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0954-691x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:25:10 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basu KK, Bale R, West KP, de Caestecker JS</AU>
<TI>Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>11</NO>
<PG>1187-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellnier-2003" MODIFIED="2009-07-30 15:25:57 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bellnier 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:25:57 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0008-5472&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:25:57 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, et al</AU>
<TI>Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients</TI>
<SO>Cancer Research</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>8</NO>
<PG>1806-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowers-2002" MODIFIED="2009-07-30 15:26:20 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bowers 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:26:20 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1091-255x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:26:20 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowers SP, Mattar SG, Smith CD, Waring JP, Hunter JG</AU>
<TI>Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>4</NO>
<PG>532-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowers-2003" MODIFIED="2009-07-30 15:26:40 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bowers 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:26:40 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1432-2218&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:26:40 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowers SP, Mattar SG, Waring PJ, Galloway K, Nasir A, Pascal R, et al</AU>
<TI>KTP laser ablation of Barrett's esophagus after anti-reflux surgery results in long-term loss of intestinal metaplasia. Potassium-titanyl-phosphate</TI>
<SO>Surgical Endoscopy</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braghetto-2002" MODIFIED="2009-07-30 15:26:53 -0400" MODIFIED_BY="Karin L Dearness" NAME="Braghetto 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:26:53 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1120-8694&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:26:53 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braghetto I, Csendes A, Burdiles P, Botero F, Korn O</AU>
<TI>Results of surgical treatment for recurrent postoperative gastroesophageal reflux</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>4</NO>
<PG>315-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cameron-2002" MODIFIED="2009-07-30 15:27:43 -0400" MODIFIED_BY="Karin L Dearness" NAME="Cameron 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:27:43 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:27:43 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron AJ, Souto EO, Smyrk TC</AU>
<TI>Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>6</NO>
<PG>1375-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canto-1996" MODIFIED="2009-07-30 15:28:08 -0400" MODIFIED_BY="Karin L Dearness" NAME="Canto 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-30 15:28:08 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canto M</AU>
<TI>Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1996</YR>
<VL>44</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caos-2000" MODIFIED="2009-07-30 15:28:16 -0400" MODIFIED_BY="Karin L Dearness" NAME="Caos 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 15:28:16 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:28:16 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J</AU>
<TI>Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>11</NO>
<PG>3081-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlson-2002" MODIFIED="2009-07-30 15:31:01 -0400" MODIFIED_BY="Karin L Dearness" NAME="Carlson 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:31:01 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:31:01 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlson N, Lechago J, Richter J, Sampliner RE, Peterson L, Santella RM, et al</AU>
<TI>Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>6</NO>
<PG>1340-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Csendes-2000" MODIFIED="2009-07-30 15:31:19 -0400" MODIFIED_BY="Karin L Dearness" NAME="Csendes 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 15:31:19 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0007-1323&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:31:19 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csendes A, Burdiles P, Korn O, Braghetto I, Huertas C, Rojas J</AU>
<TI>Late results of a randomized clinical trial comparing total fundoplication versus calibration of the cardia with posterior gastropexy</TI>
<SO>British Journal of Surgery</SO>
<YR>2000</YR>
<VL>87</VL>
<NO>3</NO>
<PG>289-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Csendes-2002" MODIFIED="2009-08-27 12:00:36 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Csendes 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-27 12:00:36 -0400" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;0364-2313&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 12:00:36 -0400" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Csendes A, Burdiles P, Braghetto I, Korn O, Diaz JC, Rojas J</AU>
<TI>Early and late results of the acid suppression and duodenal diversion operation in patients with Barrett's esophagus: analysis of 210 cases</TI>
<SO>World Journal of Surgery</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>5</NO>
<PG>566-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dar-2003" NAME="Dar 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dar MS, Goldblum JR, Rice TW, Falk GW</AU>
<TI>Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>4</NO>
<PG>486-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeMeester-2002" MODIFIED="2009-07-30 15:31:43 -0400" MODIFIED_BY="Karin L Dearness" NAME="DeMeester 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:31:43 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeMeester TR</AU>
<TI>Surgical therapy for Barrett's esophagus: prevention, protection and excision</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>2</NO>
<PG>109-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deviere-2002" NAME="Deviere 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;0017-5749&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deviere J</AU>
<TI>Argon plasma coagulation therapy for ablation of Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>6</NO>
<PG>763-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dietz-2003" MODIFIED="2009-07-30 15:31:56 -0400" MODIFIED_BY="Karin L Dearness" NAME="Dietz 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:31:56 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1120-8694&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:31:56 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dietz J, Meurer L, Maffazzoni DR, Furtado AD, Prolla JC</AU>
<TI>Intestinal metaplasia in the distal esophagus and correlation with symptoms of gastroesophageal reflux disease</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>1</NO>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doak-2003" MODIFIED="2009-07-30 15:32:09 -0400" MODIFIED_BY="Karin L Dearness" NAME="Doak 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:32:09 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0017-5749&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:32:09 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doak SH, Jenkins GJ, Parry EM, D'Souza FR, Griffiths AP, Toffazal N, et al</AU>
<TI>Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>5</NO>
<PG>623-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egger-2003" MODIFIED="2009-07-30 15:32:22 -0400" MODIFIED_BY="Karin L Dearness" NAME="Egger 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:32:22 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0017-5749&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:32:22 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egger K, Werner M, Meining A, Ott R, Allescher HD, Hofler H, et al</AU>
<TI>Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>1</NO>
<PG>18-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eubanks-2000" MODIFIED="2009-07-30 15:32:38 -0400" MODIFIED_BY="Karin L Dearness" NAME="Eubanks 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 15:32:38 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9610&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:32:38 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eubanks TR, Omelanczuk P, Richards C, Pohl D, Pellegrini CA</AU>
<TI>Outcomes of laparoscopic antireflux procedures</TI>
<SO>American Journal of Surgery</SO>
<YR>2000</YR>
<VL>179</VL>
<NO>5</NO>
<PG>391-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Familiari-2003" MODIFIED="2009-08-27 12:00:49 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Familiari 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-27 12:00:49 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Familiari L, Scaffidi M, Bonica M, Consolo P, Giacobbe G, Fichera D, et al</AU>
<TI>Endoscopic treatment of Barrett's epithelium with argon plasma coagulation</TI>
<SO>Minerva Gastroenterologica e Dietologica</SO>
<YR>2003</YR>
<VL>49</VL>
<PG>63-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farrell-2001" MODIFIED="2009-07-30 15:33:10 -0400" MODIFIED_BY="Karin L Dearness" NAME="Farrell 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 15:33:10 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1432-2218&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:33:10 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farrell TM, Archer SB, Metreveli RE, Smith CD, Hunter JG</AU>
<TI>Resection and advancement of esophageal mucosa. A potential therapy for Barrett's esophagus</TI>
<SO>Surgical Endoscopy</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>9</NO>
<PG>937-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Felix-2002" MODIFIED="2009-07-30 15:34:07 -0400" MODIFIED_BY="Karin L Dearness" NAME="Felix 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:34:07 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0004-2803&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:34:07 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Felix VN, Yogi I, Perini M, Echeverria R, Bernardi C</AU>
<TI>Surgical treatment of the non-complicated gastroesophageal reflux: fundoplication without division of the short gastric vessels</TI>
<SO>Arquivos de Gastroenterologia</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>2</NO>
<PG>93-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferguson-1997" MODIFIED="2009-07-30 15:35:27 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ferguson 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-30 15:35:27 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0022-5223&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:35:27 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson MK, Naunheim KS</AU>
<TI>Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1997</YR>
<VL>114</VL>
<NO>5</NO>
<PG>824-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzgerald-2001" MODIFIED="2009-07-30 15:35:39 -0400" MODIFIED_BY="Karin L Dearness" NAME="Fitzgerald 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 15:35:39 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:35:39 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald RC, Saeed IT, Khoo D, Farthing MJ, Burnham WR</AU>
<TI>Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2001</YR>
<VL>46</VL>
<NO>9</NO>
<PG>1892-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischer-2008" MODIFIED="2009-08-27 12:01:01 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Fleischer 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-27 12:01:01 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischer DE, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, et al</AU>
<TI>Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2008</YR>
<VL>68</VL>
<NO>5</NO>
<PG>867-76</PG>
<IDENTIFIERS MODIFIED="2009-08-27 12:01:01 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foroulis-2006" MODIFIED="2009-07-30 15:36:15 -0400" MODIFIED_BY="Karin L Dearness" NAME="Foroulis 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-30 15:36:15 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foroulis CN, Thorpe JA</AU>
<TI>Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia and early cancer</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>1</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujii-2003" MODIFIED="2009-07-30 15:36:50 -0400" MODIFIED_BY="Karin L Dearness" NAME="Fujii 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:36:50 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1021-335x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:36:50 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujii T, Nakagawa S, Hanzawa M, Sueyoshi S, Fujita H, Shirouzu K, et al</AU>
<TI>Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus</TI>
<SO>Oncology Reports</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>2</NO>
<PG>427-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gastal-1999" MODIFIED="2009-07-30 15:37:15 -0400" MODIFIED_BY="Karin L Dearness" NAME="Gastal 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-07-30 15:37:15 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0004-0010&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:37:15 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gastal OL, Hagen JA, Peters JH, Campos GM, Hashemi M, Theisen J, et al</AU>
<TI>Short esophagus: analysis of predictors and clinical implications</TI>
<SO>Archives of Surgery</SO>
<YR>1999</YR>
<VL>134</VL>
<NO>6</NO>
<PG>633-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gossner-1995" MODIFIED="2009-08-27 16:13:06 -0400" MODIFIED_BY="Karin L Dearness" NAME="Gossner 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-27 16:13:06 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gossner L, Sroka R, Hahn EG, Ell C</AU>
<TI>Orale gabe von 5-aminolaevulinsaure zur photodynamischen therapie von gastrointetinalen neoplasien</TI>
<SO>Endoskopie Heute</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gurski-2003" MODIFIED="2009-07-30 15:38:13 -0400" MODIFIED_BY="Karin L Dearness" NAME="Gurski 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:38:13 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1072-7515&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:38:13 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gurski RR, Peters JH, Hagen JA, DeMeester SR, Bremner CG, Chandrasoma PT, et al</AU>
<TI>Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2003</YR>
<VL>196</VL>
<NO>5</NO>
<PG>706-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hage-2005" MODIFIED="2009-07-30 15:38:29 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hage 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-30 15:38:29 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuippers EJ, et al</AU>
<TI>Molecular evaluation of ablative therapy of Barrett's oesophagus</TI>
<SO>Journal of Pathology</SO>
<YR>2005</YR>
<VL>205</VL>
<PG>57-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Headrick-2002" MODIFIED="2009-07-30 15:39:04 -0400" MODIFIED_BY="Karin L Dearness" NAME="Headrick 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:39:04 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4975&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:39:04 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Headrick JR, Nichols FC 3rd, Miller DL, Allen MS, Trastek VF, Deschamps C, et al</AU>
<TI>High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>6</NO>
<PG>1697-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heath-2002" MODIFIED="2009-08-27 12:01:51 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Heath 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-27 12:01:51 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heath E, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, et al</AU>
<TI>Chemoprevention for Barrett's esophagus trial: design and outcome measures</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>177-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebbard-2004" MODIFIED="2009-07-30 15:39:46 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hebbard 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-30 15:39:46 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0025-729x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:39:46 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebbard GS, Nandurkar S</AU>
<TI>Managing Barrett's oesophagus</TI>
<SO>Medical Journal of Australia</SO>
<YR>2004</YR>
<VL>180</VL>
<NO>8</NO>
<PG>375-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hetzel-1988" MODIFIED="2009-07-30 15:39:59 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hetzel 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-07-30 15:39:59 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0016-5085&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:39:59 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al</AU>
<TI>Healing and relapse of severe peptic esophagitis after treatment with omeprazole</TI>
<SO>Gastroenterology</SO>
<YR>1988</YR>
<VL>95</VL>
<NO>4</NO>
<PG>903-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1997" MODIFIED="2009-07-30 15:40:21 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hill 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-30 15:40:21 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0959-8278&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:40:21 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill MJ</AU>
<TI>ECP-EURONUT study of diet and intestinal metaplasia. ECP-EURONUT-IM Study Group</TI>
<SO>European Journal of Cancer Prevention</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>2</NO>
<PG>201-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hillman-2003" MODIFIED="2009-08-27 16:12:57 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hillman 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-27 16:12:57 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0815-9319&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 16:12:57 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hillman LC, Chiragakis L, Clarke AC, Kaushik SP, Kaye GL</AU>
<TI>Barrett's esophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>5</NO>
<PG>526-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinnen-2002" MODIFIED="2009-07-30 15:41:02 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hinnen 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:41:02 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1011-1344&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:41:02 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hinnen P, de Rooij FW, Hop WC, Edixhoven A, van Dekken H, Wilson JH, et al</AU>
<TI>Timing of 5-aminolaevulinic acid-induced photodynamic therapy for the treatment of patients with Barrett's oesophagus</TI>
<SO>Journal of Photochemistry and Photobiology. B, Biology</SO>
<YR>2002</YR>
<VL>68</VL>
<NO>1</NO>
<PG>8-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofstetter-2001" MODIFIED="2009-07-30 15:41:12 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hofstetter 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 15:41:12 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4932&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:41:12 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, DeMeester SR, Crookes PF, et al</AU>
<TI>Long-term outcome of antireflux surgery in patients with Barrett's esophagus</TI>
<SO>Annals of Surgery</SO>
<YR>2001</YR>
<VL>234</VL>
<NO>4</NO>
<PG>532-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hornick-2008" MODIFIED="2009-08-27 12:05:37 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Hornick 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-27 12:05:37 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornick JL, Mino-Kenudson M, Lauwers GY, Liu W, Goyal R, Odze RD</AU>
<TI>Buried Barrett's epithelium following photodynamic therapy show reduced crypt proliferation and absence of DNA content abnormalities</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>1</NO>
<PG>38-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hur-2003" MODIFIED="2009-07-30 15:41:41 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hur 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:41:41 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0163-2116&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:41:41 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hur C, Nishioka NS, Gazelle GS</AU>
<TI>Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>7</NO>
<PG>1273-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incarbone-2002" MODIFIED="2009-08-27 12:05:55 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Incarbone 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-27 12:05:55 -0400" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;0009-4773&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 12:05:55 -0400" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incarbone R, Bonavina L, Bassi F, Peracchia A</AU>
<TI>Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma</TI>
<SO>Chirurgia Italiana</SO>
<YR>2002</YR>
<VL>54</VL>
<NO>5</NO>
<PG>591-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ito-2002" MODIFIED="2009-07-30 15:42:37 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ito 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:42:37 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0269-2813&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:42:37 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al</AU>
<TI>Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>8</NO>
<PG>1449-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Javaid-2002" MODIFIED="2009-07-30 15:43:42 -0400" MODIFIED_BY="Karin L Dearness" NAME="Javaid 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:43:42 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0268-8921&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:43:42 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Javaid B, Watt P, Krasner N</AU>
<TI>Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study</TI>
<SO>Lasers in Medical Science</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>1</NO>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnston-2005" MODIFIED="2009-07-30 15:43:58 -0400" MODIFIED_BY="Karin L Dearness" NAME="Johnston 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-30 15:43:58 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR</AU>
<TI>Cryoablation of Barrett's esophagus: a pilot study</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>6</NO>
<PG>842-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-2003" MODIFIED="2009-08-27 12:06:06 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Jung 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-27 12:06:06 -0400" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;0020-9554&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 12:06:06 -0400" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung M, Ell C</AU>
<TI>Barrett esophagus: ablative methods of treatment</TI>
<SO>Der Internist</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>1</NO>
<PG>52-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamolz-2003" MODIFIED="2009-07-30 15:45:09 -0400" MODIFIED_BY="Karin L Dearness" NAME="Kamolz 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:45:09 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1432-2218&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:45:09 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamolz T, Granderath F, Pointner R</AU>
<TI>Laparoscopic antireflux surgery: disease-related quality of life assessment before and after surgery in GERD patients with and without Barrett's esophagus</TI>
<SO>Surgical Endoscopy</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>6</NO>
<PG>880-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kashtan-2002" MODIFIED="2009-08-27 12:06:17 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Kashtan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-27 12:06:17 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kashtan H, Umansky M, Birkenfeld S, Scherbubl H, Haddad R, Greenberg R, et al</AU>
<TI>Photodynamic therapy of Barrett's oesophagus with dysplasia using systemic aminolevulinic acid and a non-laser light source. A phase I/II study</TI>
<SO>Gastrointestinal Oncology</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>2-3</NO>
<PG>153-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaur-2002" NAME="Kaur 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G</AU>
<TI>Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>123</VL>
<NO>1</NO>
<PG>60-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keeley-2007" MODIFIED="2009-08-27 12:06:28 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Keeley 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-27 12:06:28 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keeley SB, Pennathur A, Gooding W, Landreneau RJ, Christie NA, Luketich J</AU>
<TI>Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial cancer</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>8</NO>
<PG>2406-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krska-2002" MODIFIED="2009-08-27 16:12:46 -0400" MODIFIED_BY="Karin L Dearness" NAME="Krska 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-27 16:12:46 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0036-5327&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 16:12:46 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krska Z, Urbanek P, Krechler T, Peskova M, Svab J, Demes R, et al</AU>
<TI>Laparoscopic fundoplication in the treatment of Barrett's esophagus</TI>
<SO>Sborník Lékarský</SO>
<YR>2002</YR>
<VL>103</VL>
<NO>2</NO>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanas-2007" MODIFIED="2009-08-27 12:06:58 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Lanas 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-27 12:06:58 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanas A, Ortego J, Sopena F, Alcedo J, Barrio E, Bujandas L, et al</AU>
<TI>Effect of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>26</VL>
<PG>913-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luostarinen-1993" MODIFIED="2009-07-30 15:48:21 -0400" MODIFIED_BY="Karin L Dearness" NAME="Luostarinen 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-07-30 15:48:21 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4932&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:48:21 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luostarinen M</AU>
<TI>Nissen fundoplication for reflux esophagitis. Long-term clinical and endoscopic results in 109 of 127 consecutive patients</TI>
<SO>Annals of Surgery</SO>
<YR>1993</YR>
<VL>217</VL>
<NO>4</NO>
<PG>329-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malhi_x002d_Chowla-2001" MODIFIED="2009-07-30 15:48:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="Malhi-Chowla 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 15:48:33 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0025-6196&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:48:33 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malhi-Chowla N, Wolfsen HC, DeVault KR</AU>
<TI>Esophageal dysmotility in patients undergoing photodynamic therapy</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2001</YR>
<VL>76</VL>
<NO>10</NO>
<PG>987-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manner-2006" MODIFIED="2009-08-27 12:07:15 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Manner 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-27 12:07:15 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manner H, May A, Miehkle S, Dertinger S, Wigginhaus B, Schimming W, et al</AU>
<TI>Ablation of nonneoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (ABPBANEX): a prospective multicenter evaluation</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>8</NO>
<PG>1762-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcus-1996" MODIFIED="2009-07-30 15:49:07 -0400" MODIFIED_BY="Karin L Dearness" NAME="Marcus 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-30 15:49:07 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1044-5471&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:49:07 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcus SL, Sobel RS, Golub AL, Carroll RL, Lundahl S, Shulman DG</AU>
<TI>Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status</TI>
<SO>Journal of Clinical Laser Medicine and Surgery</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>2</NO>
<PG>59-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-May-2002" MODIFIED="2009-07-30 15:49:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="May 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:49:33 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0954-691x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:49:33 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G, et al</AU>
<TI>Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>10</NO>
<PG>1085-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menke_x002d_Pluymers-1992" NAME="Menke-Pluymers 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;0017-5749&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW</AU>
<TI>Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>1992</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1454-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Messmann-1998" MODIFIED="2009-08-27 16:12:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="Messmann 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-08-27 16:12:33 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0012-0472&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 16:12:33 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Messmann H, Knuchel R, Endlicher E, Hauser T, Szeimies RM, Kullmann F, et al</AU>
<TI>Photodynamic diagnosis of gastrointestinal precancerous lesions after sensitization with 5-aminolevulinic acid. A pilot study</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1998</YR>
<VL>123</VL>
<NO>17</NO>
<PG>515-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mino_x002d_Kenudson-2007" MODIFIED="2009-07-30 15:50:25 -0400" MODIFIED_BY="Karin L Dearness" NAME="Mino-Kenudson 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-30 15:50:25 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mino-Kenudson M, Ban S, Ohana M, Puricelli W, Dehpande V, Shimizu M, et al</AU>
<TI>Buried dysplasia and early adenocarcinoma arising in Barrett's esophagus after porfimer-photodynamic therapy</TI>
<SO>American Journal of Surgical Pathology</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>3</NO>
<PG>403-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miros-1991" MODIFIED="2009-07-30 15:50:40 -0400" MODIFIED_BY="Karin L Dearness" NAME="Miros 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-30 15:50:40 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miros M, Kerlin P, Walker N</AU>
<TI>Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>1991</YR>
<VL>32</VL>
<PG>1441-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montgomery-2002" MODIFIED="2009-07-30 15:50:55 -0400" MODIFIED_BY="Karin L Dearness" NAME="Montgomery 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:50:55 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:50:55 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery E, Bronner MP, Greenson JK, Haber MM, Hart J, Lamps LW, et al</AU>
<TI>Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morino-2003" MODIFIED="2009-07-30 15:51:07 -0400" MODIFIED_BY="Karin L Dearness" NAME="Morino 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:51:07 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1432-2218&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:51:07 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morino M, Rebecchi F, Giaccone C, Taraglio S, Sidoli L, Ferraris R</AU>
<TI>Endoscopic ablation of Barrett's esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication</TI>
<SO>Surgical Endoscopy</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>4</NO>
<PG>539-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mork-2003" MODIFIED="2009-07-30 15:51:27 -0400" MODIFIED_BY="Karin L Dearness" NAME="Mork 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:51:27 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0020-7136&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:51:27 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mork H, Scheurlen M, Al-Taie O, Zierer A, Kraus M, Schottker K, et al</AU>
<TI>Glutathione peroxidase isoforms as part of the local antioxidative defense system in normal and Barrett's esophagus</TI>
<SO>International Journal of Cancer</SO>
<YR>2003</YR>
<VL>105</VL>
<NO>3</NO>
<PG>300-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-2001" MODIFIED="2009-07-30 15:51:47 -0400" MODIFIED_BY="Karin L Dearness" NAME="Morris 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 15:51:47 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:51:47 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris CD, Byrne JP, Armstrong GR, Attwood SE</AU>
<TI>Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation</TI>
<SO>British Journal of Surgery</SO>
<YR>2001</YR>
<VL>88</VL>
<NO>10</NO>
<PG>1357-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niemantsverdriet-199" NAME="Niemantsverdriet 199" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niemantsverdriet E, Breumelhof R, Timmer R, Smout A</AU>
<TI>Oesophageal acid perception in Barrett's oesophagus</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>12</NO>
<PG>A52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Riordan-2004" MODIFIED="2009-07-30 15:52:09 -0400" MODIFIED_BY="Karin L Dearness" NAME="O'Riordan 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-30 15:52:09 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9610&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:52:09 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV</AU>
<TI>Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery</TI>
<SO>American Journal of Surgery</SO>
<YR>2004</YR>
<VL>188</VL>
<NO>1</NO>
<PG>27-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oberg-2001" MODIFIED="2009-07-30 15:52:25 -0400" MODIFIED_BY="Karin L Dearness" NAME="Oberg 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 15:52:25 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4932&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:52:25 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oberg S, Johansson J, Wenner J, Johnsson F, Zilling T, von Holstein CS, et al</AU>
<TI>Endoscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery</TI>
<SO>Annals of Surgery</SO>
<YR>2001</YR>
<VL>234</VL>
<NO>5</NO>
<PG>619-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ochando_x002d_Cerdan-2002" MODIFIED="2009-07-30 15:52:50 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ochando-Cerdan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:52:50 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1130-0108&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:52:50 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ochando Cerdan F, Hernandez Garcia-Gallardo D, Moreno Gonzalez E</AU>
<TI>Barrett's esophagus control after antireflux surgery</TI>
<SO>Revista Espanola de Enfermedades Digestivas</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>4</NO>
<PG>188-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oelschlager-2003" MODIFIED="2009-07-30 15:53:04 -0400" MODIFIED_BY="Karin L Dearness" NAME="Oelschlager 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:53:04 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4932&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:53:04 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA</AU>
<TI>Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery</TI>
<SO>Annals of Surgery</SO>
<YR>2003</YR>
<VL>238</VL>
<NO>4</NO>
<PG>458-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ofman-2000" MODIFIED="2009-08-27 16:12:20 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ofman 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-08-27 16:12:20 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ofman JJ, Lewin K, Ramers C, Ippoliti A, Lieberman D, Weinstein W</AU>
<TI>The economic impact of the diagnosis of dysplasia in Barrett's esophagus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>10</NO>
<PG>2946-52</PG>
<IDENTIFIERS MODIFIED="2009-08-27 12:08:23 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oleynikov-2003" MODIFIED="2009-07-30 15:54:09 -0400" MODIFIED_BY="Karin L Dearness" NAME="Oleynikov 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:54:09 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9610&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:54:09 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oleynikov D, Oelschlager B</AU>
<TI>New alternatives in the management of gastroesophageal reflux disease</TI>
<SO>American Journal of Surgery</SO>
<YR>2003</YR>
<VL>186</VL>
<NO>2</NO>
<PG>106-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olliver-2003" NAME="Olliver 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;1474-547x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olliver JR, Wild CP, Sahay P, Dexter S, Hardie LJ</AU>
<TI>Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9381</NO>
<PG>373-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ormsby-2002" MODIFIED="2009-07-30 15:54:31 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ormsby 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 15:54:31 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0017-5749&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:54:31 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ormsby AH, Petras RE, Henricks WH, Rice TW, Rybicki LA, Richter JE, et al</AU>
<TI>Observer variation in the diagnosis of superficial oesophageal adenocarcinoma</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>5</NO>
<PG>671-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortiz-1996b" MODIFIED="2009-08-27 12:09:48 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Ortiz 1996b" YEAR="1996">
<REFERENCE MODIFIED="2009-08-27 12:09:48 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J, et al</AU>
<TI>Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study</TI>
<SO>British Journal of Surgery</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>2</NO>
<PG>274-8</PG>
<IDENTIFIERS MODIFIED="2009-08-27 12:09:48 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortner-2003" MODIFIED="2009-07-30 15:55:31 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ortner 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:55:31 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0017-5749&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:55:31 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortner MA, Ebert B, Hein E, Zumbusch K, Nolte D, Sukowski U, et al</AU>
<TI>Time gated fluorescence spectroscopy in Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>1</NO>
<PG>28-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pacifico-2003" MODIFIED="2009-07-30 15:58:23 -0400" MODIFIED_BY="Karin L Dearness" NAME="Pacifico 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:58:23 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1542-3565&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:58:23 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pacifico RJ, Wang KK, Wongkeesong LM, Buttar NS, Lutzke LS</AU>
<TI>Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>4</NO>
<PG>252-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagani-2003" MODIFIED="2009-07-30 15:58:36 -0400" MODIFIED_BY="Karin L Dearness" NAME="Pagani 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 15:58:36 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1120-8694&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:58:36 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pagani M, Granelli P, Chella B, Antoniazzi L, Bonavina L, Peracchia A</AU>
<TI>Barrett's esophagus: combined treatment using argon plasma coagulation and laparoscopic antireflux surgery</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>4</NO>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panjehpour-2000" MODIFIED="2009-07-30 15:58:48 -0400" MODIFIED_BY="Karin L Dearness" NAME="Panjehpour 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 15:58:48 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 15:58:48 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panjehpour M, Overholt BF, Haydek JM, Lee SG</AU>
<TI>Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>9</NO>
<PG>2177-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panjehpour-2008" MODIFIED="2009-08-27 12:10:07 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Panjehpour 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-27 12:10:07 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panjehpour M, Coppola D, Overholt BF, Vo-Dinh T, Overholt S</AU>
<TI>Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression</TI>
<SO>Anticancer Research</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>1b</NO>
<PG>485-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1999b" MODIFIED="2009-08-27 12:10:14 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Peters 1999b" YEAR="1999">
<REFERENCE MODIFIED="2009-08-27 12:10:14 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters FT, Kuipers EJ, Ganesh S, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al</AU>
<TI>The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>7</NO>
<PG>921-6</PG>
<IDENTIFIERS MODIFIED="2009-08-27 12:10:14 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-2000" MODIFIED="2009-07-30 16:04:46 -0400" MODIFIED_BY="Karin L Dearness" NAME="Peters 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 16:04:46 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0036-5521&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:04:46 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Karrenbeld A, de Jager-Krikken A, et al</AU>
<TI>Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>12</NO>
<PG>1238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponce-2003" MODIFIED="2009-07-30 16:05:06 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ponce 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 16:05:06 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9610&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:05:06 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponce M, Ortiz V, Juan M, Garrigues V, Castellanos C, Ponce J</AU>
<TI>Gastroesophageal reflux, quality of life, and satisfaction in patients with achalasia treated with open cardiomyotomy and partial fundoplication</TI>
<SO>American Journal of Surgery</SO>
<YR>2003</YR>
<VL>185</VL>
<NO>6</NO>
<PG>560-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pouw-2008" MODIFIED="2009-08-27 16:12:01 -0400" MODIFIED_BY="Karin L Dearness" NAME="Pouw 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-27 16:12:01 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pouw RE, Gondrie JJ, Van Vilseren FG, Sondermeijer C, Rosmolen W, Curvers WL, et al</AU>
<TI>Stepwise circumferential and focal radiofrequency ablation in Barrett's esophagus with high-grade dysplasia and intramucosal cancer</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>134</VL>
<NO>4 Suppl 1</NO>
<PG>A-844</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pouw-2008b" MODIFIED="2009-08-27 12:10:47 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Pouw 2008b" YEAR="2008">
<REFERENCE MODIFIED="2009-08-27 12:10:47 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pouw RE, Gondrie JJ, Herrero LA, Van Vilsteren FG, Peters F, Rosmolen W, et al</AU>
<TI>A randomised prospective trial comparing the cap-technique and multi-band mucosectomy technique for piecemeal endoscopic resection in Barrett's esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2008</YR>
<VL>67</VL>
<NO>5</NO>
<PG>AB75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prasad-2007" MODIFIED="2009-08-27 16:11:52 -0400" MODIFIED_BY="Karin L Dearness" NAME="Prasad 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-27 16:11:52 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prasad GA, Wang KK, Buttar NS, Wongkeesing LM, Lutzke LS, Borkenhagen LS</AU>
<TI>Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>1</NO>
<PG>60-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ragunath-2003" NAME="Ragunath 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;0013-726x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ragunath K, Krasner N, Raman VS, Haqqani MT, Cheung WY</AU>
<TI>A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus</TI>
<SO>Endoscopy</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>12</NO>
<PG>998-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reed-1995" MODIFIED="2009-08-27 16:11:42 -0400" MODIFIED_BY="Karin L Dearness" NAME="Reed 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-27 16:11:42 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reed PI, Johnston BJ</AU>
<TI>Primary prevention of gastric cancer - the ECP-IM intervention study</TI>
<SO>Acta Endoscopica</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>1</NO>
<PG>45-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2002" MODIFIED="2009-07-30 16:06:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="Robinson 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:06:33 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0269-2813&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:06:33 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L</AU>
<TI>Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>445-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salminen-2002" MODIFIED="2009-07-30 16:06:48 -0400" MODIFIED_BY="Karin L Dearness" NAME="Salminen 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:06:48 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0785-3890&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:06:48 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salminen JT, Ramo OJ, Ahotupa MO, Farkkila MA, Salo JA</AU>
<TI>Increased DNA adducts in Barrett's esophagus and reflux-related esophageal malignancies</TI>
<SO>Annals of Medicine</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>7-8</NO>
<PG>565-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salo-1998" MODIFIED="2009-07-30 16:07:02 -0400" MODIFIED_BY="Karin L Dearness" NAME="Salo 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-07-30 16:07:02 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4932&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:07:02 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salo JA, Salminen JT, Kiviluoto TA, Nemlander AT, Ramo OJ, Farkkila MA, et al</AU>
<TI>Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery</TI>
<SO>Annals of Surgery</SO>
<YR>1998</YR>
<VL>227</VL>
<NO>1</NO>
<PG>40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sampliner-2002" MODIFIED="2009-07-30 16:07:18 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sampliner 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:07:18 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sampliner R, Camargo L, Fass R</AU>
<TI>Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>270-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sampliner-2004" MODIFIED="2009-07-30 16:07:31 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sampliner 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-30 16:07:31 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0016-5107&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:07:31 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sampliner RE</AU>
<TI>Endoscopic ablative therapy for Barrett's esophagus: current status</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>1</NO>
<PG>66-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-Bolton-2001" MODIFIED="2009-07-30 16:09:32 -0400" MODIFIED_BY="Karin L Dearness" NAME="Scott Bolton 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1091-255x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:07:45 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott Bolton J, Wu TT, Yeo CJ, Cameron JL, Heitmiller RF</AU>
<TI>Esophagectomy for adenocarcinoma in patients 45 years of age and younger</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>6</NO>
<PG>620-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2003" NAME="Sharma 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;0017-5749&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE</AU>
<TI>Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>1</NO>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2007" MODIFIED="2009-08-27 12:11:50 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Smith 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-27 12:11:50 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simth CD, Bejarano PA, Melvin WS, Patti MG, Muthusamy R, Dunkin BJ</AU>
<TI>Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patient using a balloon-based ablation system</TI>
<SO>Surgical Endoscopy</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>4</NO>
<PG>560-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smythe-2003" MODIFIED="2009-07-30 16:11:01 -0400" MODIFIED_BY="Karin L Dearness" NAME="Smythe 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 16:11:01 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0954-691x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:11:01 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smythe A, Bird NC, Troy GP, Ackroyd R, Johnson AG</AU>
<TI>Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastro-oesophageal reflux in patients with Barrett's oesophagus?</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>305-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soni-2000" MODIFIED="2009-07-30 16:11:14 -0400" MODIFIED_BY="Karin L Dearness" NAME="Soni 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 16:11:14 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:11:14 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soni A, Sampliner RE, Sonnenberg A</AU>
<TI>Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>8</NO>
<PG>2086-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sontag-1997" MODIFIED="2009-08-27 12:11:36 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Sontag 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-08-27 12:11:36 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sontag SJ, Schnell TG, Chejfec G, Kurucar C, Karpf J, Levine G</AU>
<TI>Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>1</NO>
<PG>147-56</PG>
<IDENTIFIERS MODIFIED="2009-08-27 12:11:36 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spechler-1992" MODIFIED="2009-07-30 16:12:15 -0400" MODIFIED_BY="Karin L Dearness" NAME="Spechler 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-07-30 16:12:15 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spechler SJ</AU>
<TI>Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>12</NO>
<PG>786-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spechler-2001" MODIFIED="2009-07-30 16:12:27 -0400" MODIFIED_BY="Karin L Dearness" NAME="Spechler 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 16:12:27 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:12:27 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al</AU>
<TI>Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>18</NO>
<PG>2331-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stolte-2000" MODIFIED="2009-07-30 16:12:38 -0400" MODIFIED_BY="Karin L Dearness" NAME="Stolte 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-30 16:12:38 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0036-5521&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:12:38 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stolte M, Vieth M, Schmitz JM, Alexandridis T, Seifert E</AU>
<TI>Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>11</NO>
<PG>1125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Streitz-1991" MODIFIED="2009-07-30 16:13:08 -0400" MODIFIED_BY="Karin L Dearness" NAME="Streitz 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-30 16:13:08 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4932&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:13:08 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Streitz JM Jr, Ellis FH Jr, Gibb SP, Balogh K, Watkins E Jr</AU>
<TI>Adenocarcinoma in Barrett's esophagus. A clinicopathologic study of 65 cases</TI>
<SO>Annals of Surgery</SO>
<YR>1991</YR>
<VL>213</VL>
<NO>2</NO>
<PG>122-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suspiro-2003" MODIFIED="2009-07-30 16:13:28 -0400" MODIFIED_BY="Karin L Dearness" NAME="Suspiro 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 16:13:28 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:13:28 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suspiro A, Pereira AD, Afonso A, Albuquerque C, Chaves P, Soares J, et al</AU>
<TI>Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>4</NO>
<PG>728-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taha-2003" MODIFIED="2009-08-27 12:12:07 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Taha 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-27 12:12:07 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taha AS, Angerson WJ, Morran CG</AU>
<TI>Reflux and Barrett's oesophagitis after gastric surgery: long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>4</NO>
<PG>547-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theisen-2002" MODIFIED="2009-07-30 16:14:15 -0400" MODIFIED_BY="Karin L Dearness" NAME="Theisen 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:14:15 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:14:15 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theisen J, Stein HJ, Dittler HJ, Feith M, Moebius C, Kauer WK, et al</AU>
<TI>Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus</TI>
<SO>Surgical Endoscopy</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>4</NO>
<PG>671-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomson-2003" MODIFIED="2009-07-30 16:15:08 -0400" MODIFIED_BY="Karin L Dearness" NAME="Thomson 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-30 16:15:08 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;1445-1433&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:15:08 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomson BN, Cade RJ</AU>
<TI>Oesophagectomy for early adenocarcinoma and dysplasia arising in Barrett's oesophagus</TI>
<SO>ANZ Journal of Surgery</SO>
<YR>2003</YR>
<VL>73</VL>
<NO>3</NO>
<PG>121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Todd-2002" MODIFIED="2009-07-30 16:15:31 -0400" MODIFIED_BY="Karin L Dearness" NAME="Todd 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:15:31 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0954-691x&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:15:31 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Todd JA, de Caestecker J</AU>
<TI>Surgery or endotherapy for high-grade dysplasia/early adenocarcinoma in Barrett's oesophagus?</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>10</NO>
<PG>1049-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tseng-2003" MODIFIED="2009-08-27 16:11:29 -0400" MODIFIED_BY="Karin L Dearness" NAME="Tseng 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-27 16:11:29 -0400" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tseng EE WT, Yeo CJ, Heitmiller RF</AU>
<TI>Barrett's esophagus with high grade dysplasia. Surgical results and long-term outcome - an update</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>2</NO>
<PG>164-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wehrmann-2001" MODIFIED="2009-08-27 16:11:21 -0400" MODIFIED_BY="Karin L Dearness" NAME="Wehrmann 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-27 16:11:21 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0044-2771&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 16:11:21 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wehrmann T, Lange P, Nakamura M, Riphaus A, Stergiou N</AU>
<TI>Endoscopic mucosal resection of premalignant lesions of the upper gastrointestinal tract</TI>
<SO>Zeitschrift fur Gastroenterologie</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>11</NO>
<PG>919-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiss-2006" MODIFIED="2009-08-27 12:13:04 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Weiss 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-27 12:13:04 -0400" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiss AA, Weisinger HA, Owen D</AU>
<TI>Photodynamic therapy in Barrett's esophagus: results of treatment of 17 patients</TI>
<SO>Canadian Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>4</NO>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weston-2002" MODIFIED="2009-07-30 16:17:16 -0400" MODIFIED_BY="Karin L Dearness" NAME="Weston 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:17:16 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0002-9270&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:17:16 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weston AP, Sharma P</AU>
<TI>Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>12</NO>
<PG>2998-3006</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetscher-2001" MODIFIED="2009-07-30 16:17:34 -0400" MODIFIED_BY="Karin L Dearness" NAME="Wetscher 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-30 16:17:34 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0003-4932&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:17:34 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetscher GJ, Gadenstaetter M, Klingler PJ, Weiss H, Obrist P, Wykypiel H, et al</AU>
<TI>Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease</TI>
<SO>Annals of Surgery</SO>
<YR>2001</YR>
<VL>234</VL>
<NO>5</NO>
<PG>627-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-2002" MODIFIED="2009-07-30 16:17:55 -0400" MODIFIED_BY="Karin L Dearness" NAME="White 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:17:55 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0007-1145&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:17:55 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White KL, Chalmers DM, Martin IG, Everett SM, Neville PM, Naylor G, et al</AU>
<TI>Dietary antioxidants and DNA damage in patients on long-term acid-suppression therapy: a randomized controlled study</TI>
<SO>British Journal of Nutrition</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>3</NO>
<PG>265-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wickramasinghe-2002" MODIFIED="2009-07-30 16:18:05 -0400" MODIFIED_BY="Karin L Dearness" NAME="Wickramasinghe 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:18:05 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0301-5629&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:18:05 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wickramasinghe KS, Chandrasoma PT, Chandraratna PA</AU>
<TI>Detection of Barrett's epithelium by acoustic microscopy</TI>
<SO>Ultrasound in Medicine and Biology</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>2</NO>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfsen-2002" MODIFIED="2009-07-30 16:18:15 -0400" MODIFIED_BY="Karin L Dearness" NAME="Wolfsen 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-30 16:18:15 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0025-6196&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 16:18:15 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfsen HC, Woodward TA, Raimondo M</AU>
<TI>Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>11</NO>
<PG>1176-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zopf-2001" MODIFIED="2009-08-27 16:11:10 -0400" MODIFIED_BY="Karin L Dearness" NAME="Zopf 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-27 16:11:10 -0400" MODIFIED_BY="Karin L Dearness" NOTES="&lt;p&gt;0723-5003&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 16:11:10 -0400" NOTES_MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zopf T, Rosenbaum A, Apel D, Jakobs R, Arnold JC, Riemann JF</AU>
<TI>Photodynamic therapy of dysplasias and early carcinomas in Barrett esophagus with a diode laser system - a pilot study</TI>
<SO>Medizinische Klinik</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>4</NO>
<PG>212-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-06-07 14:10:09 -0400" MODIFIED_BY="Karin Dearness">
<ADDITIONAL_REFERENCES MODIFIED="2011-06-07 14:10:09 -0400" MODIFIED_BY="Karin Dearness">
<REFERENCE ID="REF-Adballa-2004" MODIFIED="2009-07-31 10:07:17 -0400" MODIFIED_BY="Karin L Dearness" NAME="Adballa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat L, Sanderson IR, Fiztgerald RC</AU>
<TI>Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>14</NO>
<PG>4784-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andersohn-2006" MODIFIED="2009-08-27 16:10:56 -0400" MODIFIED_BY="Karin L Dearness" NAME="Andersohn 2006" TYPE="JOURNAL_ARTICLE">
<AU>Andersohn F, Suissa S, Garbe E</AU>
<TI>Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>113</VL>
<NO>16</NO>
<PG>1950-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AspECT" MODIFIED="2009-08-27 12:15:12 -0400" MODIFIED_BY="Jenny Bellorini" NAME="AspECT" TYPE="OTHER">
<AU>2004-003836-77</AU>
<TI>AspECT: A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia</TI>
<SO>http://www.octo-oxford.org.uk/alltrials/infollowup/aspect.html</SO>
<YR>(accessed 30 July 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bani_x002d_Hani-2000" MODIFIED="2009-07-31 10:08:01 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bani-Hani 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bani-Hani K, Sue-Ling H, Johnston D, Axon AT, Martin IG</AU>
<TI>Barrett's oesophagus: results from a 13-year surveillance programme</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>6</NO>
<PG>649-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baron-2003" MODIFIED="2009-07-31 10:08:16 -0400" MODIFIED_BY="Karin L Dearness" NAME="Baron 2003" TYPE="JOURNAL_ARTICLE">
<AU>Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al</AU>
<TI>A randomized trial of aspirin to prevent colorectal adenomas</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>10</NO>
<PG>891-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Basu-2002b" MODIFIED="2009-07-31 10:08:55 -0400" MODIFIED_BY="Karin L Dearness" NAME="Basu 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Basu KK, Pick B, Bale R, West KP, de Caestecker JS</AU>
<TI>Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>6</NO>
<PG>776-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-2003" MODIFIED="2009-08-27 12:16:07 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Bateman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, et al</AU>
<TI>Mortality study of 18,000 patients treated with omeprazole</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<PG>942-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blot-1991" MODIFIED="2009-07-31 10:09:32 -0400" MODIFIED_BY="Karin L Dearness" NAME="Blot 1991" TYPE="JOURNAL_ARTICLE">
<AU>Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF</AU>
<TI>Rising incidence of adenocarcinoma of the esophagus and gastric cardia</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>265</VL>
<PG>1287-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonelli-1993" MODIFIED="2009-07-31 10:10:00 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bonelli 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bonelli L, GOSPE (Gruppo Operativo per lo Studio delle Precancerosi Esofagee)</AU>
<TI>Barrett's esophagus: results of a multicentric survey</TI>
<SO>Endoscopy</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>9</NO>
<PG>652-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bresalier-2005" MODIFIED="2009-07-31 10:10:16 -0400" MODIFIED_BY="Karin L Dearness" NAME="Bresalier 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al</AU>
<TI>Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>11</NO>
<PG>1092-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BSG-2005" MODIFIED="2009-07-31 10:10:37 -0400" MODIFIED_BY="Karin L Dearness" NAME="BSG 2005" TYPE="OTHER">
<AU>Working Party of the British Society of Gastroenterology</AU>
<TI>Guidelines for the diagnosis and management of Barrett's columnar lined oesophagus</TI>
<SO>http://www.bsg.org.uk/images/stories/docs/clinical/guidelines/oesophageal/Barretts_Oes.pdf</SO>
<YR>2005</YR>
<PG>39p</PG>
<PB>British Society of Gastroenterology</PB>
<IDENTIFIERS MODIFIED="2009-07-30 11:07:44 -0400" MODIFIED_BY="Karin L Dearness"/>
</REFERENCE>
<REFERENCE ID="REF-Buttar-2002" NAME="Buttar 2002" TYPE="JOURNAL_ARTICLE">
<AU>Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, et al</AU>
<TI>Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>4</NO>
<PG>1101-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cameron-1990" MODIFIED="2009-08-27 13:57:15 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Cameron 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cameron A, Zinsmeister A, Ballard D, Carney J</AU>
<TI>Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings</TI>
<SO>Gastroenterology</SO>
<YR>1990</YR>
<VL>99</VL>
<PG>1918-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cameron-1992" MODIFIED="2009-08-27 16:10:46 -0400" MODIFIED_BY="Karin L Dearness" NAME="Cameron 1992" TYPE="JOURNAL_ARTICLE">
<AU>Cameron AJ, Lomboy CT</AU>
<TI>Barrett&#8217;s esophagus: age, prevalence and extent of columnar epithelium</TI>
<SO>Gastroenterology</SO>
<YR>1992</YR>
<VL>103</VL>
<PG>1241-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2007" MODIFIED="2009-07-31 10:11:34 -0400" MODIFIED_BY="Karin L Dearness" NAME="Chang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chang CL, Lao-Sirieix P, Save V, De La Cueva Mendez G, Laskey R, Fitzgerald  RC</AU>
<TI>Retinoic acid induced glandular differentiation of the oesophagus</TI>
<SO>Gut</SO>
<YR>2007</YR>
<VL>56</VL>
<PG>906-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2002" MODIFIED="2009-07-31 10:11:55 -0400" MODIFIED_BY="Karin L Dearness" NAME="Chen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chen X, Li N, Wang S, Hong J, Fang M, Youselfson J, et al</AU>
<TI>Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in rat surgical model</TI>
<SO>Carcinogenesis</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>12</NO>
<PG>2095-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2005" MODIFIED="2009-07-31 10:12:11 -0400" MODIFIED_BY="Karin L Dearness" NAME="Chen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chen LQ, Ferraro P, Martin J, Duranceau AC</AU>
<TI>Antireflux surgery for Barrett's esophagus: comparative results of the Nissen and Collis-Nissen operations</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>5</NO>
<PG>320-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2001" NAME="Clarke 2001" TYPE="OTHER">
<AU>Clarke</AU>
<TI>Cochrane Reviewers Handbook 4.1.4</TI>
<SO>Cochrane Collaboration</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clemons-2007" MODIFIED="2009-07-31 10:12:25 -0400" MODIFIED_BY="Karin L Dearness" NAME="Clemons 2007" TYPE="JOURNAL_ARTICLE">
<AU>Clemons NJ, McColl KE, Fitzgerald RC</AU>
<TI>Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms</TI>
<SO>Gastroenterology</SO>
<YR>2007</YR>
<VL>133</VL>
<NO>4</NO>
<PG>1198-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1998" MODIFIED="2009-07-31 10:12:34 -0400" MODIFIED_BY="Karin L Dearness" NAME="Cooper 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cooper BT, Neumann CS, Cox MA, Iqbal TH</AU>
<TI>Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>9</NO>
<PG>893-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corley-2003" MODIFIED="2009-08-27 16:10:28 -0400" MODIFIED_BY="Karin L Dearness" NAME="Corley 2003" TYPE="JOURNAL_ARTICLE">
<AU>Corley DA, Kerlikowske K, Verma R, Buffler P</AU>
<TI>Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>1</NO>
<PG>47-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CRUK-2006" MODIFIED="2009-07-31 10:13:05 -0400" MODIFIED_BY="Karin L Dearness" NAME="CRUK 2006" TYPE="OTHER">
<AU>Cancer Stats</AU>
<TI>Cancer Research UK 2006 website</TI>
<SO>http://info.cancerresearchuk.org/cancerstats</SO>
<YR>(accessed 6 June 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dekel-2003" MODIFIED="2009-08-27 16:10:38 -0400" MODIFIED_BY="Karin L Dearness" NAME="Dekel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dekel R, Wakelin DE, Wendel C, Green C, Sampliner RE, Garewal HS, et al</AU>
<TI>Progression or regression of Barrett's esophagus - it it all in the eye of the beholder?</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>12</NO>
<PG>2612-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dragnev-2005" MODIFIED="2009-07-31 10:13:46 -0400" MODIFIED_BY="Karin L Dearness" NAME="Dragnev 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, et al</AU>
<TI>Bexarotene and erlotinib for aerodigestive tract cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>34</NO>
<PG>8757-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunn-2008" MODIFIED="2009-07-31 10:13:55 -0400" MODIFIED_BY="Karin L Dearness" NAME="Dunn 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dunn J, Lovat L</AU>
<TI>Photodynamic therapy using 5-aminulaevulinic acid for the treatment of dysplasia in Barrett's oesophagus</TI>
<SO>Expert Opinion in Pharmacotherapy</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>5</NO>
<PG>851-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Serag-2004" MODIFIED="2009-07-31 10:14:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="El-Serag 2004" TYPE="JOURNAL_ARTICLE">
<AU>El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE</AU>
<TI>Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>10</NO>
<PG>1877-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ell-2000" MODIFIED="2009-07-31 10:14:43 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, et al</AU>
<TI>Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<PG>670-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enzinger-2003" MODIFIED="2009-07-31 10:14:58 -0400" MODIFIED_BY="Karin L Dearness" NAME="Enzinger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Enzinger PC, Mayer RJ</AU>
<TI>Esophageal Cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>23</NO>
<PG>2241-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-1996" MODIFIED="2009-08-27 12:16:51 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Fitzgerald 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald RC, Omary MB, Triadafilopoulos G</AU>
<TI>Dynamic effects of acid on Barrett&#8217;s esophagus: an ex vivo differentiation and proliferation model</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1996</YR>
<VL>98</VL>
<NO>9</NO>
<PG>2120-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-2005" MODIFIED="2009-08-27 16:09:56 -0400" MODIFIED_BY="Karin L Dearness" NAME="Fitzgerald 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald RC</AU>
<TI>Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>Suppl 1</NO>
<PG>21-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fountoulakis-2004" MODIFIED="2009-07-31 10:16:11 -0400" MODIFIED_BY="Karin L Dearness" NAME="Fountoulakis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Fountoulakis A, Zafirellis KD, Dolan K, Dexter SPL, Martin IG, Sue-Ling HM</AU>
<TI>Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer</TI>
<SO>British Journal of Surgery</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>8</NO>
<PG>997-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freemantle-2003" MODIFIED="2009-07-31 10:16:23 -0400" MODIFIED_BY="Karin L Dearness" NAME="Freemantle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Freemantle SJ, Spinella MJ, Dmiwtrovsky E</AU>
<TI>Retinoids in cancer therapy and chemoprevention: promise meets resistance</TI>
<SO>Oncogene</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>47</NO>
<PG>7305-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freemantle-2006" MODIFIED="2009-07-31 10:16:44 -0400" MODIFIED_BY="Karin L Dearness" NAME="Freemantle 2006" TYPE="JOURNAL_ARTICLE">
<AU>Freemantle SJ, Dragnev KH, Dmitrovsky E</AU>
<TI>The retinoic acid paradox in cancer chemoprevention</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>7</NO>
<PG>426-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ganz-2004" MODIFIED="2009-07-31 10:17:20 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ganz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ganz RA, Utley DS, Stern RA, Jackson J, Batts KP, Termin P</AU>
<TI>Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2004</YR>
<VL>60</VL>
<NO>6</NO>
<PG>1002-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gerner-1994" MODIFIED="2009-07-31 10:17:39 -0400" MODIFIED_BY="Karin L Dearness" NAME="Gerner 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gerner EW, Garewal HS, Emerson SS, Sampliner RE</AU>
<TI>Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine</TI>
<SO>Cancer Epidemiology, Biomarkers and Prevention</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>4</NO>
<PG>325-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gopal-2006" MODIFIED="2009-07-31 10:18:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="Gopal 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gopal DV, Chang EY, Kim CY, Sandone C, Pfau PR, Frick TJ, et al</AU>
<TI>EUS characteristics of Nissen fundoplication: normal appearance and mechanisms of failure</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>1</NO>
<PG>35-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haigh-2003" NAME="Haigh 2003" TYPE="JOURNAL_ARTICLE">
<AU>Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, et al</AU>
<TI>Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>3</NO>
<PG>615-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2004" MODIFIED="2009-07-31 10:19:03 -0400" MODIFIED_BY="Karin L Dearness" NAME="Harris 2004" TYPE="JOURNAL_ARTICLE">
<AU>Harris JC, Clarke PA, Awan A, Jankowski J, Watson SA</AU>
<TI>An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus</TI>
<SO>Cancer Research</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>6</NO>
<PG>1915-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Havelund-1988" MODIFIED="2009-07-31 10:19:22 -0400" MODIFIED_BY="Karin L Dearness" NAME="Havelund 1988" TYPE="JOURNAL_ARTICLE">
<AU>Havelund T, Laursen LS, Skoubo-Kristensen E, Andersen BN, Pedersen SA, Jensen KB, et al</AU>
<TI>Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial</TI>
<SO>British Medical Journal (Clinical Research Ed.)</SO>
<YR>1988</YR>
<VL>296</VL>
<NO>6615</NO>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heath-2003" MODIFIED="2009-09-22 16:11:14 -0400" MODIFIED_BY="Karin L Dearness" NAME="Heath 2003" TYPE="JOURNAL_ARTICLE">
<AU>Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, et al</AU>
<TI>Chemoprevention for Barrett's esophagus trial. Design and outcome measures</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>177-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-08-27 16:09:43 -0400" MODIFIED_BY="Karin L Dearness" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="http://www. cochrane.org/resources/handbook/hbook.htm"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hillman-2004" MODIFIED="2009-07-31 10:19:40 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hillman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC</AU>
<TI>Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus</TI>
<SO>Medical Journal of Australia</SO>
<YR>2004</YR>
<VL>180</VL>
<NO>8</NO>
<PG>387-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hinder-1997" MODIFIED="2009-07-31 10:20:00 -0400" MODIFIED_BY="Karin L Dearness" NAME="Hinder 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hinder RA, Perdikis G, Klinger PJ, DeVault KR</AU>
<TI>The surgical option for gastroesophageal reflux disease</TI>
<SO>American Journal of Medicine</SO>
<YR>1997</YR>
<VL>103</VL>
<NO>5A</NO>
<PG>144S-8S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-2005" MODIFIED="2009-07-31 10:21:08 -0400" MODIFIED_BY="Karin L Dearness" NAME="Jackson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Jackson CC, DeMeester SR</AU>
<TI>Surgical therapy for Barrett's esophagus</TI>
<SO>Thoracic Surgery Clinics</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>3</NO>
<PG>429-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnston-1999" MODIFIED="2009-07-31 10:21:27 -0400" MODIFIED_BY="Karin L Dearness" NAME="Johnston 1999" TYPE="JOURNAL_ARTICLE">
<AU>Johnston CM, Schoenfeld LP, Mysore JV, Dubois A</AU>
<TI>Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1999</YR>
<VL>50</VL>
<NO>1</NO>
<PG>86-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jolly-2004" MODIFIED="2009-07-31 10:21:50 -0400" MODIFIED_BY="Karin L Dearness" NAME="Jolly 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jolly AJ, Wild CP, Hardie LJ</AU>
<TI>Acid and bile salts induce DNA damage in human oesophageal cell lines</TI>
<SO>Mutagenesis</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>4</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khuri-2006" MODIFIED="2009-07-31 10:22:03 -0400" MODIFIED_BY="Karin L Dearness" NAME="Khuri 2006" TYPE="JOURNAL_ARTICLE">
<AU>Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al</AU>
<TI>Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>7</NO>
<PG>441-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-1995" NAME="Kim 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kim R, Baggott BB, Rose S, Shar AO, Mallory DL, Lasky SS, et al</AU>
<TI>Quantitative endoscopy: precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus</TI>
<SO>Gastroenterology</SO>
<YR>1995</YR>
<VL>108</VL>
<NO>2</NO>
<PG>360-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lao_x002d_Sirieix-2007" MODIFIED="2009-07-31 10:22:25 -0400" MODIFIED_BY="Karin L Dearness" NAME="Lao-Sirieix 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lao-Sirieix P, Roy A, Worral C, Vowler SL, Gardiner S, Fiztgerald RC</AU>
<TI>Effect of acid suppression on molecular predictors for esophageal cancer</TI>
<SO>Cancer Epidemiology, Biomarkers and Prevention</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>2</NO>
<PG>288-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luman-1995" MODIFIED="2009-08-04 11:04:48 -0400" MODIFIED_BY="Karin L Dearness" NAME="Luman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Luman W, Lessels AM, Palmer KR</AU>
<TI>Laser photoablation of Barrett's oesophagus - Nd-YAG is ineffective</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1995</YR>
<VL>1995</VL>
<NO>10</NO>
<PG>A95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mehta-2006" MODIFIED="2009-07-31 10:22:39 -0400" MODIFIED_BY="Karin L Dearness" NAME="Mehta 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mehta S, Bennett J, Mahon D, Rhodes M</AU>
<TI>Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: seven-year follow-up</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>9</NO>
<PG>1312-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miwa-2005" MODIFIED="2009-08-27 16:09:33 -0400" MODIFIED_BY="Karin L Dearness" NAME="Miwa 2005" TYPE="JOURNAL_ARTICLE">
<AU>Miwa K, Oyama K, Fujimura T</AU>
<TI>A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats</TI>
<SO>Nippon Rinsho. Japanese Journal of Clinical Medicine</SO>
<YR>2005</YR>
<VL>63</VL>
<NO>8</NO>
<PG>1387-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2001" MODIFIED="2009-07-31 10:23:08 -0400" MODIFIED_BY="Karin L Dearness" NAME="Moore 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moore KH, Barry P, Burn J, Falk G</AU>
<TI>Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study</TI>
<SO>Diseases of the Esophagus</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC-working-party-2002" MODIFIED="2009-07-17 06:28:58 -0400" MODIFIED_BY="[Empty name]" NAME="MRC working party 2002" TYPE="JOURNAL_ARTICLE">
<AU>MRC Oesophageal Cancer Working Party</AU>
<TI>Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9319</NO>
<PG>1727-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2004" MODIFIED="2009-08-27 12:18:30 -0400" MODIFIED_BY="Jenny Bellorini" NAME="NICE 2004" TYPE="OTHER">
<AU>NICE</AU>
<TI>Photodynamic therapy for high-grade dysplasia in Barrett's oesophagus</TI>
<SO>National Institute for Clinical Excellence Interventional Procedure Guidance</SO>
<YR>2004</YR>
<VL>82 (http://www.nice.org.uk/page.aspx?o=IPG082guidance)</VL>
<IDENTIFIERS MODIFIED="2009-08-27 12:18:18 -0400" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2005" MODIFIED="2009-08-27 12:20:35 -0400" MODIFIED_BY="Jenny Bellorini" NAME="NICE 2005" TYPE="OTHER">
<AU>NICE</AU>
<TI>Dyspepsia - management of dyspepsia in adults in primary care</TI>
<SO>National Institute for Clinical Excellence Clinical Guidance</SO>
<YR>2005</YR>
<VL>CG17</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nijhawan-2000" MODIFIED="2009-07-31 10:23:32 -0400" MODIFIED_BY="Karin L Dearness" NAME="Nijhawan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nijhawan PK, Wang KK</AU>
<TI>Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2000</YR>
<VL>52</VL>
<NO>3</NO>
<PG>328-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norberto-2004" MODIFIED="2009-07-31 10:23:42 -0400" MODIFIED_BY="Karin L Dearness" NAME="Norberto 2004" TYPE="JOURNAL_ARTICLE">
<AU>Norberto L, Polese L, Angriman I, Erroi F, Cecchetto A, D'Amico DF</AU>
<TI>High-energy laser therapy of Barrett's esophagus: preliminary results</TI>
<SO>World Journal of Surgery</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>4</NO>
<PG>350-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ortiz-1996" MODIFIED="2009-08-04 11:10:27 -0400" MODIFIED_BY="Karin L Dearness" NAME="Ortiz 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J, et al</AU>
<TI>Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study</TI>
<SO>British Journal of Surgery</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>2</NO>
<PG>274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ouatu_x002d_Lascar-1999" MODIFIED="2009-08-27 13:57:30 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Ouatu-Lascar 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ouatu-Lascar R, Fitzgerald R, Triadafilopoulos G</AU>
<TI>Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>117</VL>
<PG>327-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overholt-1997" MODIFIED="2009-08-27 16:10:14 -0400" MODIFIED_BY="Karin L Dearness" NAME="Overholt 1997" TYPE="JOURNAL_ARTICLE">
<AU>Overholt BF, Panjehpour M, Ayres M</AU>
<TI>Photodynamic therapy for Barrett's esophagus: cardiac effects</TI>
<SO>Lasers in Surgery and Medicine</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>4</NO>
<PG>317-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overholt-2007" MODIFIED="2009-08-27 16:09:22 -0400" MODIFIED_BY="Karin L Dearness" NAME="Overholt 2007" TYPE="JOURNAL_ARTICLE">
<AU>Overholt BF, Wang KK, Burdick S, Lightdale C, Kimmney M, Nava H, et al</AU>
<TI>A 5-year randomized phase III trial of efficacy and safety of photodynamic therapy using porfimer sodium in high-grade dysplasia in Barrett's esophagus</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>3</NO>
<PG>460-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pera-1993" MODIFIED="2009-07-31 10:25:17 -0400" MODIFIED_BY="Karin L Dearness" NAME="Pera 1993" TYPE="JOURNAL_ARTICLE">
<AU>Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zermeister AR</AU>
<TI>Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction</TI>
<SO>Gastroenterology</SO>
<YR>1993</YR>
<VL>104</VL>
<PG>510-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pessaux-2002" NAME="Pessaux 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pessaux P, Arnaud JP, Ghavami B, Flament JB, Trebuchet G, Meyer C, et al</AU>
<TI>Morbidity of laparoscopic fundoplication for gastroesophageal reflux: a retrospective study about 1470 patients</TI>
<SO>Hepatogastroenterology</SO>
<YR>2002</YR>
<VL>49</VL>
<NO>44</NO>
<PG>447-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-08-27 12:24:13 -0400" MODIFIED_BY="Jenny Bellorini" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0.20</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1998" MODIFIED="2009-08-27 16:09:15 -0400" MODIFIED_BY="Karin L Dearness" NAME="Robinson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Robinson M, Earnest D, Rodriguez-Stanley S, Greenwood-Van Meerveld B, Jaffe P, et al</AU>
<TI>Heartburn requiring frequent antacid use may indicate significant illness</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>21</NO>
<PG>2373-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romagnoli-2003" MODIFIED="2009-07-31 10:26:46 -0400" MODIFIED_BY="Karin L Dearness" NAME="Romagnoli 2003" TYPE="JOURNAL_ARTICLE">
<AU>Romagnoli R, Collard JM, Gutschow C, Yamusah N, Salizzoni M</AU>
<TI>Outcomes of dysplasia arising in Barrett's esophagus: a dynamic view</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2003</YR>
<VL>197</VL>
<NO>3</NO>
<PG>365-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ronkainen-2005" NAME="Ronkainen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al</AU>
<TI>Prevalence of Barrett's esophagus in the general population: an endoscopic study</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>6</NO>
<PG>1825-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossi-2006" MODIFIED="2009-07-31 10:29:02 -0400" MODIFIED_BY="Karin L Dearness" NAME="Rossi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rossi M, Barreca M, de Bortoli N, Renzi C, Santi S, Gennai A, et al</AU>
<TI>Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett's esophagus</TI>
<SO>Annals of Surgery</SO>
<YR>2006</YR>
<VL>243</VL>
<NO>1</NO>
<PG>58-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sadeghi-2008" MODIFIED="2009-07-31 10:29:21 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sadeghi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC, et al</AU>
<TI>Aspirin, nonsteroidal antiinflammatory drugs, and the risks of cancers of the esophagus</TI>
<SO>Cancer Epidemiology, Biomarkers and Prevention</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>5</NO>
<PG>1169-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sampliner-2001" MODIFIED="2009-07-31 10:29:32 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sampliner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sampliner RE, Faigel D, Fennerty MB, Lieberman D, Ippoliti A, Lewin K, et al</AU>
<TI>Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>2001</YR>
<VL>53</VL>
<NO>6</NO>
<PG>554-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandler-2003" MODIFIED="2009-07-31 10:29:43 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sandler 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al</AU>
<TI>A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>10</NO>
<PG>883-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sarr-1985" MODIFIED="2009-08-27 16:09:04 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sarr 1985" TYPE="JOURNAL_ARTICLE">
<AU>Sarr MG, Hamilton SR, Marrone GC, Cameron JL</AU>
<TI>Barrett&#8217;s esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux</TI>
<SO>American Journal of Surgery</SO>
<YR>1985</YR>
<VL>149</VL>
<PG>187-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharma-1997" MODIFIED="2009-07-31 10:35:13 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sharma 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sharma P, Sampliner RE, Camargo E</AU>
<TI>Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>4</NO>
<PG>582-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shirvani-2000" MODIFIED="2009-08-27 16:08:57 -0400" MODIFIED_BY="Karin L Dearness" NAME="Shirvani 2000" TYPE="JOURNAL_ARTICLE">
<AU>Shirvani V, Ouatu-Luscar R, Kaur B, Omary M, Traidafilopoulos G</AU>
<TI>Cyclo-oxygenase 2 expression in Barrett's esophagus and adenocarcinoma. Ex vivo induction by bile salts and acid exposure</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>3</NO>
<PG>487-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simon-2005" MODIFIED="2009-08-27 16:08:44 -0400" MODIFIED_BY="Karin L Dearness" NAME="Simon 2005" TYPE="JOURNAL_ARTICLE">
<AU>Simon LS, White WB, Macdonald TM, Pan S, Rosenstein RB, Gaffney M</AU>
<TI>Cardiovascular safety of celecoxib: a meta-analysis of 41 clinical studies in 44,300 patients</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>9</NO>
<PG>S406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2005" MODIFIED="2009-07-31 10:35:43 -0400" MODIFIED_BY="Karin L Dearness" NAME="Smith 2005" TYPE="JOURNAL_ARTICLE">
<AU>Smith CD, McClusky DA, Rajad MA, Lederman AB, Hunter JG</AU>
<TI>When fundoplication fails: redo?</TI>
<SO>Annals of Surgery</SO>
<YR>2005</YR>
<VL>241</VL>
<NO>6</NO>
<PG>861-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Souza-2002" NAME="Souza 2002" TYPE="JOURNAL_ARTICLE">
<AU>Souza RF, Shewmake K, Terada LS, Spechler SJ</AU>
<TI>Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>2</NO>
<PG>299-307</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Streitz-1993" MODIFIED="2009-07-31 10:36:43 -0400" MODIFIED_BY="Karin L Dearness" NAME="Streitz 1993" TYPE="JOURNAL_ARTICLE">
<AU>Streitz JM Jr, Andrews CW Jr, Ellis FH Jr</AU>
<TI>Endoscopic surveillance of Barrett's esophagus. Does it help?</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1993</YR>
<VL>105</VL>
<NO>3</NO>
<PG>383-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturmer-1998" MODIFIED="2009-07-31 10:36:59 -0400" MODIFIED_BY="Karin L Dearness" NAME="Sturmer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH</AU>
<TI>Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1998</YR>
<VL>128</VL>
<NO>9</NO>
<PG>713-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Theisen-2003" MODIFIED="2009-08-27 16:08:27 -0400" MODIFIED_BY="Karin L Dearness" NAME="Theisen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Theisen J, Peters JH, Stein HJ</AU>
<TI>Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus</TI>
<SO>World Journal of Surgery</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1018-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thun-2002" MODIFIED="2009-07-31 10:37:23 -0400" MODIFIED_BY="Karin L Dearness" NAME="Thun 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thun MJ, Henley SJ, Patrono C</AU>
<TI>Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>4</NO>
<PG>252-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Triadafilopoulos-2000" MODIFIED="2009-08-27 08:48:21 -0400" MODIFIED_BY="Jenny Bellorini" NAME="Triadafilopoulos 2000" TYPE="JOURNAL_ARTICLE">
<AU>Triadafilopoulos G</AU>
<TI>Proton pump inhibitors for Barrett's oesophagus</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>2</NO>
<PG>144-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tytgat-2001" MODIFIED="2009-07-31 10:37:54 -0400" MODIFIED_BY="Karin L Dearness" NAME="Tytgat 2001" TYPE="JOURNAL_ARTICLE">
<AU>Tytgat GNJ</AU>
<TI>Review article: long-term use of proton pump inhibitors in GORD- help or hindrance</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>Suppl 2</NO>
<PG>6-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vallb_x00f6_hmer-2006" MODIFIED="2009-11-02 09:46:55 -0500" MODIFIED_BY="Karin L Dearness" NAME="Vallböhmer 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vallböhmer D, DeMeester SR, Oh DS, Banki F, Kuramochi H, Shimizu D, et al</AU>
<TI>Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>7</NO>
<PG>1458-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vaughan-2005" MODIFIED="2009-08-27 16:08:20 -0400" MODIFIED_BY="Karin L Dearness" NAME="Vaughan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al</AU>
<TI>Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study</TI>
<SO>Lancet Oncology</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>12</NO>
<PG>945-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Viljakka-1997" MODIFIED="2009-07-31 10:38:17 -0400" MODIFIED_BY="Karin L Dearness" NAME="Viljakka 1997" TYPE="JOURNAL_ARTICLE">
<AU>Viljakka MT, Luostarinen ME, Isolauri JO</AU>
<TI>Complications of open and laparoscopic antireflux surgery: 32-year audit at a teaching hospital</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>1997</YR>
<VL>185</VL>
<NO>5</NO>
<PG>446-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2008" MODIFIED="2009-07-31 10:38:41 -0400" MODIFIED_BY="Karin L Dearness" NAME="Wang 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wang KK, Sampliner RE</AU>
<TI>Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>103</VL>
<PG>788-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winters-1987" MODIFIED="2009-08-27 16:08:11 -0400" MODIFIED_BY="Karin L Dearness" NAME="Winters 1987" TYPE="JOURNAL_ARTICLE">
<AU>Winters C, Spurling T, Chobanian S, Curtis D, Esposito RL, Hacker JF 3rd, et al</AU>
<TI>Barrett's esophagus: a prevalent occult complication of gastro-oesophageal reflux disease</TI>
<SO>Gastroenterology</SO>
<YR>1987</YR>
<VL>92</VL>
<NO>1</NO>
<PG>118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2005" MODIFIED="2009-07-31 10:40:34 -0400" MODIFIED_BY="Karin L Dearness" NAME="Yeh 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yeh RW, Triadafilopoulos G</AU>
<TI>Endoscopic therapy for Barrett's esophagus</TI>
<SO>Gastrointestinal Endoscopy Clinics of North America</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>3</NO>
<PG>377-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yousef-2008" MODIFIED="2009-08-27 16:07:57 -0400" MODIFIED_BY="Karin L Dearness" NAME="Yousef 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L</AU>
<TI>The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2008</YR>
<VL>168</VL>
<PG>237-49</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-09-23 15:24:53 -0400" MODIFIED_BY="Karin L Dearness">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-09-23 15:13:51 -0400" MODIFIED_BY="Karin L Dearness" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-09-22 16:15:46 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Ackroyd-2000">
<CHAR_METHODS MODIFIED="2009-08-27 11:14:43 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Prospective randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>36 individuals with Barrett's oesophagus and confirmed LGD<BR/>30 M: 6 F<BR/>Median age 56 (30 to 71)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-22 16:15:46 -0400" MODIFIED_BY="Karin L Dearness">
<P>5-ALA (aminolevulinic acid) PDT and omeprazole 20 mg od and laser (green light 514 nm) per 3 cm<BR/>vs<BR/>Placebo (omeprazole 20 mg od)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>Presence or absence of Barrett's and/or dysplasia (length/area)<BR/>(endoscopic/histological-6 Bx) at T 1/12, 6/12, 12/12, 24/12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Bright-2007">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>Prospective randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>0 individuals 32 M :8 F<BR/>Mean age 49</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>Post-surgery<BR/>Argon plasma coagulation (up to 6 treatments)<BR/>or<BR/>Surveillance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>Presence or absence of Barrett's (endoscopic/histological)<BR/>Regression of Barrett's by length<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness">
<P>This study is looking at long-term follow up from the patients in <LINK REF="STD-Ackroyd-2004" TYPE="STUDY">Ackroyd 2004</LINK>. Data from this article will only be used to discuss long-term efficacy of PDT.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Caldwell-1996">
<CHAR_METHODS>
<P>Prospective randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 individuals<BR/>20 completed study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness">
<P>Omeprazole 20 mg od vs Cimetidine 300 mg tds</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness">
<P>Endoscopic length of Barrett's oesophagus and presence of squamous islands</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 11:58:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dulai-2005">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness">
<P>Prospective, single blind, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-16 11:58:26 -0400" MODIFIED_BY="[Empty name]">
<P>52 individuals<BR/>26 APC vs 26 MPEC<BR/>APC mean age 58 (21 M: 5 F)<BR/>MPEC mean age 56 (18 M : 8F)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness">
<P>Argon plasma coagulation + pantoprazole 40 mg bd vs multipolar coagulation + pantoprazole 40 mg bd pantoprazole inc. if symptomatic or persistent oesophagitis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness">
<P>Primary:<BR/>Number of treatments with APC vs MPEC to achieve endoscopic ablation or treatment failure (6 or more Rx with no endoscopic or histological response)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness">
<P>Secondary<BR/>Proportion of patients with endoscopic regression<BR/>Proportion of patients with histological Barrett's oesophagus regression<BR/>Proportion of patients with post-treatment symptoms</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 11:59:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hage-2004">
<CHAR_METHODS MODIFIED="2009-08-27 11:13:31 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Prospective randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness">
<P>40 individuals<BR/>31 M: 9 F<BR/>Mean age 59</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 11:18:49 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Argon plasma coagulation (65 w)<BR/>or<BR/>5-ALA PDT 60 mg/kg (100 J/cm<SUP>2</SUP>)<BR/>or<BR/>5-ALA PDT 60 mg/kg (high dose 100 + 20 J/cm<SUP>2</SUP> divided) administration regime)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 11:59:46 -0400" MODIFIED_BY="[Empty name]">
<P>Presence or absence of BE/IM (endoscopic/histological)<BR/>&amp;<BR/>Regression of Barrett's<BR/>6/52, 6/12, 12/12, 18/12, 24/12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness">
<P>25 watts max dose 1000 J</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Heath-2007">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness">
<P>Phase IIb, randomised, parallel treatment, placebo controlled, double masked, multicentre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness">
<P>100 patients randomised to celecoxib (n = 49) or placebo (n = 51)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness">
<P>Celecoxib 200 mg twice daily or placebo twice daily for at least a year and a maximum of 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness">
<P>Primary study outcomes: safety and efficacy of celecoxib for regression of dysplasia in patients with Barrett's oesophagus (including overall mortality, morbidity, adverse drug reactions)</P>
<P>Secondary study outcomes: change from baseline in the highest grade of dysplasia, extend of HGD, extent of LGD and surface area of Barrett's oesophagus</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-23 15:13:51 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Kelty-2004">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness">
<P>72 individuals; 4 withdrew; N = 68<BR/>58 M:14 F. Median age 61</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness">
<P>APC (65 W) +PPI or ALA (85 J/cm<SUP>2</SUP>) + PPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-23 15:13:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>Presence or absence of BE/IM (endoscopic/histological) at 4/52, 6/12, 12/12, 24/12<BR/>Median number of treatments to achieve complete macroscopic reversal<BR/>Side effects at 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Maximal 5 treatments</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Luman-1996">
<CHAR_METHODS>
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 individuals, 6M, 2F. All completed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness">
<P>Omeprazole 40 mg od vs omeprazole 40 mg od with 4 to 6-weekly Nd-Yag laser for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness">
<P>Omeprazole 40 mg od vs omeprazole 40mg od with 4 to 6-weekly Nd-Yag laser for 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Full publication of abstract version</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Mackenzie-2008">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>Prospective randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>Planned 66, 40 recruited and 32 treated so far (16 for ALA and 16 for porfimer sodium)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>Porfimer sodium: use the standard protocol (no more details)</P>
<P>ALA: 60 mg/kg, activated by 1178 J/cm of red laser light</P>
<P>Follow up with quadrantic biopsies every 2 cm at 6 weeks, 4 months and 1 year post-therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 11:04:35 -0400" MODIFIED_BY="[Empty name]">
<P>Not clearly stated in the abstract</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 11:04:51 -0400" MODIFIED_BY="[Empty name]">
<P>Published in abstract format</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Overholt-2005">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>Multicentre, randomised, partially blinded clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>485 patients screened, 208 in the intention-to-treat group and 202 in the safety group<BR/>Randomised 2:1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>PDT (130 J/cm<SUP>2</SUP>) after 2 mg/kg porfimer sodium, using diffuser with centring balloon. Focal nodules pretreated with 50 J/cm<SUP>2</SUP> PDT with bare fibre with omeprazole 20 mg bd versus omeprazole 20 mg bd alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>Primary: complete ablation of HGD at any time<BR/>Secondary:<BR/>Occurrence of cancer, duration of complete ablation, quality and duration of a complete response, time to progression to cancer and time to treatment failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Parrilla-2003">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>Prospective, randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness">
<P>113 individuals<BR/>(12 declined surveillance)<BR/>101 in study<BR/>72 M: 29 F<BR/>Median age medical 50, surgical 43</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 11:27:30 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Acid suppression (ranitidine 1982 to 1992 omeprazole 20 mg 1992 to 2000)<BR/>vs<BR/>Surgery (Short Nissen 56 or Collis Nissen 2); no acid suppression</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness">
<P>Clinical symptoms<BR/>Presence or absence of Barrett's oesophagus (endoscopic and histological)<BR/>Surgical group functional studies</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomisation not specified<BR/>Paper using same patients published 1996; concern re. the prospective nature of study<BR/>Medical 51 to 43<BR/>Surgical 62 to 58<BR/>Only per protocol data given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Peters-1999">
<CHAR_METHODS>
<P>Prospective randomised double blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>68 individuals entered, 61 suitable, 43M, 18F. 53 completed study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-07 15:14:57 -0400" MODIFIED_BY="Karin L Dearness">
<P>Acid suppression with ranitidine 150 mg bd versus omeprazole 20 mg bd</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness">
<P>Clinical symptoms, length and surface area of Barrett's oesophagus, % reflux, presence of oesophagitis and lower oesophageal sphincter pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Ragunath-2005">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>Prospective, randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>32 patients identified, 26 patients suitable<BR/>21 M, 5 F. 22 completed 12 months of follow up</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>APC was performed at a power setting of 65 W and argon gas flow at 1.8 l/min in 1 to 6 sessions (mean 5)<BR/>versus<BR/>PDT was performed 48 hours after intravenous injection of porfimer sodium 2 mg/kg with a 630 nm red laser light, 200 J/cm through a PDT<BR/>balloon in 1 session</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>Cost-effectiveness and eradication of dysplastic Barrett's</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Shaheen-2008">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>Randomised, sham-controlled design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>127 patients enrolled (64 LGD and 63 HGD); 117 completed the study (59 LGD and 58 HGD)<BR/>RFA: 40 LGD and 38 HGD completed<BR/>Sham: 19 LGD and 20 HGD completed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>Radio frequency ablation: 40 W/cm<SUP>2</SUP> and 12 J/cm<SUP>2</SUP>; repeat RFA at 2, 4, 9 months if residual Barrett's oesophagus</P>
<P>All patients had high-dose PPI for the duration of the study (40 mg bd)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>12 months primary outcome:<BR/>Complete response for dysplasia (HGD and LGD cohorts)<BR/>Complete response for intestinal metaplasia</P>
<P>Secondary outcome:<BR/>Histological progression (HGD to AC, LGD to AC)<BR/>Adverse event incidence<BR/>Sub-squamous intestinal metaplasia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Sharma-2006">
<CHAR_METHODS MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>Prospective, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>35 patients enrolled</P>
<P>34 M: 1 F. 35 completed the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>Multipolar electrocoagulation 20 W continuous power</P>
<P>APC: 60W gas flow 1.4 to 1.8 L/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>Primary: endoscopic and histological reversal of Barrett's oesophagus</P>
<P>Secondary: side effects, number of treatments, clinical factor (age, length of Barrett's oesophagus, hiatus hernia size, PPI, pH score)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Weinstein-1996">
<CHAR_METHODS MODIFIED="2009-08-27 11:34:21 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Controlled, randomised double blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>106 individuals<BR/>(97 completed more than 6 months follow up)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-07 15:29:19 -0400" MODIFIED_BY="Karin L Dearness">
<P>Acid suppression with ranitidine (150 mg bd) for 2 years vs omeprazole 80 mg for 1 year, then 40 mg in second year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>Length, area and presence of squamous islands at T0, T12/12 and T24/12 (endoscopically)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>No information on randomisation, diagnostic criteria of Barrett's oesophagus</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AC = adenocarcinoma<BR/>ALA = aminolevulinic acid<BR/>APC = argon plasma coagulation<BR/>bd = twice daily<BR/>F = female<BR/>HGD = high-grade dysplasia<BR/>IM = intestinal metaplasia<BR/>LGD = low-grade dysplasia<BR/>M = male<BR/>MPEC = multipolar electrocautery<BR/>od = once daily<BR/>PDT = photodynamic therapy<BR/>PPI = proton pump inhibitor<BR/>RFA = radiofrequency ablation<BR/>tds = three times daily<BR/>vs = versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-09-23 15:24:53 -0400" MODIFIED_BY="Karin L Dearness" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:43 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ackroyd-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:43 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:44 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ackroyd-1996b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:44 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:43:25 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ackroyd-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:43:25 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:19:49 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Ackroyd-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:19:49 -0400" MODIFIED_BY="Karin L Dearness">
<P>Short-term follow up of the patients presented in <LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aguirre-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aguirre-2003b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:45 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Attwood-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:45 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:46 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Barham-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:46 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barr-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:47 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Basu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:47 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:47 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Bellnier-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:47 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:48 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Bowers-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:48 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:48 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Bowers-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:48 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:49 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Braghetto-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:49 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:49 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Cameron-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:49 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:50 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Canto-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:50 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:17 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Caos-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:17 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Detected difference not change in Barrett's oesophagus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:51 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Carlson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:51 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:45:14 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Csendes-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:45:14 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:51 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Csendes-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:51 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:52 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Dar-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:52 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DeMeester-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deviere-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:53 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Dietz-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:53 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:53 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Doak-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:53 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:54 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Egger-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:54 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:54 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Eubanks-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:54 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:55 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Familiari-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:55 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:45:24 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Farrell-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:45:24 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised, non-human</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:56 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Felix-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:56 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:56 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ferguson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:56 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:57 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fitzgerald-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:57 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:57 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fleischer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:57 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:24:53 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Foroulis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:24:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:58 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Fujii-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:58 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:41:59 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Gastal-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:41:59 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:00 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Gossner-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:00 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:00 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Gurski-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:00 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-31 11:11:10 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Hage-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-08 06:03:18 -0500" MODIFIED_BY="[Empty name]">
<P>Did not fulfil endpoints</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:01 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Headrick-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:01 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:01 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Heath-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:01 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hebbard-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:02 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Hetzel-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:02 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:03 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Hill-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:03 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:04 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Hillman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:04 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:23:56 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Hinnen-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:23:56 -0400" MODIFIED_BY="Karin L Dearness">
<P>Endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:04 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Hofstetter-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:04 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:23:52 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Hornick-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:23:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:05 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Hur-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:05 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:05 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Incarbone-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:05 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:06 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ito-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:06 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised gastric study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:07 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Javaid-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:07 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:23:42 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Johnston-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:23:42 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jung-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:07 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Kamolz-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:07 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:08 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Kashtan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:08 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:08 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Kaur-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:08 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:23:30 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Keeley-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:23:30 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:09 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Krska-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:09 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:23:20 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Lanas-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:23:20 -0400" MODIFIED_BY="Karin L Dearness">
<P>Only 6-month follow up and regression of Barrett's oesophagus not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:10 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Luostarinen-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:10 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:10 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Malhi_x002d_Chowla-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:10 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:22:54 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Manner-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:22:54 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marcus-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:11 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-May-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:11 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:12 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Menke_x002d_Pluymers-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:12 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:13 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Messmann-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:13 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:22:43 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Mino_x002d_Kenudson-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:22:43 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:13 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Miros-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:13 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:14 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Montgomery-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:14 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:15 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Morino-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:15 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:15 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Mork-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:15 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:16 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Morris-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:16 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:16 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Niemantsverdriet-199">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:16 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:17 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-O_x0027_Riordan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:17 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:18 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Oberg-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:18 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:19 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ochando_x002d_Cerdan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:19 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:20 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Oelschlager-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:20 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:22:16 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Ofman-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:22:16 -0400" MODIFIED_BY="Karin L Dearness">
<P>Endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oleynikov-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:21 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Olliver-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:21 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:22 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ormsby-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:22 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:46:49 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ortiz-1996b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:46:49 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Data included in later study <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:22 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ortner-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:22 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:23 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Pacifico-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:23 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:23 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Pagani-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:23 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:21 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Panjehpour-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:21 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Detected difference not change in Barrett's oesophagus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:22:01 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Panjehpour-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:22:01 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:22 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Peters-1999b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:22 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Study endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:22 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Peters-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:22 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Study endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:24 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ponce-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:24 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:24 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Pouw-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:24 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:25 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Pouw-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:25 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:21:51 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Prasad-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:21:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:23 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Ragunath-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:23 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Study endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:25 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Reed-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:25 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:26 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Robinson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:26 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:27 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Salminen-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:27 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:27 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Salo-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:27 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:28 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Sampliner-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:28 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sampliner-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:28 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Scott-Bolton-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:28 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:29 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Sharma-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:29 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:21:31 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Smith-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:21:31 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:24 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Smythe-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:24 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Study endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:30 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Soni-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:30 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:24 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Sontag-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:24 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Study endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:25 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Spechler-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:25 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Not Barrett's oesophagus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:44:26 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Spechler-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:44:26 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Study endpoint not Barrett's oesophagus regression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:30 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Stolte-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:30 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:31 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Streitz-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:31 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:32 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Suspiro-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:32 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:39 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Taha-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:39 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:42 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Theisen-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:42 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:44 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Thomson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:44 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:49:06 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Todd-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:49:06 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Leading article comment - not clinical study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:45 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Tseng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:45 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:46 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Wehrmann-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:46 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 15:20:52 -0400" MODIFIED_BY="Karin L Dearness" STUDY_ID="STD-Weiss-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 15:20:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:47 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Weston-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:47 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:48 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Wetscher-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:48 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:49 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-White-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:49 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:50 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Wickramasinghe-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:50 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:50 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Wolfsen-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:50 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 11:42:51 -0400" MODIFIED_BY="Jenny Bellorini" STUDY_ID="STD-Zopf-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 11:42:51 -0400" MODIFIED_BY="Jenny Bellorini">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Ackroyd-2000">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Bright-2007">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-1996">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dulai-2005">
<DESCRIPTION>
<P>Quote "table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Hage-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Heath-2007">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-03 11:51:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kelty-2004">
<DESCRIPTION>
<P>Quote "patients were randomised by a computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Luman-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Mackenzie-2008">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:25:59 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Overholt-2005">
<DESCRIPTION>
<P>Refer to <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Parrilla-2003">
<DESCRIPTION>
<P>Quote "Randomisation was performed...by computer-generated numbers..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Peters-1999">
<DESCRIPTION>
<P>Quote "Treatment with either...according to a computer generated randomisation list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Ragunath-2005">
<DESCRIPTION>
<P>Quote "computer-generated randomisation was done for allocating the enrolled patients in either...."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:32:29 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="YES" STUDY_ID="STD-Shaheen-2008">
<DESCRIPTION>
<P>Quote "...assigned to a study group with the use of a computer generated block randomisation sequence..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-2006">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Weinstein-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Ackroyd-2000">
<DESCRIPTION>
<P>Quote "performed 1:1 by opening 36 previously sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Bright-2007">
<DESCRIPTION>
<P>Quote "performed ... by opening 1 in 40 sealed opaque envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-1996">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dulai-2005">
<DESCRIPTION>
<P>Quote "randomisation was determined by opening a sealed opaque envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Hage-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Heath-2007">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:23:01 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Kelty-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Luman-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Mackenzie-2008">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:26:05 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Overholt-2005">
<DESCRIPTION>
<P>Refer to <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Parrilla-2003">
<DESCRIPTION>
<P>Quote "...computer-generated numbers...concealed in sequentially numbered, sealed, opaque envelopes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1999">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Ragunath-2005">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:32:33 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Shaheen-2008">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Sharma-2006">
<DESCRIPTION>
<P>Quote "...using sealed opaque envelopes..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Weinstein-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Ackroyd-2000">
<DESCRIPTION>
<P>Quote "pharmacy staff and the outcome was unknown to clinical staff and patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Bright-2007">
<DESCRIPTION>
<P>Nature of the study made blinding impossible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-1996">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dulai-2005">
<DESCRIPTION>
<P>Quote "treatment allocation was concealed from the investigators...patients, primary care provider(s), investigators....were blinded to the endoscopic treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Hage-2004">
<DESCRIPTION>
<P>Nature of the study made blinding impossible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Heath-2007">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 11:23:02 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Kelty-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Luman-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Mackenzie-2008">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 11:26:11 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Overholt-2005">
<DESCRIPTION>
<P>Refer to <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Parrilla-2003">
<DESCRIPTION>
<P>Nature of the study made blinding impossible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Peters-1999">
<DESCRIPTION>
<P>Quote "...double blind using the double dummy technique"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Ragunath-2005">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Shaheen-2008">
<DESCRIPTION>
<P>Patients were randomised to either treatment or sham. Endoscopists were not blinded. Not clear wether pathologists were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-2006">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-27 16:07:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Weinstein-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Ackroyd-2000">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Bright-2007">
<DESCRIPTION>
<P>Quote "statistical significance claimed if p&lt;0.01"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-1996">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dulai-2005">
<DESCRIPTION>
<P>Quote " collected and analysed on an intention to treat basis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Hage-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Heath-2007">
<DESCRIPTION>
<P>Quote "All analyses between the two randomized groups (celecoxib vs placebo) will be based on the intention to-treat principle."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 11:23:02 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Kelty-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Luman-1996">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Mackenzie-2008">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 11:26:19 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Overholt-2005">
<DESCRIPTION>
<P>Refer to <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Parrilla-2003">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1999">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Ragunath-2005">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Shaheen-2008">
<DESCRIPTION>
<P>Quote "the study population for the primary intention-to-treat analysis included all patients who underwent randomisation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-2006">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-27 16:07:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Weinstein-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Ackroyd-2000">
<DESCRIPTION>
<P>Outcomes not clearly outlined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-03 11:38:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bright-2007">
<DESCRIPTION>
<P>Outcomes not clearly outlined in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Caldwell-1996">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dulai-2005">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-03 11:38:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hage-2004">
<DESCRIPTION>
<P>Outcomes not clearly outlined in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Heath-2007">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-03 11:56:47 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kelty-2004">
<DESCRIPTION>
<P>Outcomes not clearly outlined in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Luman-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Mackenzie-2008">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:26:27 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Overholt-2005">
<DESCRIPTION>
<P>Refer to <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Parrilla-2003">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Peters-1999">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Ragunath-2005">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Shaheen-2008">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Sharma-2006">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Weinstein-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-09-22 16:13:10 -0400" MODIFIED_BY="Karin L Dearness" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:44 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Ackroyd-2000">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Bright-2007">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:45 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Caldwell-1996">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:46 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Dulai-2005">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:47 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Hage-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:48 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Heath-2007">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:23:05 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Kelty-2004">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-03 12:00:40 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luman-1996">
<DESCRIPTION>
<P>Very small study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:49 -0400" MODIFIED_BY="Karin L Dearness" RESULT="NO" STUDY_ID="STD-Mackenzie-2008">
<DESCRIPTION>
<P>Published only in abstract format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 11:26:36 -0400" MODIFIED_BY="Jenny Bellorini" RESULT="UNKNOWN" STUDY_ID="STD-Overholt-2005">
<DESCRIPTION>
<P>Refer to <LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:50 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Parrilla-2003">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:51 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Peters-1999">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Ragunath-2005">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:52 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Shaheen-2008">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:53 -0400" MODIFIED_BY="Karin L Dearness" RESULT="YES" STUDY_ID="STD-Sharma-2006">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-27 16:07:54 -0400" MODIFIED_BY="Karin L Dearness" RESULT="UNKNOWN" STUDY_ID="STD-Weinstein-1996">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-09-25 10:44:05 -0400" MODIFIED_BY="Karin L Dearness">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-09-25 10:44:05 -0400" MODIFIED_BY="Karin L Dearness" NO="1">
<TITLE MODIFIED="2009-08-27 11:49:30 -0400" MODIFIED_BY="Jenny Bellorini">Summary of outcome measures per treatment category</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="3">
<P>Primary Outcome</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>Significant secondary outcomes</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Studies</P>
</TH>
<TH>
<P>Eradication of Barrett's oesophagus at 12 months</P>
</TH>
<TH>
<P>Eradication of dysplasia at 12 months</P>
</TH>
<TH>
<P>Reduction of cancer at 5 years or latest time point</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PPI vs H<SUB>2</SUB>RA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Caldwell-1996" TYPE="STUDY">Caldwell 1996</LINK>
</P>
<P>
<LINK REF="STD-Peters-1999" TYPE="STUDY">Peters 1999</LINK>
</P>
<P>
<LINK REF="STD-Weinstein-1996" TYPE="STUDY">Weinstein 1996</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Both induced some degree of reduction of area of Barrett's oesophagus</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>COX-2 inhibitor vs placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Heath-2007" TYPE="STUDY">Heath 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No reduction at 1 year</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences in progression to dysplasia from IM</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nissen fundoplication + PPI and H<SUB>2</SUB>RA vs PPI and H<SUB>2</SUB>RA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Parrilla-2003" TYPE="STUDY">Parrilla 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No complete eradication</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences at 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Reduction of dysplasia in surgery group (P = 0.03)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nd-YAG + omeprazole vs omeprazole</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Luman-1996" TYPE="STUDY">Luman 1996</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No eradication at 5 years</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences identified in any of the reported outcomes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>APC vs surveillance</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bright-2007" TYPE="STUDY">Bright 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>APC induced eradication of Barrett's oesophagus (P = 0.003) but very wide confidence interval</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Only 2 dysplastic patients</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences identified in any of the reported outcomes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>APC + PPI vs MPEC</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Dulai-2005" TYPE="STUDY">Dulai 2005</LINK>
</P>
<P>
<LINK REF="STD-Sharma-2006" TYPE="STUDY">Sharma 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences in eradication (63% to 88% vs 63% to 75%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences identified in any of the reported outcomes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>APC + PPI vs PDT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hage-2004" TYPE="STUDY">Hage 2004</LINK>
</P>
<P>
<LINK REF="STD-Kelty-2004" TYPE="STUDY">Kelty 2004</LINK>
</P>
<P>
<LINK REF="STD-Ragunath-2005" TYPE="STUDY">Ragunath 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Degree of eradication and most successful arm dependent on the PDT regimen</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No differences identified</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Photosensitivity in PDT patients</P>
<P>Fever, nausea and vomiting more common in PDT patients</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PDT (ALA or Porfimer sodium) + PPI vs PPI alone</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ackroyd-2000" TYPE="STUDY">Ackroyd 2000</LINK>
</P>
<P>
<LINK REF="STD-Overholt-2005" TYPE="STUDY">Overholt 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>PDT induced more eradication at 2 years (P &lt; 0.00001, OR 14.18; 95% CI 5.38 to 37.37)</P>
</TD>
<TD VALIGN="TOP">
<P>PDT induced eradication at 2 years (P &lt; 0.0001, OR 9.13; 95% CI 4.42 to 18.86)</P>
</TD>
<TD VALIGN="TOP">
<P>Reduction in progression to cancer (P = 0.007, OR 0.38; 95% CI 0.18 to 0.77)</P>
</TD>
<TD VALIGN="TOP">
<P>Reduction in the length, area and reduction of progression to dysplasia in the PDT group</P>
<P>Increase in photosensitivity, fever and stricture rates in the PDT group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ALA PDT vs porfimer sodium PDT</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mackenzie-2008" TYPE="STUDY">Mackenzie 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>HGD eradicated in 14/14 ALA vs 9/14 porfimer sodium</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>No differences identified in any of the reported outcomes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>RFA vs sham</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Shaheen-2008" TYPE="STUDY">Shaheen 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>RFA induced eradication (P &lt; 0.00001, OR 143.64; 95% CI 18.53 to 1113.87)</P>
</TD>
<TD VALIGN="TOP">
<P>Induced eradication at 2 years (P &lt; 0.0001, OR 22.67; 95% CI 8.72 to 58.94)</P>
</TD>
<TD VALIGN="TOP">
<P>No reduction identified</P>
</TD>
<TD VALIGN="TOP">
<P>Reduction in the number of patients with worsening dysplasia at 12 months (P = 0.02, OR 0.19; 95% CI 0.02 to 0.78)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>APC = argon plasma coagulation<BR/>H<SUB>2</SUB>RA = H<SUB>2</SUB>-receptor antagonist<BR/>IM = intestinal metaplasia<BR/>MPEC = multipolar electrocautery<BR/>PDT = photodynamic therapy<BR/>PPI = proton pump inhibitor<BR/>RFA = radiofrequency ablation<BR/>vs = versus</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-07-20 10:24:52 -0400" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin L Dearness">
<COMPARISON ID="CMP-001" MODIFIED="2013-05-15 14:22:39 -0400" MODIFIED_BY="Karin L Dearness" NO="1">
<NAME>Omeprazole vs histamine type 2 receptor antagonists</NAME>
<CONT_OUTCOME CHI2="8.057592356077883" CI_END="0.29761792513502483" CI_START="-1.5032075273813785" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6027948011231768" ESTIMABLE="YES" I2="50.35737943502715" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2009-08-27 12:26:50 -0400" MODIFIED_BY="Jenny Bellorini" NO="1" P_CHI2="0.08949120667313926" P_Q="0.6662102868105073" P_Z="0.1894771933098269" Q="0.18606711792036273" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="162" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="1.3121272787637364">
<NAME>Reduction in length (cm) of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>Omeprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>H2R antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.348562344128947" CI_END="0.8161370743070618" CI_START="-1.6506886736855022" DF="2" EFFECT_SIZE="-0.41727579968922013" ESTIMABLE="YES" I2="62.60677409518511" ID="CMP-001.01.01" NO="1" P_CHI2="0.06895654002453677" P_Z="0.507282370825745" STUDIES="3" TAU2="0.0" TOTAL_1="86" TOTAL_2="77" WEIGHT="53.29252466965467" Z="0.6630752412703346">
<NAME>All trials</NAME>
<CONT_DATA CI_END="5.908828226106925" CI_START="-1.1088282261069256" EFFECT_SIZE="2.4" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="-1.7" ORDER="1" SD_1="3.3" SD_2="4.6" SE="1.7902513789968155" STUDY_ID="STD-Caldwell-1996" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.585049339309332"/>
<CONT_DATA CI_END="0.560037393202026" CI_START="-12.820037393202025" EFFECT_SIZE="-6.13" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="0.53" ORDER="2" SD_1="10.86" SD_2="13.86" SE="3.4133471053408058" STUDY_ID="STD-Peters-1999" TOTAL_1="26" TOTAL_2="27" WEIGHT="1.811449198033063"/>
<CONT_DATA CI_END="0.7438093964928434" CI_START="-1.9438093964928436" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.2" ORDER="3" SD_1="3.32" SD_2="3.16" SE="0.6856296376324466" STUDY_ID="STD-Weinstein-1996" TOTAL_1="50" TOTAL_2="40" WEIGHT="44.89602613231227"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.522962894028574" CI_END="0.5030241558328545" CI_START="-2.1319625214488056" DF="1" EFFECT_SIZE="-0.8144691828079755" ESTIMABLE="YES" I2="60.36406233453411" ID="CMP-001.01.02" MODIFIED="2009-08-27 12:26:50 -0400" MODIFIED_BY="Jenny Bellorini" NO="2" P_CHI2="0.11219989889218729" P_Z="0.22564947201609042" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="67" WEIGHT="46.70747533034533" Z="1.2116420007620146">
<NAME>Trials using omeprazole 40 mg</NAME>
<CONT_DATA CI_END="0.560037393202026" CI_START="-12.820037393202025" EFFECT_SIZE="-6.13" ESTIMABLE="YES" MEAN_1="-5.6" MEAN_2="0.53" ORDER="4" SD_1="10.86" SD_2="13.86" SE="3.4133471053408058" STUDY_ID="STD-Peters-1999" TOTAL_1="26" TOTAL_2="27" WEIGHT="1.811449198033063"/>
<CONT_DATA CI_END="0.7438093964928434" CI_START="-1.9438093964928436" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.2" ORDER="5" SD_1="3.32" SD_2="3.16" SE="0.6856296376324466" STUDY_ID="STD-Weinstein-1996" TOTAL_1="50" TOTAL_2="40" WEIGHT="44.89602613231227"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.02142479292174654" CI_END="8.042937796434787" CI_START="0.07829656364949811" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.060617180042143" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-05-15 14:22:39 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.8836276584903088" P_Q="1.0" P_Z="0.045662597537439516" Q="0.0" RANDOM="NO" SCALE="10.75" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="1.998498914207589">
<NAME>Reduction in area (%) of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>Omeprazole</GROUP_LABEL_1>
<GROUP_LABEL_2>H2R Antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2R Antagonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Omeprazole</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.442411895560948" CI_START="-1.6424118955609464" EFFECT_SIZE="4.4" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="0.8" ORDER="6" SD_1="11.22" SD_2="11.22" SE="3.0829198613968014" STUDY_ID="STD-Peters-1999" TOTAL_1="26" TOTAL_2="27" WEIGHT="43.43619667369042"/>
<CONT_DATA CI_END="9.095011654570353" CI_START="-1.4950116545703542" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="0.5" MODIFIED="2013-05-15 10:58:14 -0400" MODIFIED_BY="Karin Dearness" ORDER="7" SD_1="12.02" SD_2="13.28" SE="2.701586200734672" STUDY_ID="STD-Weinstein-1996" TOTAL_1="50" TOTAL_2="40" WEIGHT="56.56380332630958"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-10-23 12:54:41 -0400" MODIFIED_BY="Karin L Dearness" NO="2">
<NAME>Celecoxib vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:54:19 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="49" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>celecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.436684866280975" CI_START="0.200277725799511" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7353341601487257" LOG_CI_START="-0.6983673487606995" LOG_EFFECT_SIZE="0.018483405694013133" MODIFIED="2008-07-31 07:06:17 -0400" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.8421633632703234" STUDY_ID="STD-Heath-2007" TOTAL_1="49" TOTAL_2="51" VAR="0.7092391304347826" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:54:41 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="49" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>Any serious drug reactions</NAME>
<GROUP_LABEL_1>celecoxib</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.26068972307763" CI_START="0.10879885681591252" EFFECT_SIZE="0.6808510638297872" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6294799086520736" LOG_CI_START="-0.9633756678836966" LOG_EFFECT_SIZE="-0.1669478796158115" MODIFIED="2008-07-31 07:17:35 -0400" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.9356512504193791" STUDY_ID="STD-Heath-2007" TOTAL_1="49" TOTAL_2="51" VAR="0.8754432624113476" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-10-23 12:55:36 -0400" MODIFIED_BY="Karin L Dearness" NO="3">
<NAME>Anti-reflux surgery vs omeprazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:55:02 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="14.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Any reduction/reversal of Barrett's oesophagus/dysplasia at 12 months</NAME>
<GROUP_LABEL_1>Antireflux surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.530198378939199" CI_START="0.10038900053881125" EFFECT_SIZE="0.7450980392156863" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7427407105693149" LOG_CI_START="-0.9983138695315673" LOG_EFFECT_SIZE="-0.1277865794811262" ORDER="58" O_E="0.0" SE="1.022704078710425" STUDY_ID="STD-Parrilla-2003" TOTAL_1="53" TOTAL_2="40" VAR="1.0459236326109391" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:55:11 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.24" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Progression to cancer at latest possible time point</NAME>
<GROUP_LABEL_1>Antireflux surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.530198378939199" CI_START="0.10038900053881125" EFFECT_SIZE="0.7450980392156863" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7427407105693149" LOG_CI_START="-0.9983138695315673" LOG_EFFECT_SIZE="-0.1277865794811262" ORDER="59" O_E="0.0" SE="1.022704078710425" STUDY_ID="STD-Parrilla-2003" TOTAL_1="53" TOTAL_2="40" VAR="1.0459236326109391" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:55:19 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="121.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Any complication</NAME>
<GROUP_LABEL_1>Antireflux surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="57.073362647949466" CI_START="0.09025096887606465" EFFECT_SIZE="2.2695652173913046" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7564334610617824" LOG_CI_START="-1.044548127092444" LOG_EFFECT_SIZE="0.3559426669846693" MODIFIED="2008-07-30 07:12:58 -0400" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.6453104499642672" STUDY_ID="STD-Parrilla-2003" TOTAL_1="58" TOTAL_2="43" VAR="2.7070464767616196" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:55:24 -0400" MODIFIED_BY="Karin L Dearness" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Complete eradication of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>Antireflux surgery</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="60" O_E="0.0" SE="0.0" STUDY_ID="STD-Parrilla-2003" TOTAL_1="53" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:55:30 -0400" MODIFIED_BY="Karin L Dearness" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="148.92" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Numbers progressing to dysplasia from intestinal metaplasia</NAME>
<GROUP_LABEL_1>Sucessful Surgical</GROUP_LABEL_1>
<GROUP_LABEL_2>Medical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Sucessful Surgical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Medical</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7816988022252223" CI_START="0.011069898146952821" EFFECT_SIZE="0.09302325581395349" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.10696055349941919" LOG_CI_START="-1.9558563750038294" LOG_EFFECT_SIZE="-1.0314084642516241" MODIFIED="2008-07-30 07:11:55 -0400" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.0860505577336115" STUDY_ID="STD-Parrilla-2003" TOTAL_1="44" TOTAL_2="40" VAR="1.1795058139534884" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:55:36 -0400" MODIFIED_BY="Karin L Dearness" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="58" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Complete eradication of dysplasia (at 5-year follow up)</NAME>
<GROUP_LABEL_1>Surgical</GROUP_LABEL_1>
<GROUP_LABEL_2>medical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.575999287982568" CI_START="0.28375467994923365" EFFECT_SIZE="1.2578616352201257" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7463227096334858" LOG_CI_START="-0.5470569669464265" LOG_EFFECT_SIZE="0.09963287134352969" MODIFIED="2008-07-30 07:09:43 -0400" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.759737624355695" STUDY_ID="STD-Parrilla-2003" TOTAL_1="58" TOTAL_2="43" VAR="0.5772012578616352" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-10-23 12:56:23 -0400" MODIFIED_BY="Karin L Dearness" NO="4">
<NAME>Nd-YAG laser therapy vs omeprazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:55:45 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="4" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Any reduction/reversal of Barrett's oesophagus/dysplasia at 12 months</NAME>
<GROUP_LABEL_1>Nd-YAG Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="65" O_E="0.0" SE="0.0" STUDY_ID="STD-Luman-1996" TOTAL_1="4" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:56:23 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="385.37" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="4" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Any complication</NAME>
<GROUP_LABEL_1>Nd-YAG Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-10-23 12:56:07 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<DICH_DATA CI_END="126.7321884686204" CI_START="0.1173936250938484" EFFECT_SIZE="3.857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.102886934527228" LOG_CI_START="-0.9303554862377668" LOG_EFFECT_SIZE="0.5862657241447304" ORDER="66" O_E="0.0" SE="1.781741612749496" STUDY_ID="STD-Luman-1996" TOTAL_1="4" TOTAL_2="4" VAR="3.174603174603175" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-10-23 12:56:21 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Odynophagia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-10-23 12:56:22 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Fever</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-10-23 12:56:22 -0400" MODIFIED_BY="Karin L Dearness" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-10-23 12:56:23 -0400" MODIFIED_BY="Karin L Dearness" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Stricture formation</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-10-23 12:56:23 -0400" MODIFIED_BY="Karin L Dearness" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Photosensitivity</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin L Dearness" NO="5">
<NAME>Argon plasma coagulation vs no treatment after anti-reflux surgery</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-06-05 10:18:18 -0400" MODIFIED_BY="Karin L Dearness" NO="1" NOTES="&lt;p&gt;Should Ackroyd 2004 be included? (Validation error occurring because it isn't at the moment)&lt;/p&gt;" NOTES_MODIFIED="2013-06-05 10:18:18 -0400" NOTES_MODIFIED_BY="Karin L Dearness" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Any reduction/reversal of Barrett's oesophagus/dysplasia at 12 months</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>None</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4247.469532481653" CI_START="9.894126297698534" EFFECT_SIZE="205.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" LOG_CI_END="3.6281302723150555" LOG_CI_START="0.9953774497964532" LOG_EFFECT_SIZE="2.311753861055754" MODIFIED="2008-07-22 04:02:11 -0400" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="1.5464920402840814" STUDY_ID="STD-Bright-2007" TOTAL_1="20" TOTAL_2="20" VAR="2.3916376306620206" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:56:45 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Complete eradication of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1754.4969415088744" CI_START="4.767869820597899" EFFECT_SIZE="91.46153846153847" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="3.2441526154770584" LOG_CI_START="0.6783243891466515" LOG_EFFECT_SIZE="1.9612385023118548" MODIFIED="2008-07-22 04:03:23 -0400" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="1.5071802012010413" STUDY_ID="STD-Bright-2007" TOTAL_1="20" TOTAL_2="20" VAR="2.2715921588924113" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:56:53 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Presence of buried subsquamous Barrett's glands</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>Surveillance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="91.87152730649127" CI_START="0.13442907115750138" EFFECT_SIZE="3.5142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9631809363085033" LOG_CI_START="-0.8715068021302589" LOG_EFFECT_SIZE="0.5458370670891223" MODIFIED="2009-09-16 11:54:00 -0400" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="1.6651096094895381" STUDY_ID="STD-Bright-2007" TOTAL_1="18" TOTAL_2="20" VAR="2.772590011614402" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-10-23 14:38:58 -0400" MODIFIED_BY="Karin L Dearness" NO="6">
<NAME>Argon plasma coagulation vs multipolar electrocoagulation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 14:38:28 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Any reduction/reversal of Barrett's oesophagus/dysplasia at 12 months</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>MPEC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Dulai-2005" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-21 06:21:45 -0400" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.0" STUDY_ID="STD-Sharma-2006" TOTAL_1="19" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.064054136255624" CI_END="2.1370709614464647" CI_START="0.23937907389427257" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7152412653066078" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="2.0905027589982614" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.3298189431528215" LOG_CI_START="-0.6209138175447554" LOG_EFFECT_SIZE="-0.14554743719596697" METHOD="MH" MODIFIED="2009-10-23 12:58:42 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.38185458202996403" P_Q="0.5713955847262889" P_Z="0.5484390769083964" Q="1.1193475416240695" RANDOM="NO" SCALE="128.6786646823487" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="60" WEIGHT="100.00000000000001" Z="0.6001007785550432">
<NAME>Any complication</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>MPEC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8097508026094564" CI_END="1.7874219433349365" CI_START="0.12938812394854915" DF="1" EFFECT_SIZE="0.4809066145860102" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="44.743773642309606" ID="CMP-006.02.01" LOG_CI_END="0.25222708525963633" LOG_CI_START="-0.8881055841024638" LOG_EFFECT_SIZE="-0.31793924942141377" MODIFIED="2008-07-21 06:27:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17853827738160932" P_Z="0.2744264113496587" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="36" WEIGHT="84.84369982861621" Z="1.0929257661034244">
<NAME>Pain</NAME>
<DICH_DATA CI_END="80.68389088418331" CI_START="0.12124172875851626" EFFECT_SIZE="3.127659574468085" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9067868333779345" LOG_CI_START="-0.9163478797530177" LOG_EFFECT_SIZE="0.49521947681245865" ORDER="63" O_E="0.0" SE="1.6583233052353332" STUDY_ID="STD-Dulai-2005" TOTAL_1="24" TOTAL_2="24" VAR="2.7500361846866404" WEIGHT="6.3533571799503425"/>
<DICH_DATA CI_END="1.2948795018945156" CI_START="0.05491716488450831" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.11222935598704664" LOG_CI_START="-1.2602918914424843" LOG_EFFECT_SIZE="-0.5740312677277188" MODIFIED="2008-07-21 06:27:39 -0400" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Sharma-2006" TOTAL_1="19" TOTAL_2="12" VAR="0.6499999999999999" WEIGHT="78.49034264866587"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Odynophagia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.87353219175629" CI_START="0.07626822302412098" DF="0" EFFECT_SIZE="2.027027027027027" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="1.7313754507844796" LOG_CI_START="-1.1176563721350694" LOG_EFFECT_SIZE="0.3068595393247051" MODIFIED="2009-10-23 12:58:14 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="1.0" P_Z="0.6728774914765596" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="12" WEIGHT="7.578150085691897" Z="0.4222021253329874">
<NAME>Fever</NAME>
<DICH_DATA CI_END="53.87353219175627" CI_START="0.076268223024121" EFFECT_SIZE="2.027027027027027" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7313754507844796" LOG_CI_START="-1.1176563721350692" LOG_EFFECT_SIZE="0.3068595393247051" MODIFIED="2009-10-23 12:58:14 -0400" MODIFIED_BY="Karin L Dearness" ORDER="70" O_E="0.0" SE="1.6735353957179155" STUDY_ID="STD-Sharma-2006" TOTAL_1="19" TOTAL_2="12" VAR="2.8007207207207205" WEIGHT="7.578150085691897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-08-27 13:58:57 -0400" MODIFIED_BY="Jenny Bellorini" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.87353219175629" CI_START="0.07626822302412098" DF="0" EFFECT_SIZE="2.027027027027027" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.02.05" LOG_CI_END="1.7313754507844796" LOG_CI_START="-1.1176563721350694" LOG_EFFECT_SIZE="0.3068595393247051" MODIFIED="2008-07-21 06:32:43 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6728774914765596" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="12" WEIGHT="7.578150085691897" Z="0.4222021253329874">
<NAME>Stricture formation</NAME>
<DICH_DATA CI_END="53.87353219175627" CI_START="0.076268223024121" EFFECT_SIZE="2.027027027027027" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7313754507844796" LOG_CI_START="-1.1176563721350692" LOG_EFFECT_SIZE="0.3068595393247051" MODIFIED="2008-07-21 06:32:43 -0400" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="1.6735353957179155" STUDY_ID="STD-Sharma-2006" TOTAL_1="19" TOTAL_2="12" VAR="2.8007207207207205" WEIGHT="7.578150085691897"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Photosensitivity</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 14:38:58 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>MPEC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="64" O_E="0.0" SE="0.0" STUDY_ID="STD-Dulai-2005" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.3154661624261" CI_START="0.36094898868863623" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="1.2384341880046899" LOG_CI_START="-0.4425541706606145" LOG_EFFECT_SIZE="0.3979400086720376" METHOD="MH" MODIFIED="2009-07-30 11:02:14 -0400" MODIFIED_BY="Karin L Dearness" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.35342641267971353" Q="0.0" RANDOM="NO" SCALE="23.88289754397344" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.9279636958628615">
<NAME>Control of acid reflux</NAME>
<GROUP_LABEL_1>APC</GROUP_LABEL_1>
<GROUP_LABEL_2>MPEC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.3154661624261" CI_START="0.36094898868863623" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="1.2384341880046899" LOG_CI_START="-0.4425541706606145" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2008-07-21 06:35:06 -0400" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.9874208829065749" STUDY_ID="STD-Sharma-2006" TOTAL_1="12" TOTAL_2="12" VAR="0.975" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-10-23 14:39:14 -0400" MODIFIED_BY="Karin L Dearness" NO="7">
<NAME>Photodynamic therapy vs argon plasma coagulation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="68" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 14:39:14 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="68" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>Any reduction/reversal of Barrett's oesophagus/dysplasia at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Hage-2004" TOTAL_1="21" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="10" O_E="0.0" SE="0.0" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.058755765765093" CI_END="245.12005054797146" CI_START="4.043872090012618" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="31.483870967741936" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="0" I2="5.549510818732976" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="2.389378837511513" LOG_CI_START="0.6067974101533256" LOG_EFFECT_SIZE="1.498088123832419" METHOD="MH" MODIFIED="2009-07-30 11:01:52 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.3034995167359612" P_Q="1.0" P_Z="9.865934491887851E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="48" WEIGHT="99.99999999999999" Z="3.2943221816578823">
<NAME>Any serious drug reactions</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1754.4969415088744" CI_START="4.767869820597899" EFFECT_SIZE="91.46153846153847" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="0" LOG_CI_END="3.2441526154770584" LOG_CI_START="0.6783243891466515" LOG_EFFECT_SIZE="1.9612385023118548" ORDER="11" O_E="0.0" SE="1.5071802012010413" STUDY_ID="STD-Hage-2004" TOTAL_1="26" TOTAL_2="14" VAR="2.2715921588924113" WEIGHT="26.209677419354836"/>
<DICH_DATA CI_END="196.86719026493506" CI_START="0.5264415841860759" EFFECT_SIZE="10.180327868852459" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2941733429832354" LOG_CI_START="-0.27864981265160926" LOG_EFFECT_SIZE="1.007761765165813" ORDER="12" O_E="0.0" SE="1.5112890572999267" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="2.283994614714501" WEIGHT="73.79032258064515"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="67.81431600069457" CI_END="3.613051620209474" CI_START="0.14909100664158903" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="OR" EFFECT_SIZE="0.733943801053633" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="102" I2="80.83000645488063" I2_Q="49.79410861214009" ID="CMP-007.03" LOG_CI_END="0.5578741664426364" LOG_CI_START="-0.8265485529502896" LOG_EFFECT_SIZE="-0.13433719325382654" METHOD="MH" MODIFIED="2009-08-27 13:58:12 -0400" MODIFIED_BY="Jenny Bellorini" NO="3" P_CHI2="2.0222082897092264E-9" P_Q="0.07640563978244508" P_Z="0.7036711827916393" Q="9.95899059210615" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="7.218643607952882" TOTALS="YES" TOTAL_1="365" TOTAL_2="305" WEIGHT="100.0" Z="0.38036945923157545">
<NAME>Any complication</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="33.682594184310275" CI_END="3231.5522279245047" CI_START="5.572780449227715E-6" DF="1" EFFECT_SIZE="0.13419661350584047" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="50" I2="97.03110753724008" ID="CMP-007.03.01" LOG_CI_END="3.5094111793260345" LOG_CI_START="-5.253928066501869" LOG_EFFECT_SIZE="-0.8722584435879177" NO="1" P_CHI2="6.488141690574878E-9" P_Z="0.6964109968196213" STUDIES="3" TAU2="51.43713225172459" TOTAL_1="73" TOTAL_2="61" WEIGHT="15.197170247509558" Z="0.39016979411294483">
<NAME>Pain</NAME>
<DICH_DATA CI_END="70.12535293698998" CI_START="2.7157082570567144" EFFECT_SIZE="13.8" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="5" LOG_CI_END="1.8458750600496223" LOG_CI_START="0.4338831127528508" LOG_EFFECT_SIZE="1.1398790864012365" ORDER="13" O_E="0.0" SE="0.8294110593149876" STUDY_ID="STD-Hage-2004" TOTAL_1="26" TOTAL_2="14" VAR="0.6879227053140098" WEIGHT="8.364206026973811"/>
<DICH_DATA CI_END="0.024110069184411418" CI_START="5.1548574179973615E-5" EFFECT_SIZE="0.0011148272017837235" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="32" LOG_CI_END="-1.617801543402513" LOG_CI_START="-4.287783342685671" LOG_EFFECT_SIZE="-2.952792443044092" ORDER="14" O_E="0.0" SE="1.5683605255219883" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="2.4597547380156075" WEIGHT="6.832964220535746"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.160690495442108" CI_END="10.596437697236023" CI_START="8.545478774963991E-4" DF="2" EFFECT_SIZE="0.0951586220118591" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="45" I2="88.34545730819397" ID="CMP-007.03.02" LOG_CI_END="1.0251598889955567" LOG_CI_START="-3.0682636001755403" LOG_EFFECT_SIZE="-1.0215518555899918" NO="2" P_CHI2="1.877608583541468E-4" P_Z="0.32794851129643277" STUDIES="3" TAU2="15.241040505111323" TOTAL_1="73" TOTAL_2="61" WEIGHT="21.346287223082214" Z="0.9782544369490026">
<NAME>Odynophagia</NAME>
<DICH_DATA CI_END="15.990629862320336" CI_START="0.25014649419316726" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="1.2038655707094992" LOG_CI_START="-0.6018055793815368" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="16" O_E="0.0" SE="1.0606601717798212" STUDY_ID="STD-Hage-2004" TOTAL_1="26" TOTAL_2="14" VAR="1.125" WEIGHT="7.926051580997549"/>
<DICH_DATA CI_END="0.024110069184411418" CI_START="5.1548574179973615E-5" EFFECT_SIZE="0.0011148272017837235" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="32" LOG_CI_END="-1.617801543402513" LOG_CI_START="-4.287783342685671" LOG_EFFECT_SIZE="-2.952792443044092" ORDER="17" O_E="0.0" SE="1.5683605255219883" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="2.4597547380156075" WEIGHT="6.832964220535746"/>
<DICH_DATA CI_END="8.299523790184068" CI_START="0.011477751173517344" EFFECT_SIZE="0.30864197530864196" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9190531741557734" LOG_CI_START="-1.940143194568998" LOG_EFFECT_SIZE="-0.5105450102066121" ORDER="18" O_E="0.0" SE="1.6795061002392164" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" VAR="2.8207407407407405" WEIGHT="6.5872714215489205"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.411160329648996" CI_END="7.436363629261146" CI_START="0.47496180269635185" DF="2" EFFECT_SIZE="1.8793585807023256" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-007.03.03" LOG_CI_END="0.8713606180983022" LOG_CI_START="-0.32334131573352115" LOG_EFFECT_SIZE="0.2740096511823905" NO="3" P_CHI2="0.4938220564100456" P_Z="0.36862544947000664" STUDIES="3" TAU2="0.0" TOTAL_1="73" TOTAL_2="61" WEIGHT="21.52223857693614" Z="0.899051106431821">
<NAME>Fever</NAME>
<DICH_DATA CI_END="14.7885351307794" CI_START="0.4808529748366182" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.1699251573554716" LOG_CI_START="-0.31798769281090933" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="19" O_E="0.0" SE="0.8740073734751264" STUDY_ID="STD-Hage-2004" TOTAL_1="26" TOTAL_2="14" VAR="0.763888888888889" WEIGHT="8.284607627499133"/>
<DICH_DATA CI_END="78.55113206670812" CI_START="0.12151744710954356" EFFECT_SIZE="3.08955223880597" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.895152448405676" LOG_CI_START="-0.9153613628934938" LOG_EFFECT_SIZE="0.4898955427560913" ORDER="20" O_E="0.0" SE="1.6509097250248725" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="2.7255029201817003" WEIGHT="6.650359527888085"/>
<DICH_DATA CI_END="8.299523790184068" CI_START="0.011477751173517344" EFFECT_SIZE="0.30864197530864196" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9190531741557734" LOG_CI_START="-1.940143194568998" LOG_EFFECT_SIZE="-0.5105450102066121" ORDER="21" O_E="0.0" SE="1.6795061002392164" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" VAR="2.8207407407407405" WEIGHT="6.5872714215489205"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.28033530166724036" CI_END="153.78000279889702" CI_START="2.508252017466889" DF="1" EFFECT_SIZE="19.639730198411517" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" I2="0.0" ID="CMP-007.03.04" LOG_CI_END="2.1868998644723323" LOG_CI_START="0.3993711702354438" LOG_EFFECT_SIZE="1.293135517353888" MODIFIED="2009-08-27 13:58:12 -0400" MODIFIED_BY="Jenny Bellorini" NO="4" P_CHI2="0.5964815948551844" P_Z="0.004571712982822009" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="48" WEIGHT="14.034178519902625" Z="2.8357576013348313">
<NAME>Nausea and vomiting</NAME>
<DICH_DATA CI_END="211.4669901234302" CI_START="0.588310657616365" EFFECT_SIZE="11.153846153846153" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.3252425838807746" LOG_CI_START="-0.23039328402449838" LOG_EFFECT_SIZE="1.047424649928138" ORDER="22" O_E="0.0" SE="1.5011931594091297" STUDY_ID="STD-Hage-2004" TOTAL_1="26" TOTAL_2="14" VAR="2.2535809018567643" WEIGHT="6.981691527856746"/>
<DICH_DATA CI_END="601.2414331554488" CI_START="1.8963095678818662" EFFECT_SIZE="33.765957446808514" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.7790489013406043" LOG_CI_START="0.2779092362976572" LOG_EFFECT_SIZE="1.5284790688191308" ORDER="23" O_E="0.0" SE="1.4691818200872446" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="2.158495220474869" WEIGHT="7.0524869920458775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8972581167008841" CI_END="2.4447230080003415" CI_START="0.10736099710062844" DF="2" EFFECT_SIZE="0.5123162107270902" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-007.03.05" LOG_CI_END="0.38822965981480484" LOG_CI_START="-0.9691534637055419" LOG_EFFECT_SIZE="-0.29046190194536853" NO="5" P_CHI2="0.6385029294327309" P_Z="0.40157462517602627" STUDIES="3" TAU2="0.0" TOTAL_1="73" TOTAL_2="61" WEIGHT="21.137921678928258" Z="0.8388123541973499">
<NAME>Stricture formation</NAME>
<DICH_DATA CI_END="4.454657476412589" CI_START="0.006473199075158391" EFFECT_SIZE="0.16981132075471697" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6488143162690104" LOG_CI_START="-2.1888810365919387" LOG_EFFECT_SIZE="-0.7700333601614642" ORDER="24" O_E="0.0" SE="1.6668762970890625" STUDY_ID="STD-Hage-2004" TOTAL_1="26" TOTAL_2="14" VAR="2.7784765897973442" WEIGHT="6.615119984750964"/>
<DICH_DATA CI_END="8.22927097125844" CI_START="0.012730561275052881" EFFECT_SIZE="0.32367149758454106" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9153613628934936" LOG_CI_START="-1.8951524484056765" LOG_EFFECT_SIZE="-0.4898955427560913" ORDER="25" O_E="0.0" SE="1.6509097250248725" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="2.7255029201817003" WEIGHT="6.650359527888085"/>
<DICH_DATA CI_END="8.420805498345374" CI_START="0.11875348506701558" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9253536362448672" LOG_CI_START="-0.9253536362448672" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="1.087114613009218" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" VAR="1.1818181818181817" WEIGHT="7.872442166289207"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="135.14578742267585" CI_START="0.25492319441271194" DF="0" EFFECT_SIZE="5.869565217391305" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-007.03.06" LOG_CI_END="2.13080251301958" LOG_CI_START="-0.5935906480647531" LOG_EFFECT_SIZE="0.7686059324774133" NO="6" P_CHI2="1.0" P_Z="0.26877403377266695" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="6.762203753641198" Z="1.1058902712558405">
<NAME>Photosensitivity</NAME>
<DICH_DATA CI_END="135.14578742267585" CI_START="0.25492319441271194" EFFECT_SIZE="5.869565217391305" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.13080251301958" LOG_CI_START="-0.5935906480647531" LOG_EFFECT_SIZE="0.7686059324774133" ORDER="27" O_E="0.0" SE="1.6003220287845832" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" VAR="2.5610305958132042" WEIGHT="6.762203753641198"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 14:36:48 -0400" MODIFIED_BY="Karin L Dearness" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="90.68" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="73" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="44.65498370849515" CI_START="0.06516707342393499" EFFECT_SIZE="1.7058823529411764" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.649869935258515" LOG_CI_START="-1.1859717822171507" LOG_EFFECT_SIZE="0.23194907652068214" ORDER="28" O_E="0.0" SE="1.665787462488104" STUDY_ID="STD-Hage-2004" TOTAL_1="26" TOTAL_2="14" VAR="2.774847870182556" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="29" O_E="0.0" SE="0.0" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30" O_E="0.0" SE="0.0" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2009-10-23 12:59:44 -0400" MODIFIED_BY="Karin L Dearness" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in length (cm) of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2750521911696817" CI_START="-2.0950521911696818" EFFECT_SIZE="-0.9100000000000001" ESTIMABLE="YES" MEAN_1="2.31" MEAN_2="3.22" ORDER="31" SD_1="1.75" SD_2="1.3" SE="0.6046295750928192" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.0401459297475" CI_END="4.927103384581855" CI_START="0.023622851337187757" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3411630559965891" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="75.24841880989933" I2_Q="0.0" ID="CMP-007.06" LOG_CI_END="0.6925916750986055" LOG_CI_START="-1.626667683129383" LOG_EFFECT_SIZE="-0.4670380040153887" METHOD="MH" MODIFIED="2009-08-04 05:05:16 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.04443006797396398" P_Q="1.0" P_Z="0.42989539480085304" Q="0.0" RANDOM="YES" SCALE="219.58" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.8288854838051862" TOTALS="YES" TOTAL_1="42" TOTAL_2="47" WEIGHT="100.00000000000001" Z="0.7893706790783607">
<NAME>Persistence of sub-squamous glands</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7329680726031081" CI_START="0.0076742769709232" EFFECT_SIZE="0.075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.13491494240427435" LOG_CI_START="-2.114962530812326" LOG_EFFECT_SIZE="-1.1249387366083" ORDER="32" O_E="0.0" SE="1.1630897548245267" STUDY_ID="STD-Hage-2004" TOTAL_1="25" TOTAL_2="14" VAR="1.3527777777777779" WEIGHT="44.38383062323459"/>
<DICH_DATA CI_END="4.621922829528303" CI_START="0.28259287252376947" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.6648226899553333" LOG_CI_START="-0.54883879599996" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="33" O_E="0.0" SE="0.712910764571386" STUDY_ID="STD-Kelty-2004" TOTAL_1="17" TOTAL_2="33" VAR="0.5082417582417582" WEIGHT="55.61616937676543"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.74942050918224" CI_END="32.59943933577468" CI_START="0.0030165988536926605" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.31359118503446703" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="41" I2="91.48894195063923" I2_Q="0.0" ID="CMP-007.07" LOG_CI_END="1.5132101308816472" LOG_CI_START="-2.52048243832046" LOG_EFFECT_SIZE="-0.5036361537194064" METHOD="MH" MODIFIED="2009-10-23 13:09:49 -0400" MODIFIED_BY="Karin L Dearness" NO="7" P_CHI2="6.086300042805748E-4" P_Q="1.0" P_Z="0.6245360235837094" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="10.275580560266642" TOTALS="YES" TOTAL_1="68" TOTAL_2="59" WEIGHT="100.0" Z="0.4894318075398454">
<NAME>Complete eradication of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.63710202212682" CI_START="0.5409595966911956" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="1.2210776798028529" LOG_CI_START="-0.26683517036352794" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="34" O_E="0.0" SE="0.8740073734751262" STUDY_ID="STD-Hage-2004" TOTAL_1="21" TOTAL_2="12" VAR="0.7638888888888888" WEIGHT="50.8548751247668"/>
<DICH_DATA CI_END="0.24744808716505684" CI_START="0.003710974920302581" EFFECT_SIZE="0.030303030303030304" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="33" LOG_CI_END="-0.6065158990436574" LOG_CI_START="-2.4305119807121174" LOG_EFFECT_SIZE="-1.5185139398778875" ORDER="35" O_E="0.0" SE="1.0714243272982744" STUDY_ID="STD-Kelty-2004" TOTAL_1="34" TOTAL_2="34" VAR="1.1479500891265597" WEIGHT="49.1451248752332"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="36" O_E="0.0" SE="0.0" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:59:52 -0400" MODIFIED_BY="Karin L Dearness" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="34.93" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Eradication of dysplasia at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>APC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.071018239312199" CI_START="0.25090535646614115" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="1.0441875662606448" LOG_CI_START="-0.6004900670279322" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2008-07-30 09:26:31 -0400" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.9660917830792959" STUDY_ID="STD-Ragunath-2005" TOTAL_1="13" TOTAL_2="9" VAR="0.9333333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2009-10-23 14:40:03 -0400" MODIFIED_BY="Karin L Dearness" NO="8">
<NAME>Photodynamic therapy versus omeprazole</NAME>
<DICH_OUTCOME CHI2="1.4691465227271867" CI_END="1078.735794888904" CI_START="38.10146291810115" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="202.7348314606742" ESTIMABLE="YES" EVENTS_1="154" EVENTS_2="29" I2="31.93326979097407" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="3.0329150898430965" LOG_CI_START="1.5809416508740881" LOG_EFFECT_SIZE="2.3069283703585928" METHOD="MH" MODIFIED="2009-08-27 12:30:25 -0400" MODIFIED_BY="Jenny Bellorini" NO="1" P_CHI2="0.22548071793960212" P_Q="1.0" P_Z="4.722143756083761E-10" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="88" WEIGHT="100.00000000000001" Z="6.228070568600847">
<NAME>Any reduction/reversal of Barrett's oesophagus/dysplasia at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="511.70015559425053" CI_START="8.004687814181349" EFFECT_SIZE="64.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="2.709015549029405" LOG_CI_START="0.903344398938369" LOG_EFFECT_SIZE="1.806179973983887" ORDER="40" O_E="0.0" SE="1.0606601717798212" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" VAR="1.125" WEIGHT="62.921348314606746"/>
<DICH_DATA CI_END="7333.102059555923" CI_START="26.180921889832693" EFFECT_SIZE="438.1636363636364" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="27" LOG_CI_END="3.865287729396745" LOG_CI_START="1.4179849349809013" LOG_EFFECT_SIZE="2.641636332188823" ORDER="41" O_E="0.0" SE="1.4375577757840765" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="2.066572358717261" WEIGHT="37.07865168539327"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:00:01 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="138" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Progression to cancer at latest possible time point</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7682330431225306" CI_START="0.1830499237945052" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="-0.1145070169610589" LOG_CI_START="-0.7374304475835033" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="42" O_E="0.0" SE="0.3659083066683358" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="0.1338888888888889" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 14:37:24 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Any serious drug reactions</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="43" O_E="0.0" SE="0.0" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="44" O_E="0.0" SE="0.0" STUDY_ID="STD-Overholt-2005" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.895567316244106" CI_END="208.4534792882314" CI_START="20.79660835852156" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="65.84166894701661" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="0" I2="59.71956037245522" I2_Q="8.682963249580224" ID="CMP-008.04" LOG_CI_END="2.3190091483136928" LOG_CI_START="1.317992513266471" LOG_EFFECT_SIZE="1.8185008307900818" METHOD="MH" MODIFIED="2009-10-23 13:09:20 -0400" MODIFIED_BY="Karin L Dearness" NO="4" P_CHI2="0.021084729915298084" P_Q="0.35697240659824325" P_Z="1.0702816766535885E-12" Q="4.380343627369854" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="607" TOTAL_2="266" WEIGHT="99.99999999999999" Z="7.121152655043723">
<NAME>Any complication</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.317313874852818" CI_END="182.42392117513373" CI_START="2.9930056163114407" DF="1" EFFECT_SIZE="23.366553460592574" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="0" I2="87.97688754991593" ID="CMP-008.04.01" LOG_CI_END="2.261081786586639" LOG_CI_START="0.476107531785323" LOG_EFFECT_SIZE="1.3685946591859808" NO="1" P_CHI2="0.0039269372274077785" P_Z="0.0026511902249346836" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="19" WEIGHT="33.51721925901336" Z="3.0055293337964346">
<NAME>Pain</NAME>
<DICH_DATA CI_END="72720.79285147876" CI_START="25.772009992076022" EFFECT_SIZE="1369.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="4.861658605213156" LOG_CI_START="1.4111482910548239" LOG_EFFECT_SIZE="3.13640344813399" ORDER="45" O_E="0.0" SE="2.026846838838127" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" VAR="4.108108108108109" WEIGHT="0.5534521507812253"/>
<DICH_DATA CI_END="19.501423448134403" CI_START="0.030700211035995937" EFFECT_SIZE="0.7737556561085973" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="0" LOG_CI_END="1.2900663125475347" LOG_CI_START="-1.5128586391334484" LOG_EFFECT_SIZE="-0.11139616329295685" ORDER="46" O_E="0.0" SE="1.6464519913196887" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="1" VAR="2.7108041597205683" WEIGHT="32.96376710823213"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="174.49795945195365" CI_START="0.40002376007121127" DF="0" EFFECT_SIZE="8.35483870967742" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="2.241790352762602" LOG_CI_START="-0.3979142122686438" LOG_EFFECT_SIZE="0.9219380702469792" NO="2" P_CHI2="1.0" P_Z="0.17097851990325516" STUDIES="2" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="17.15701667421799" Z="1.3690664005341437">
<NAME>Odynophagia</NAME>
<DICH_DATA CI_END="174.49795945195348" CI_START="0.40002376007121143" EFFECT_SIZE="8.35483870967742" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.2417903527626017" LOG_CI_START="-0.3979142122686436" LOG_EFFECT_SIZE="0.9219380702469792" ORDER="47" O_E="0.0" SE="1.5505755282476883" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" VAR="2.4042844688005975" WEIGHT="17.15701667421799"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.0" STUDY_ID="STD-Overholt-2005" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="605.212696256081" CI_START="2.1852209682837667" DF="0" EFFECT_SIZE="36.366515837104075" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="0" I2="0.0" ID="CMP-008.04.03" LOG_CI_END="2.781908030151084" LOG_CI_START="0.3394953591344378" LOG_EFFECT_SIZE="1.5607016946427605" NO="3" P_CHI2="1.0" P_Z="0.012250888647466209" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="70" WEIGHT="22.132815058384434" Z="2.5048339688126293">
<NAME>Fever</NAME>
<DICH_DATA CI_END="605.212696256081" CI_START="2.1852209682837667" EFFECT_SIZE="36.366515837104075" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="0" LOG_CI_END="2.781908030151084" LOG_CI_START="0.3394953591344378" LOG_EFFECT_SIZE="1.5607016946427605" ORDER="49" O_E="0.0" SE="1.4346852930928866" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="2.058321890217022" WEIGHT="22.132815058384434"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-08-27 13:58:40 -0400" MODIFIED_BY="Jenny Bellorini" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nausea and vomiting</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1286.5177420351476" CI_START="4.72701273915607" DF="0" EFFECT_SIZE="77.98324022346368" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="0" I2="0.0" ID="CMP-008.04.05" LOG_CI_END="3.109415779831116" LOG_CI_START="0.6745867727149575" LOG_EFFECT_SIZE="1.8920012762730367" NO="5" P_CHI2="1.0" P_Z="0.0023190163757012537" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="70" WEIGHT="17.92657871244712" Z="3.0460080353577452">
<NAME>Stricture formation</NAME>
<DICH_DATA CI_END="1286.5177420351465" CI_START="4.727012739156073" EFFECT_SIZE="77.98324022346368" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="0" LOG_CI_END="3.1094157798311155" LOG_CI_START="0.6745867727149578" LOG_EFFECT_SIZE="1.8920012762730367" ORDER="50" O_E="0.0" SE="1.4302306113779981" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="2.0455596017226823" WEIGHT="17.92657871244712"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4287289484042196" CI_END="4765.01257072033" CI_START="29.171323958463166" DF="1" EFFECT_SIZE="372.82935153583617" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="0" I2="0.0" ID="CMP-008.04.06" LOG_CI_END="3.67806405070095" LOG_CI_START="1.464956140290966" LOG_EFFECT_SIZE="2.5715100954959578" MODIFIED="2008-07-30 11:06:03 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5126133137665281" P_Z="5.245004777189314E-6" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="88" WEIGHT="9.266370295937088" Z="4.554741455982188">
<NAME>Photosensitivity</NAME>
<DICH_DATA CI_END="72720.79285147876" CI_START="25.772009992076022" EFFECT_SIZE="1369.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="4.861658605213156" LOG_CI_START="1.4111482910548239" LOG_EFFECT_SIZE="3.13640344813399" MODIFIED="2008-07-30 11:06:03 -0400" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="2.026846838838127" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" VAR="4.108108108108109" WEIGHT="0.5534521507812253"/>
<DICH_DATA CI_END="5114.084144828817" CI_START="18.736936507714262" EFFECT_SIZE="309.55172413793105" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="0" LOG_CI_END="3.7087678694341957" LOG_CI_START="1.2726985851347818" LOG_EFFECT_SIZE="2.490733227284489" ORDER="52" O_E="0.0" SE="1.430959156334914" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="2.0476441070987286" WEIGHT="8.712918145155863"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 14:40:03 -0400" MODIFIED_BY="Karin L Dearness" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="28.98" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="156" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53" O_E="0.0" SE="0.0" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.38698832729725" CI_START="0.09042145280973057" EFFECT_SIZE="1.0147058823529411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.056408875458648" LOG_CI_START="-1.04372851939661" LOG_EFFECT_SIZE="0.006340178031018975" ORDER="54" O_E="0.0" SE="1.233631101585745" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="1.521845694799659" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.06" MODIFIED="2009-10-23 13:00:11 -0400" MODIFIED_BY="Karin L Dearness" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in length (cm) of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5871356285233527" CI_START="0.41286437147664734" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="1.11" MEAN_2="0.11" ORDER="55" SD_1="1.23" SD_2="0.32" SE="0.29956449871252916" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.07" MODIFIED="2009-10-23 13:00:16 -0400" MODIFIED_BY="Karin L Dearness" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="52.79" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in area (%) of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="39.473107443328736" CI_START="20.526892556671264" EFFECT_SIZE="30.0" ESTIMABLE="YES" MEAN_1="31.11" MEAN_2="1.11" ORDER="56" SD_1="20.25" SD_2="3.23" SE="4.8333068964794235" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:00:21 -0400" MODIFIED_BY="Karin L Dearness" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Numbers progressing to dysplasia from intestinal metaplasia</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Omeprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Sucessful Surgical</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Medical</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2724661774688747" CI_START="7.249209321653746E-4" EFFECT_SIZE="0.014054054054054054" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.5646874010948548" LOG_CI_START="-3.139709359769537" LOG_EFFECT_SIZE="-1.8521983804321958" ORDER="57" O_E="0.0" SE="1.5125806450897776" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" VAR="2.2879002079002078" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:00:26 -0400" MODIFIED_BY="Karin L Dearness" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="47.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="138" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Complete eradication over the course of the study (5 years)</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="37.3732183221934" CI_START="5.381499800425667" EFFECT_SIZE="14.181818181818182" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="5" LOG_CI_END="1.5725604978867733" LOG_CI_START="0.7309033285056997" LOG_EFFECT_SIZE="1.1517319131962365" MODIFIED="2008-05-14 12:19:19 -0400" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.49439358756462387" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="0.24442501942501943" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2748909943642007" CI_END="18.864515957420785" CI_START="4.421547452213172" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="9.132926829268294" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="1.2756456661647322" LOG_CI_START="0.6455742902408382" LOG_EFFECT_SIZE="0.9606099782027853" METHOD="MH" MODIFIED="2009-08-27 12:30:56 -0400" MODIFIED_BY="Jenny Bellorini" NO="10" P_CHI2="0.6000696186470105" P_Q="1.0" P_Z="2.282039039777771E-9" Q="0.0" RANDOM="NO" SCALE="560.7406586730405" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="88" WEIGHT="100.0" Z="5.976341831769497">
<NAME>Complete eradication of dysplasia</NAME>
<GROUP_LABEL_1>PDT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="373.00619695488956" CI_START="0.9924167561343985" EFFECT_SIZE="19.24" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.571716047039135" LOG_CI_START="-0.003305911635546881" LOG_EFFECT_SIZE="1.2842050677017942" MODIFIED="2008-07-30 10:31:59 -0400" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="1.5125806450897776" STUDY_ID="STD-Ackroyd-2000" TOTAL_1="18" TOTAL_2="18" VAR="2.2879002079002078" WEIGHT="5.662020905923346"/>
<DICH_DATA CI_END="18.05610226957747" CI_START="4.026232231987103" EFFECT_SIZE="8.526315789473685" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="10" LOG_CI_END="1.2566240059161489" LOG_CI_START="0.6048988212634554" LOG_EFFECT_SIZE="0.930761413589802" MODIFIED="2008-07-30 10:31:12 -0400" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.3828265995566859" STUDY_ID="STD-Overholt-2005" TOTAL_1="138" TOTAL_2="70" VAR="0.14655620532813515" WEIGHT="94.33797909407666"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2009-10-23 13:00:47 -0400" MODIFIED_BY="Karin L Dearness" NO="9">
<NAME>5-ALA vs photofrin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 12:43:44 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="621.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Eradication of high-grade dysphagia</NAME>
<GROUP_LABEL_1>5ALA</GROUP_LABEL_1>
<GROUP_LABEL_2>photofrin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="340.0807559162349" CI_START="0.8288808516475684" EFFECT_SIZE="16.789473684210527" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="2.5315820572904144" LOG_CI_START="-0.0815078930817101" LOG_EFFECT_SIZE="1.2250370821043521" MODIFIED="2008-07-31 11:21:43 -0400" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="1.5349419718524533" STUDY_ID="STD-Mackenzie-2008" TOTAL_1="14" TOTAL_2="14" VAR="2.356046856954298" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:00:47 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="132.93" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Strictures</NAME>
<GROUP_LABEL_1>5ALA</GROUP_LABEL_1>
<GROUP_LABEL_2>photofrin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.068169986023336" CI_START="0.011557784972321777" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.028640370780118985" LOG_CI_START="-1.9371253896587688" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2008-07-31 11:22:14 -0400" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Mackenzie-2008" TOTAL_1="16" TOTAL_2="16" VAR="1.3333333333333335" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2009-10-23 14:41:06 -0400" MODIFIED_BY="Karin L Dearness" NO="10">
<NAME>Radiofrequency ablation vs sham</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:00:54 -0400" MODIFIED_BY="Karin L Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Any reduction/reversal of Barrett's oesophagus/dysplasia at 12 months</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:01:01 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="185.32" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="84" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Progression to cancer at latest possible time point</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.086023811210329" CI_START="0.012706141846569471" EFFECT_SIZE="0.11746987951807229" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.03583934731902318" LOG_CI_START="-1.8959863006740971" LOG_EFFECT_SIZE="-0.930073476677537" MODIFIED="2009-07-07 10:07:59 -0400" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="1.1347639483223415" STUDY_ID="STD-Shaheen-2008" TOTAL_1="84" TOTAL_2="43" VAR="1.2876892184121098" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 14:41:06 -0400" MODIFIED_BY="Karin L Dearness" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="168" TOTAL_2="86" WEIGHT="0.0" Z="0.0">
<NAME>Any complication</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-07-30 11:25:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<DICH_DATA CI_END="56.142473031272836" CI_START="0.12379955580633102" EFFECT_SIZE="2.6363636363636362" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.749291539046195" LOG_CI_START="-0.907280913564733" LOG_EFFECT_SIZE="0.42100531274073105" MODIFIED="2008-07-30 11:25:10 -0400" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="1.560483808909384" STUDY_ID="STD-Shaheen-2008" TOTAL_1="84" TOTAL_2="43" VAR="2.4351097178683387" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-010.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-30 11:02:49 -0400" MODIFIED_BY="Karin L Dearness" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Stricture formation</NAME>
<DICH_DATA CI_END="111.43701106156584" CI_START="0.32508742605184693" EFFECT_SIZE="6.018867924528302" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.0470294550232566" LOG_CI_START="-0.48799982811047254" LOG_EFFECT_SIZE="0.7795148134563921" MODIFIED="2009-07-07 10:15:58 -0400" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.4890887495100853" STUDY_ID="STD-Shaheen-2008" TOTAL_1="84" TOTAL_2="43" VAR="2.2173853039175095" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="65" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:01:14 -0400" MODIFIED_BY="Karin L Dearness" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="84" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Complete eradication of Barrett's oesophagus at 12 months</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1113.867398380606" CI_START="18.534658959033656" EFFECT_SIZE="143.68421052631578" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="1" LOG_CI_END="3.046833492831173" LOG_CI_START="1.2679845993446803" LOG_EFFECT_SIZE="2.157409046087927" MODIFIED="2009-07-07 10:10:45 -0400" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="1.0449046454780013" STUDY_ID="STD-Shaheen-2008" TOTAL_1="84" TOTAL_2="43" VAR="1.0918257181415076" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:01:20 -0400" MODIFIED_BY="Karin L Dearness" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="39" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Numbers progressing to dysplasia from intestinal metaplasia</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2208135918911127" CI_START="0.0029169451402201374" EFFECT_SIZE="0.059674502712477394" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.08664935584216908" LOG_CI_START="-2.5350717386957906" LOG_EFFECT_SIZE="-1.2242111914268108" MODIFIED="2008-07-21 07:32:36 -0400" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="1.5400119486603177" STUDY_ID="STD-Shaheen-2008" TOTAL_1="39" TOTAL_2="19" VAR="2.371636802016549" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:01:26 -0400" MODIFIED_BY="Karin L Dearness" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="84" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Complete clearance of dysplasia</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="58.94214952384918" CI_START="8.716644742823519" EFFECT_SIZE="22.666666666666668" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="9" LOG_CI_END="1.770425969812585" LOG_CI_START="0.9403493461605626" LOG_EFFECT_SIZE="1.355387657986574" MODIFIED="2009-07-07 10:20:00 -0400" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.4875911176787531" STUDY_ID="STD-Shaheen-2008" TOTAL_1="84" TOTAL_2="43" VAR="0.23774509803921567" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-10-23 13:01:33 -0400" MODIFIED_BY="Karin L Dearness" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="31.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="84" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Numbers progressing to dysplasia from intestinal metaplasia</NAME>
<GROUP_LABEL_1>RFA</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7788816371409883" CI_START="0.04658112017057938" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="-0.10852853493612218" LOG_CI_START="-1.3317900718757918" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2009-07-07 11:23:13 -0400" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.7185498820406274" STUDY_ID="STD-Shaheen-2008" TOTAL_1="84" TOTAL_2="43" VAR="0.5163139329805996" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-11-02 09:39:04 -0500" MODIFIED_BY="Karin L Dearness">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-09-22 16:13:11 -0400" MODIFIED_BY="Karin L Dearness" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAXMUlEQVR42u1da2wc13U+FHdeXL5mloxNOxAkkfAfxUAqQ5aomI6x
klMTdqs0aFADbRFLP2gIkV0U+WMX6CP9UQkG/MOJE1RCUbXNAzVqqJBSW6olr2Et1cJUK6CInRYG
KapyzaVDcoaUSO7OzJLb+5idx764uxySu9T5JHJm7tx7z9m73945M3s/HgAEojJaQMVBQFSCsQPH
ALEGkCMI5AgCOYJAjiCQIwjkCAI5gtjuiOAQlICBQ+B7tooc2ZrpteHn7yxeaxAYjyCQIwjkCAI5
gkCOhAZ90xsiKnEkTiAqY6XqxbfKwYfL2Naia3j4UOmG8dK129PIhermkUQiMS1+vaEcHCRelZol
fvezNRoeKt0w/0oLju+oOO9Ufa3RJlcAehRRVsmHrVsWkwB2VKQP3ew2qY0MZPyMeFhLShL/4GmS
KJM9vU2K6qzKuTj/kJIfu12M2mSva1gkVexh8ZxbxrobUUmlsajYNsZNaW4/8W6J+CAQH+LsH4w5
trvzdvd0atS24tkGt69eas9pSHz3+UDRqzB75EW+KEnkdaVFYTgJ2sk9SIaq45EBUrSkW23LZD83
9f5hgJg4Td8DVTLlnWQ7Mv0v5nOp+S5We6nNaiPv7c4F8zIZ75icesnrKWZYUozu/Oz9TtL8e10n
WJkY42eF07TX/Z9Zc0fIdnWqfcntB95OER9s4kOCf+Ljju3VvN3sUWZb8WzTvj6w5vaTd/3fl7rz
DWOCdSHi+kBhft62n+0s/oE5T0x2vWuffxrgqI1kqIojNB4xr5FRVkD/Gjme1IaeIKM6od2gb8sE
jNMntDc05cCkpjzBWkRsbZx8QLMCDCmk5rjm+6rDFEA3eS9DANa+mQwrM0x+dpLVlTVQLLK9rVGL
Tj+wT3N94JQgtm1Wy7Fr7S20Tft6HBSyZ98STNeHW7BPdn2gmNNmZbaTGQLaWeRwOk0c24scKYfA
uvh4ApJv/SWd8nevZA8l6DH9kUy2oUeilS9kP6Tml7Mv/PMMu7qMWvR0vibdkELxsnuUyMeKo5QT
bl2ym7T9TUa5Dc+HYtsAz1ymtle+49kO9gW+hsR/ryH9PXKWbuze778ymKC95LpmuD95GPh9TVYt
OxhDj+1kNxPitcBtJL0qXCeboaLwZXn6n+6ScyTaJWPcosOYd+c5SgovuzVHWcwwyiuCW7eFFHgf
4evu6aAPRbYTY9R2ymfb62vUF36SfT0X8LgX9H9gO525zrvsFaTOkO0YzhdV8/kYkHlk9X/Gj3hF
0h422QgKDHxUWF1Jay30nA3nyCwv9QNtN5rUd9Gp34arbW5N8aYtszKVl0m74cgowNUx0BS3ktMP
BfFhv0ut1wpti48S21redppfPZy+xD22RKjDmGcOwE0z4HEaHuHR68rsURoZkV6eJyx6VEQyVD3n
KQd0aDve5zsxZ7PQMxET00V3k+9pwtI8OdclnrhLa4q03UK8r5W26xZe955iKK+3G6zsIC+by0q0
rvGUlL7rTQ+8H4ro8T7KTPFBdgccEzMB28IDxHZaWCJ9JbpF9R6fFXlfRqb9Kokz2tmUaQpHs8HX
N5zmMdOZjj5KsfcOiF2k6gO4SqKqeCQUxBNVV732zHLdT1H7Ulqoj3MD/WE84o9HwueIP/arhNyR
pDAv1G3m3EuLYXodffMYIEc2iyPbAbhW0bdW0cCrcMXxQQCuDUAgRxDIEQRyBLH1wJgV72vWituR
I5szvTbdfI0aLATGIwjkCAI5gkCOIJAjGyhE0LfehfsMraDUdfN8aD4DEJ+k/0vhjWy5M1WhUtsf
8LsyNWJVbvOD0i44ZYWnclrGd5RpCXucW5qNGKsuLzJ1ziP2R39Y8XxlAdS6MMhniYPG2vVq0GBl
D+K8E+61Rrc++2t3TO2o2G6TjSxpAD2yOOIqp+x2gQugZCHJq7I6epuo6K7syimLilRklVJE+Sr/
oKuipPUwyZVzjtePcxlm/3UB0qIo97gyK+YJs2crkutC0Bb3gfnk2koKtBfhej+SIVSODJia4I5p
TLQiMYBupWMZYPGKNegqp2IRW6QPcnNTicOsKq+jSpbCBFVMduWUzVv/qgIc1y3lWYeH0/MZi0mu
6Lld+fpO15YI0NVutS8SK/OW9Cr3ZJ6tvFWljoP5ekFbrGTqMheBUVvPEbZ0WFfuAYgmkiFUjlga
XHAFD+YE3DKpTGo2w4RNx1zl1PO3YOJFoMqpIa6c4nVkV1DFZFesTOFCqksKGE5zQ1MOcskVPefJ
tJxrw6cAwp8nP+WyLv2H3B7Ze55qsGYv5esFbVHc0YaeZzvU1iG6tjK5l7j/6QqSoWwsVceaK/1B
8s6NTmtF+ijy/vRmh8xEJQEUFAiqPG1W0gZ91wtnXeGVX5jlk2mx+gK9pnTbQ/81W6DBum4WabAC
4i3PJ8cW6aWlY3ajNVjN932Nur7BGBASiYQ44ByNuhItgq7cpb91613XC+5AeR1a3FJYxuVTD+/4
6b0ic9cDMi1nzEkrYWn61UW/rItWNPM9ei4E7ynsvE+OLdKLQnrRW3DCCJPfc1SvJBx3jl4egD0y
QGSgl/zOzu593X3jMwPQ77+ldOpQMZdQUJbh4qtVYbz4m+iMJ8yiMwpT1EU+IdeRtCat+qVeUooJ
vCL9PcP5ekFbFJ3wicTv7rgtOamlyHXmE/wGPFSOvDhBfk286XweT5mCPQcwv3yPvD8LHX1/Q8pe
62PzlSlagYmE17kTEzN3CsqMLomKr6KLrxTLZgxPmEWJwEIb8WOADlU8/D6Tdf0Wl3VNDogZ4tr8
t++dz9e7E5N8tijunnxmju04ttrfEqmm82PU6YUajzQA9N+/KITZn/3bP9tQDVYzxyNNq69Rww0g
cjH/hIcc8XOkaa/CRrgxZkswuF4N291VaF5gpFZyksIhaOY5EIEcQSBHEMgRxLYDxqwlb5pwCFCD
teHTa8PPz2t9zZ3Daw0C4xEEcgSBHEEgRxDIkc2HvsYxIgyO0KwTci9bWxpMExUvk4vqXHuJwrSY
q8eRMvmpKlYO7D1cUOfhmvJgRc8hF6qaRxKJaYUvJy1SL5XMRXWiVGlX+3q+ta9fuTVYfFyDBuuz
EzjvVHmt0YxVd+ZQeWYqKmjiBVxKZUelbv4p7Bcfh3iaCaDy2axUOf7EV2lmKidrFZVSyU7WrF5F
pGorp18uvXLaUfS2sTZuPSfLFUGSZcTy7LtqKr7H+6CKKycjFungnJcHq0AGVsaOJmIerGrjEV8O
CC5bektJ5R/J5abu0qxYQuoUP7a+IL/OTtO8VvvneTYrmKLap52SKf+EHFxMAfzVtJExU/PdAL8X
taJLbr8/Vm4v+9oB/Pr/2nayHafeYpul8+fB32AZsfL2I+I0X48KsUvTVPvL+6B231owZ2n2s190
nXBlYBdsnneLta1g5wvMcVQVR0hA8tXX3KNJJlt6e1xz3hInCZV5S3vM+Rz/kk7p2gSVVQmgUKHb
BPuIH5iA8Ytk+xVy9JimHNynKaSnN2fzybXo5uJEn68dQVabPcB2nHqCzfJTgZeVi9uXeVYuAvMr
2m3w9/HHZO9IPuMWR2YfUP/ATdxVzs4vkSPl4F/PSuVJvXdNn3qJ/HiprYJZsQDcPSppgkKZVEHG
LJZ3yl4dTJSUXoFfmOXUG3tqBRbZumZ997xyqLx9z7Yvi1bFPFgl7Ug+MaeB39fkymuwZgpvSnYU
6qjALcjp7lFQJlUsfGLBbG7Wdx8UkF5R9OTbOPUeX061fZffobTErpWyDzyTlteHkxFrtECDFXxJ
ZezoOZwwquS72lp4K9sPuwIFNCvWKNsTqFJvF/RLTCbli2ReKxI+sUl+Nu37qEb6U8OBdml4JOOv
RzNs/R0PjP47kJXrZt4hskfLnT4IG17je+JNqupyZGAfQ78cfEGl7Sior6kyHhEzHxZUuGFJ5wMF
c7Z4lu8xpV6raM0xCVXamySKslYxLHR822ftg/SujwLt2oaXb/jrRb8lLC3wZxfHH/Rn5ToqveHs
fVOijCZ9LN8lpHsQBrvF5Q9pxq27BjumRBhm/vlQxs6f4iqJauKRqqFa7O806A9NafHE9hgHu2Mq
VA3WdopHaudIu52LRGf4jbK5VG3Wq0ZH+4z/b34hR9bHkfsBuFYR82BVPT4IwLUBCOQIAjmCQI4g
th4Ys+J9zVpxO3Jkc6ZXzIOFwA8MAjmCQCBHEMgRRNNzRK/rVK1NdP8p1EKEhXq+9616zYhX0VFB
lAJb8l5bb3LgD4yr9qJX7hgidUm/pRx1ygpPtYv491mD977qxg1GaQyWP3Ww9t4OBSYPLyPWIddQ
gvVbgwbLSOO8EzK/490jIvnE2iela+BKrtQRSUuy8nhaUviY62+IUZ0LpKKsFnj1aT/sX0qhGq25
6AiTS12VRtJJeYSViFG+0NCOjlBe9yiSk2Wr9yQTUAHPiOWWs/66R5x+eR4sLgdjfrGuZNpnnHY2
QuVlaVE8mQRhGfNghT0Hrp5eoBmqftpxCmCnbEpU1qSfns88y8pBTv2Yz1XqoDWrMkGUOm/+aBcr
y9d3PtAJOCV1dgNowlmWNetbqUHtualB0s2peUvieq+IeJounFp8zxzkqbDu/aMV5ZcY6x1fOVNe
tZx2+qW2fmQxW9xf1tXU5d1sZ79+Nkquc11R67GnAXotJEPIHOF6KJ5xyh6HCSpe8DJXQVY7ytf+
yY+DwvcUAY7x9yFf38WZWzMmwIu3YIJmDZnTjg1OasdINz90M1y9OMHkVjTLFpdSZWZBd3Jr7fWX
U0z4VqbaR7mt264G64Y2xJfnX+LSLvEvkkdJfPNpFskQbswaFFIVSa7oRiiQRZWSW/mEUlAol/Ia
gyu3snuzWa7GsnvtJ00vI5ZbHvCtXB4sXjD29ErWyYN1u4/3gzFr+DFrqbxWzo2nznu+HkhSZUOw
vhMnjrrdfCfQy4Db2BFedeZmnLy8XbnZi87o6/7yEh4W+NYL+gts5+st7zp5sN4hFx8dnxRtDL95
xinhAvQXSK52wQBPNpUZY7KoUduXzcqpP6rpuzhBxP5eiWfNOhPopdMGdZjtSXuY8GplNs2ybNmQ
vZKOOT4o/vLRsXxjTrxi35ZA6WQ7K4JMu3CyaV3Ab8A3hiPzaZpx6s53RTOYawrOS+ZtPlE9JVKB
lNCez3QFbv32pT76vogPgJH5nassa5YdDApOdQuZ/2B7c1mJ1n2fZ9kivS082edIw6gizCsX3bCE
9MttFeTBWpB7/oTtRBeHqITLyab1Aur0woxHQnzKFgLCyYgVtgZrO8UjG8MRaTMTKmtzIaQ7ymn+
tWfIkY3Pg7WpObdDSZrWElyeiHmw/FEnXm5LADVYTT0HIpAjCOQIAjmC2HbAmLUUUIOFGqwmmF43
2gPMg4XAeASBHEEgRxDIEQRypG7om9Bife0QhQh9bYDdtZKT59wVHYUrSZR0rYtL5EzpFuoa3/eW
aVdOgxXy32dt/nvfDdRgdUqpaYiVPT1Yc6qrQ2WScGWydbVzUHjqjorzzqbRdXVC0+5m/BmunOxU
9rCbnWrYJkf5cvqh7pbdTFrnxDa60N3NpOVoqUgVnpVLdpJwXRCEutqBrbD6AD2yxDVYwnAStJOY
B2vTOCLsVm2wAPZ/YM3tZyU7F8zL5L2IfM/NTnX9S/Clf8uXU6Sm3PovTV8ks5AqmTKVTr2dcrRU
TvYsVZpyVuucFOtrB7HP27hfi1fMeXKq+137/NMAR1Ffs2kcubNiRZUev/gqK8AQ2ZO87FTvWGAL
+XKKtObWN7R9JmkzAeNUaLHPXWR6m2XPUm7ls3LZn9bXDua0WZ6sJDMEVJfVepjlwdqLOr1Ni1np
xWW3la6YnUrvM2lECXmFFVNIufXhmculZVpeVi7gkql62nnyMLv3+68MJkD/8pOJrpmw82BhzFoB
kg7aAnGgpUJ2Kk3ojvjlWYysTv0x0D/g0qmhUpTWwZHT7dDra0c1WDyPU+dqJ9VyaMs/P0O2Y5gH
a9Pomtlj610kVrjqZrgSuPjKn51K3DfjljvI1z8CNyVyToGBj/iJUb80ONMPMZ6DNfJJfe1gGR7h
UpqVuaP0/kvRtOcJPx5Ffc2mccQw2h/MGjzDFZdcJbrEEzw71RXyJrLsVF9cT7vl+XZO/Vbhm7fJ
uZiYdm5PBX8y8humdJ67LA7X1w7ahtO32c77HX206L0DYhep+gCuktjMeGQ9WPsBm5Zhf/hIf+jz
WD3tysVQr5zeUA1WM8cjjcaRNfJq5aSW1gX+EFezFutqVxrRN48BcqQ5ONIYwLWKmAer6vFBAK4N
QCBHEMgRBHIEsfXAmBXva9aK25EjDTq9hu3BSo31UYOFwHgEgRxBIEcQyBEEcqQxgHII5Eg5aIrI
8mH9GV/uWoR4YIO4DznS8xvvWfpzvQC/qlwvgW//fcuRzM0hUP7z11yEpcpCkubRElmOrS6+gNaW
2RFAShHlqwBJQZR7kAz3EUfsCfLrlsQFXytTicMAsXlLepWUtn7OaqhTl/lCx+O6pTxL2NJhXbmH
ZCiD7bgOja9t5emS4m9rdEPFM7TgbbZolW5Gzvrk4dGWS3t9y1m341rFmp/Fqw00GOGD5bDJ62X4
W/+1eDyec4/o5u/5nU/ny1S0N5873IfXmvvpWiP+Jvn1jUBeg9GA3gvs/G3xwzt+6uTCUhaRDPcR
R+R0GpKZUb8M62Ub1KhXoxM+4Wm6VoVx+s23nNR+sYJkKINWULbda1q+p+34uf4T8tZHVnZPApCf
D7uP3Ywu0z2K3b/6o/ErrfRosXVmsm8Sulu0/73mk1ZkWrb8RYTtQc1SVcU3GLgGvBgYs273mBUR
LnAdWkmsogfIkcrA6+92v69BIEcQyBEEcgSBHEEgRxDIEQQCOYJAjqwXxha3b6wOkCMInEcQyBHE
RgPXj2zI1XwbAP/2ZrUDVCfH1vvBa4AO8FqDwHgEgRxBYMyKaJwAHmPWsiGbyjZq9fGf24Zta2rq
xYlqfba9OFOt2gN+yvO6nFHkSNnhIz/sf9UUyY+u6hxV3zRwO1WPba+5AdV6YBS80rJGMR4J+365
/rtOQw2N3KFaw3kk9HfOqJsuRuGDmdptq1V7oFb9gpEjFacGg/43qo7r85casq21Kbgt67Rd1E9d
HpRqgxxZ+wqv1vR5Vutuqq7b9no9KN0G45EQLzXGOq8U67/MqeuPcIrbIEfCplP93weG9U1i2N9I
4jO0yuGjkX/OUNPTiVqbFj1gqbcDtRbnSz0fKdEG83Ii1iQeXmsQawE5gkCOIJAjCOQIAjmCaHRE
Cu7vEQgHagmO4JMSBJSaMvBag8B4BIEcQSBHEMgRRBPd+1a4C27UOx50dMs4Uji7rDaL+9mGdbQg
1UiuiSiC1xoEcgSxiRwxqjxbVM8wvNLNeN5vlLRkNJ7zrqPl7DfIoIalnVhLVdrQodpWO6829qDW
fq0xDIf5LpMN9s854/+E8JpGAfOdal7tjZtQ8pb8ruc3RuM4zzuGgLMNNKg1zyOlBKWGGjzjP84r
jF1hT1CEvLEkUb3/xZY9xxrAedppwFIDDWqd1xrVcP4VTHZq0URYNCGqmzdJqiUNqcHtFjpvFIxp
sTcNMaghajlV39/fWHtkVGPzo5MKMd6WOF+FZqsRBjUS7seWsn0Nhanh+yMqm0wSNeBAczjfAH7t
qHvSUKHgj5lUe3Psi3Y3ZlSNoqnZWOPGuCGcN9bzxGEjBzVS42tQy09n3hlOnmBN1XBP8jMbd60p
6Npvme45DjSW8yWdapBB9Wk5jbKZoVcb9quywu9rGtbRwu9r1LUeemy9y2qZQUZs1TsCjftdMHKk
MdDIawVKc2S1WYY22yyO5pqYv5FmIzU6uunAtQEI5AgCOYJAjiCQIwjkCKLZ4b/3xT8ugViDI/in
JRB4rUEgRxDIEQRyBIEcQSBHEMgRBAKBKIH/B8nGeV7GGc+hAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-09-22 16:13:11 -0400" MODIFIED_BY="Karin L Dearness" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASUAAAL6CAIAAAD/hddHAAAlcElEQVR42u2dsW7cRteGFwgQpNhC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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-08-27 12:38:41 -0400" MODIFIED_BY="Jenny Bellorini">
<APPENDIX ID="APP-01" MODIFIED="2009-08-27 12:38:41 -0400" MODIFIED_BY="Jenny Bellorini" NO="1">
<TITLE MODIFIED="2008-11-03 15:31:14 -0500" MODIFIED_BY="Karin L Dearness">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-27 12:38:41 -0400" MODIFIED_BY="Jenny Bellorini">
<OL>
<LI>(mucosal adj5 protecting adj5 agent$).tw.</LI>
<LI>exp carbenoxolone/</LI>
<LI>exp misoprostol/</LI>
<LI>exp sucralfate/</LI>
<LI>exp muscarinic antagonists/</LI>
<LI>exp dicyclomine/</LI>
<LI>exp propantheline/</LI>
<LI>carbenoxolone.tw.</LI>
<LI>misoprostol.tw.</LI>
<LI>sucralfate.tw.</LI>
<LI>antimuscarinic$.tw.</LI>
<LI>(muscarinic adj5 receptor adj5 antagonist$).tw.</LI>
<LI>dicyclomine.tw.</LI>
<LI>propantheline.tw.</LI>
<LI>exp metoclopramide/</LI>
<LI>metoclopramide$.tw.</LI>
<LI>exp domperidone/</LI>
<LI>domperidone$.tw.</LI>
<LI>exp cisapride/</LI>
<LI>cisapride$.tw.</LI>
<LI>Anti-inflammatory agents, non-steroidal/</LI>
<LI>nsaid$.tw.</LI>
<LI>nonsteroidal anti-inflammatory.tw.</LI>
<LI>non-steroidal anti-inflammatory.tw.</LI>
<LI>exp ibuprofen/</LI>
<LI>ibuprofen$.tw.</LI>
<LI>aceclofenac$.tw.</LI>
<LI>acemetacin$.tw.</LI>
<LI>dexketoprofen$.tw.</LI>
<LI>exp diclofenac/</LI>
<LI>diclofenac$.tw.</LI>
<LI>fenbufen$.tw.</LI>
<LI>fenoprofen$.tw.</LI>
<LI>flurbiprofen$.tw.</LI>
<LI>exp indometacin/</LI>
<LI>indometacin$.tw.</LI>
<LI>exp ketoprofen/</LI>
<LI>ketoprofen$.tw.</LI>
<LI>exp mefenamic acid/</LI>
<LI>(mefenamic adj3 acid$).tw.</LI>
<LI>nabumetone$.tw.</LI>
<LI>exp naproxen/</LI>
<LI>naproxen$.tw.</LI>
<LI>exp phenylbutazone/</LI>
<LI>phenylbutazone$.tw.</LI>
<LI>exp piroxicam/</LI>
<LI>piroxicam$.tw.</LI>
<LI>exp sulindac/</LI>
<LI>sulindac$.tw.</LI>
<LI>tenoxicam$.tw.</LI>
<LI>(tiaprofenic adj3 acid$).tw.</LI>
<LI>exp cyclooxygenase inhibitor/</LI>
<LI>COX 2.tw.</LI>
<LI>celecoxib$.tw.</LI>
<LI>etoriCOXib$.tw.</LI>
<LI>valdeCOXib$.tw.</LI>
<LI>rofeCOXib$.tw.</LI>
<LI>exp etodolac/</LI>
<LI>etodolac$.tw.</LI>
<LI>meloxicam$.tw.</LI>
<LI>exp aspirin/</LI>
<LI>aspirin$.tw.</LI>
<LI>(acetylsalicylic adj3 acid$).tw.</LI>
<LI>exp antioxidants/</LI>
<LI>antioxida$.tw.</LI>
<LI>exp vitamins/</LI>
<LI>exp vitamin a/</LI>
<LI>retinol$.tw.</LI>
<LI>exp vitamin c/</LI>
<LI>(ascorb$ adj3 acid$).tw.</LI>
<LI>exp vitamin d/</LI>
<LI>calcium$.tw.</LI>
<LI>exp vitamin e/</LI>
<LI>exp tocopherols/</LI>
<LI>tocopherol$.tw.</LI>
<LI>exp vitamin k/</LI>
<LI>vitamin$.tw.</LI>
<LI>exp carotenoids/</LI>
<LI>caroten$.tw.</LI>
<LI>lutein.tw.</LI>
<LI>lycopene.tw.</LI>
<LI>xanthophylls.tw.</LI>
<LI>exp selenium/</LI>
<LI>selenium$.tw.</LI>
<LI>difluoromethylornithine$.tw.</LI>
<LI>dfmo$.tw.</LI>
<LI>exp lasers/</LI>
<LI>exp laser coagulation/</LI>
<LI>exp light coagulation/</LI>
<LI>exp catheter ablation/</LI>
<LI>(argon adj5 plasma adj5 coagulat$).tw.</LI>
<LI>APC.tw.</LI>
<LI>exp sclerotherapy/</LI>
<LI>sclerotherap$.tw.</LI>
<LI>exp electrocoagulation/</LI>
<LI>electrocoagulat$.tw.</LI>
<LI>(multipolar adj5 coagulat$).tw.</LI>
<LI>(therm$ adj5 coagulat$).tw.</LI>
<LI>(heater adj5 probe).tw.</LI>
<LI>(argon$ adj5 laser$).tw.</LI>
<LI>(YAG adj5 laser$).tw.</LI>
<LI>(yag adj5 nd).tw.</LI>
<LI>(yag adj5 ktp).tw.</LI>
<LI>(monopolar adj5 coagulat$).tw.</LI>
<LI>(bipolar adj5 coagulat$).tw.</LI>
<LI>(multipolar adj5 coagulat$).tw.</LI>
<LI>mpec.tw.</LI>
<LI>exp photochemotherapy/</LI>
<LI>(photodynamic adj5 therap$).tw.</LI>
<LI>PDT.tw.</LI>
<LI>(ala adj5 pdt).tw.</LI>
<LI>(aminolaevulin$ adj5 acid).tw.</LI>
<LI>(photophrin adj5 pdt).tw.</LI>
<LI>(endoscopic adj5 mucosal adj5 resect$).tw.</LI>
<LI>(ultrasonic adj3 surgical adj3 aspirat$).tw.</LI>
<LI>exp fundoplication/</LI>
<LI>fundoplicat$.tw.</LI>
<LI>(antireflux adj5 surgery).tw.</LI>
<LI>(nissen or rossetti).tw.</LI>
<LI>(toupet or lind or watson or besley).tw.</LI>
<LI>(partial$ adj5 fundoplication$).tw.</LI>
<LI>(laparoscop$ adj5 fundoplication$).tw.</LI>
<LI>exp esophagectomy/</LI>
<LI>esophagectomy.tw.</LI>
<LI>oesophagectomy.tw.</LI>
<LI>(esophag$ adj250 neoplas$).tw.</LI>
<LI>(oesophag$ adj250 neoplas$).tw.</LI>
<LI>(esophag$ adj250 cancer$).tw.</LI>
<LI>(oesophag$ adj250 cancer$).tw.</LI>
<LI>(esophag$ adj250 carcin$).tw.</LI>
<LI>(oesophag$ adj250 carcin$).tw.</LI>
<LI>(esophag$ adj250 tumo$).tw.</LI>
<LI>(oesophag$ adj250 tumo$).tw.</LI>
<LI>(esophag$ adj250 metasta$).tw.</LI>
<LI>(oesophag$ adj250 metasta$).tw.</LI>
<LI>(esophag$ adj250 malig$).tw.</LI>
<LI>(oesophag$ adj250 malig$).tw.</LI>
<LI>(adenocarcinoma$ adj250 esophag$).tw.</LI>
<LI>(adenocarcinoma$ adj250 oesophag$).tw.</LI>
<LI>(transthoracic adj10 esophag$).tw.</LI>
<LI>(transthoracic adj10 oesophag$).tw.</LI>
<LI>(thoracic adj10 resect$).tw.</LI>
<LI>(ivor adj1 lewis).tw.</LI>
<LI>(tanner adj25 esophag$).tw.</LI>
<LI>(tanner adj25 oesophag$).tw.</LI>
<LI>(santy adj25 esophag$).tw.</LI>
<LI>(santy adj25 oesophag$).tw.</LI>
<LI>(transhiatal adj10 esophag$).tw.</LI>
<LI>(transhiatal adj10 oesophag$).tw.</LI>
<LI>(orringer adj25 esophag$).tw.</LI>
<LI>(orringer adj25 oesophag$).tw.</LI>
<LI>exp cryotherapy/</LI>
<LI>(cryothera$ adj5 endoscop$).tw.</LI>
<LI>or/39-234</LI>
<LI>38 and 235</LI>
<LI>236 and 29</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-07-30 14:58:06 -0400" MODIFIED_BY="Karin L Dearness" NO="2">
<TITLE MODIFIED="2009-07-30 14:57:21 -0400" MODIFIED_BY="Karin L Dearness">Criteria for assessment of quality of randomisation of studies</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-30 14:58:06 -0400" MODIFIED_BY="Karin L Dearness">
<OL>
<LI>Indicates adequate concealment of the allocation (for example, by telephone randomisation, or use of consecutively numbered, sealed, opaque envelopes);</LI>
<LI>Indicates uncertainty about whether the allocation was adequately concealed (for example, where the method of concealment is not known);</LI>
<LI>Indicates that the allocation was definitely not adequately concealed (for example, open random number lists or quasi-randomisation such as alternate days, odd/even date of birth, or hospital number).</LI>
<LI>Indicates randomisation was not used.</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>